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AIM OF THE STUDY 

Aim of the study 
Aim of the study 
Somatostatin has been extensively studied in relation to the endocrine and 
nervous systems. Many reports on the role of somatostatin receptor imaging 
and somatostatin treatment of neuroendocrine tumours have been published. 
The relation between somatostatin and other neuropeptides and the immune 
system is less explored. 
The aim of this study was to investigate the diagnostic applications of 
somatostatin and substance P analogues in autoimmune and haematological 
diseases. Both in vivo and in vitro studies were performed, using peptide 
receptor scintigraphy in patients and rats, peptide receptor autoradiography 
on tissue biopsies, ligand binding assays on cell homogenates, and 
polymerase chain reactions on lymphoid cell lines. Moreover, based on the 
results of these studies, speculations were made about the therapeutical 
applications of somatostatin and substance P analogues in autoimmune and 
haematological diseases. 
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CHAPTER 1 
AN INTRODUCTION TO SOMATOSTATIN AND 
SOMATOSTATIN RECEPTOR SCINTIGRAPHY 
An introduction to somatostatin and somatostatin receptor scintigraphy 
Somatostatin 
Somatostatin belongs to the expanding family of small peptides that are 
characterized by a variety of actions in different organ systems throughout 
the body (1,2). Somatostatin was originally detected as an inhibitor of the 
release of growth hormone by the pituitary gland, and was initially called 
'somatotrophin-release inhibiting factor'. It was subsequently identified as a 
cyclic peptide consisting of 14 amino acids (somatostatin 14) with a 
disulphide bridge connecting the two cysteine residues (Figure 1) (3,4). A 
larger precursor molecule was identified as somatostatin 28, or 
prosomatostatin (Figure 1) (1,2). Preprosomatostatins are even larger 
peptides with somatostatin 28 located at the C terminus (5). These larger 
molecules are spliced into the smaller somatostatin 14 by a processing 
enzyme (6). Somatostatin is found throughout the human body, but mainly in 
the endocrine glands and nervous system (1,2). In Table 1 the anatomical 
distribution of somatostatin in humans is shown. 
Somatostatin receptors 
Sch6nbrunn et al. first described somatostatin receptors on the rat pituitary 
tumour cell line GH4C1 (7). Ligand binding assays on tissue homogenates 
and autoradiography of tissue sections, using ['2'I-Tyr3]-octreotide, 
subsequently identified somatostatin receptors on a wide range of tumours 
and inflammatory tissues (8,9). The highest density of high affinity receptors 
were found on tumours with characteristics of the amine precursor uptake 
and decarboxylation (APUD) system, like paragangliomas (10-11). 
Five subtypes of human somatostatin receptors have been identified, all with 
a high affinity for somatostatin 14 (lC,o = 1.1-2.1 nM) and somatostatin 28 
(lC,o = 0.25-5.4 nM) (12). For somatostatin 14 the following order of 
increasing affinity was found: subtype 3, subtype 5, subtype 2, subtype 1, 
subtype 4. The affinity of receptor subtypes 1-4 was two- to fourfold higher 
for somatostatin 14 than for somatostatin 28, whereas receptor subtype 5 
bound somatostatin 28 with eightfold higher affinity (12). Characteristics of 
the human somatostatin receptors are shown in Table 2. 
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Somatostatin 14 
,----------------------------------------, 
Ala - Gly - Cys - Lys - Asn - Phe - Phe - Trp - Lys - Thr - Phe - Thr - Ser - Cys 
Somatostatin 28 
Ala ~ GJy ~ Cys - Lys - Asn - Phe - Phe - Trp - Lys - Thr - Phe - Thr - Ser - Cys 
I 
~-~-Glu-~-~-~---~-~-~n-~r-~n-~-~r 
Octreotide 
D-Phe - Cys - Phe - D-Trp - Lys - Thr - Cys - Thr(ol) 
D-Phe - Cys - Tyr - D-Trp - Lys - Thr - Cys - Thr(ol) 
I 
1251 
) I 
'''In - DTPA - D-Phe - Cys - Phe - D-Trp - Lys - Thr - Cys - Thr(ol) 
BIM-23014 
D-Nal - Cys - Tyr - D-Trp - Lys - Val - Cys - Thr(ol) 
RC-160 
D-Phe - Cys - Tyr - D-Trp - Lys - Val - Cys - Trp 
Figure 1. Sequence of somatostatin and some somatostatin analogues. 
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Somatostatin receptors are coupled to G proteins in the cell membrane, and 
generate a transmembrane signal after binding of somatostatin. Three 
receptor linked effector systems have been identified. Binding of somatostatin 
to the receptor leads to a reduction in the intracellular level of cyclic 
adenosine monophosphate (a) (13,14), and ionized calcium (b) (15,16), and 
an increase in the tyrosine phosphatase activity (c) (17). 
17 
An introduction to somatostatin and somatostatin receptor scintigraphy 
Table 1. Anatomical distribution and actions of somatostatin in humans (1). 
Localization 
Central nervous system 
(cortex, limbic system, brain stem, and 
spinal cord) 
Anterior pituitary gland 
Peripheral nervous system 
(sensory neurons) 
Endocrine glands 
Exocrine glands 
Gastrointestinal tract 
Vascular system 
Action 
Neurotransmitter 
Neurohormone 
Neurotransmitter 
Inhibitor of hormone~ and (neuro)peptide secretion 
(gastrin, pancreatic polypeptide, vasoactive 
intestinal peptide, insulin, glucagon, and substance 
P) 
Inhibitor of gastric acid- and salivary fluid secretion 
Regulator of intestinal epithelial electrolyte- and 
water release, and of pancreatic enzyme release. 
Inhibitor of motor activity of stomach, small 
intestine and gall bladder 
Regulator of coeliac~, mesenteric- and renal blood 
flow 
Clinical applications of somatostatin 
The general inhibitory effect of somatostatin on hormone secretion of various 
glands led to the concept of a possible beneficial effect of som~tostatin 
analogues in the treatment of patients with diseases based on an 
overproduction of hormones by endocrine active tumours. The short half-life 
of somatostatin 14, however, makes it unsuitable for routine treatment. 
Therefore, various somatostatin analogues have been developed for 
therapeutic purposes. The somatostatin analogue octreotide (Sandostatin@) 
was initially developed for the inhibition of gastric acid secretion. However, 
the required parenteral administration made the drug less suitable when 
compared with the H-2 receptor antagonists. In contrast to somatostatin 14, 
the half-life of octreotide is 90-120 minutes when administered 
subcutaneously. The pharmacodynamic effect lasts even for 8-12 hours (18). 
Octreotide has only few and infrequent side effects; cholelithiasis during 
18 
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Table 2. Characteristics of human somatostatin receptor subtypes 1-5 (12). 
Somatostatin receptor subtype 
2 3 4 5 
Chromosomal location 14 17 22 20 16 
Number of amino acids 391 369 418 388 363 
G protein coupling + + + + + 
K"/Ca 2+ channels + 
Adenylyl cyclase coupling + + + + + 
Selectivity of somatostatin analogues 
Somatostatin 14 + + + + + 
Somatostatin 28 + + + + + 
BIM-23014 + +/- + 
RC-160 + + 
Octreotide + +/- + 
chronic treatment, hyperglycaemia, and ileus with nausea and vomiting 
(19,20). Based on its inhibiting properties, octreotide is now tested in other 
diseases like pancreatitis, gut motility disorders, upper gastrointestinal 
haemorrhage (21-28), and endocrine active tumours. The application of the 
antiproliferative properties of octreotide in oncology is under current 
investigation (29,30). 
The effects of octreotide were found to be mediated mainly through 
somatostatin receptor subtypes 2 and 5 (12) (see Table 2). Other cyclic 
somatostatin analogues, like BIM-23014 and RC-160 (see Figure 1 and 
Table 2), were also studied for their possible clinical application (30). New 
subtype specific somatostatin analogues and antagonists are currently being 
developed in order to study the precise function of the somatostatin receptor 
subtypes. Moreover, subtype specific somatostatin analogues may be of 
particular interest for clinical application. 
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Somatostatin receptor scintigraphy 
The concept of peptide receptor scintigraphy is simple. After intravenous 
injection, radioactive and non-radioactive peptides (ligands) bind to cells that 
have membrane binding sites for these ligands. One mechanism by which 
ligands can enter the cells is endocytosis of ligand-receptor complexes. This 
occurs after binding of the ligand to the receptor, and clustering of the 
complexes in the plasma membrane. In the cell, metabolism of the 
radioligand takes place with recycling of the receptor after dissociation from 
the ligand. Another route of cellular entry is transport over the plasma 
membrane by a carrier mechanism. If the density of high affinity receptors on 
cells, or the number of cells with high affinity receptors, in a specific tissue is 
higher than in the surrounding tissue, the radioactive signal from this tissue 
will be higher than from the surrounding tissue. A gamma camera is used to 
display the radioactive signal. 
Somatostatin receptor positive human neuroendocrine tumours can be 
visualized using radioiodinated analogues of somatostatin (31,32). However, 
these pharmaceutical products have some major drawbacks like the hepato-
biliary clearance and subsequent faecal excretion (32). Like radioiodinated 
somatostatin analogues, ["1In-DTPA-D-Phe ']-octreotide binds specifically to 
somatostatin receptors (33). Some remarkable advantages of this radioligand 
over iodinated somatostatin analogues are its easy preparation, its 
appropriate half-life, and its mainly renal clearance. Faecal excretion of 
radioactivity amounts to only a few percent of the administered dose (33,34). 
Therefore, ['11ln-DTPA-D-Phe ']-octreotide is highly suitable for its use in 
planar imaging and single photon emission computed tomography (SPEeT) 
of the abdomen, which is of particular importance in the localization of small 
neuroendocrine tumours in this part of the body. 
After administration of ['"In-DTPA-D-Phe ']-octreotide, physiological 
accumulation of radioactivity is found in the kidneys, spleen, urinary bladder, 
liver, pituitary gland, thyroid gland, and salivary glands. Other sites of 
deposition of radioactivity are considered to be patholog ical (34). The 
excretion of ['"In-DTPA-D-Phe ']-octreotide, occurring mainly via the kidneys, 
results in 90% of the administered dose being present in the urine 24 hours 
after injection. Because of its relatively long effective half-life, ["1In-DTPA_D_ 
Phe' ]-octreotide can be used to efficiently visualize somatostatin receptor 
20 
Chapter 1 
bearing tumours and inflammatory tissue 24 and 48 hours after intravenous 
injection, at which time the interfering background radioactivity is minimized 
by renal clearance of the radiopharmaceutical (33-35). Moreover, it can be 
used to irradiate tumours which express a high density of somatostatin 
receptors, since it emits Auger- and conversion electrons (36). 
In our sCintigraphic studies 200-250 MBq of ["'In-DTPA-D-Phe']-octreotide is 
injected intravenously. Planar images are obtained with a gamma camera. 
Preset counts for images obtained 24 hours after injection of the ["'In-DTPA-
D-Phe']-octreotide are 300,000 per spotview for the head and neck, and 
500,000 per spotview for the remainder of the body. The preset counting time 
for images obtained 48 hours after injection of the ["'In-DTPA-D-Phe']-
octreotide is 15 minutes (37). Images are divided in parts that are easily 
recognized on sCintigrams, i.e. head and neck, chest, upper abdomen, lower 
abdomen (division line: lower edges of the kidneys), and the limbs. 
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CHAPTER 2 
SOMATOSTATIN AND THE IMMUNE AND 
HAEMATOPOIETIC SYSTEM 
Somatostatin and the immune and haematopoietic system 
Introduction 
Neuroimmunoendocrinology is a rapidly evolving field of research which until 
recently has had limited clinical applications. The interactions between 
(neuro)peptides and immune competent cells have been investigated in a 
wide variety of in vitro culture systems and animal models. The current 
knowledge in this field has been summarized in a number of excellent 
reviews (1-4). Our own interests stem mainly from our clinical observations 
on the value of somatostatin receptor visualization in a number of immune 
disorders. We originally developed this technique, in which an isotope 
coupled somatostatin analogue is injected, in order to localize primary 
endocrine tumours such as medullary thyroid cancers, small cell lung 
cancers, islet cell tumours and carcinoids, and in addition their metastases. 
I n the present review we summarize the knowledge on somatostatin receptor 
expression in lymphoid tissue, and on the significance of this peptide in the 
modulation of immune functions. 
Somatostatin 
Somatostatin was initially described as a growth hormone-release inhibiting 
factor synthesized in the hypothalamus (5,6). However, somatostatin 
operates also as a neurotransmitter in the brain, as an inhibitor of gut 
motility, and as an important regulatory peptide for the release of several 
peptide hormones, including gastrin, insulin, glucagon and cholecystokinin 
(5,6). Somatostatin is composed of 14 or 28 amino acids. The 14 amino acid 
structure predominates in all tissues with the exception of the duodenum and 
ileum. Because of the very short plasma half-life (several minutes) of native 
somatostatin, a number of long acting somatostatin analogues, like octreotide 
(Sandostatin\ have been developed for therapeutic purposes (7,8). 
Oclreotide is clinically used in the control of hormonal hypersecretion in 
patients with acromegaly, islet cell tumours and carcinoids, but preliminary 
data also suggest its effectiveness in variceal bleeding, acute and chronic 
pancreatitis, dumping syndrome and cancer therapy (9,10). 
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Somatostatin receptors on lymphoid cells, monocytes and cell lines 
Specific receptors for somatostatin, mediating the various actions of this 
peptide, have been described in normal as well as tumour tissues (11). 
Bhathena et al. first identified receptors on human mononuclear leucocytes 
(12). Specific low affinity receptors were found on resting monocytes and 
lymphocytes. Monocytes expressed 450-500 receptors per cell as compared 
with 220-250 receptors per cell in the lymphocyte fraction. Subsequently, 
somatostatin receptors were identified on more than 95% of normal mitogen 
activated human peripheral lymphocytes, using a binding assay (13). Resting 
peripheral blood lymphocytes, granulocytes and red blood cells did not 
present somatostatin receptors. The activated lymphocytes expressed a 
single class of low affinity receptors (Kd = 10.8 nM). No distinct predilection of 
somatostatin receptor positive cells among lymphocyte subpopulations was 
found. 
Using 1251 labelled somatostatin and fluorescent labelled somatostatin, 
approximately 50% of murine Band T lymphocytes prepared from Peyer's 
patches and 30% of lymphocytes from the spleen were shown to express 
somatostatin receptors (14). In the Peyer's patches T and B lymphocytes 
bound fluorescent somatostatin regardless of the T cell surface antigen (pan 
T cells 84%, T helper cells 79%, T suppressor cells 94%) or surface 
immunoglobulin isotype. However, in lymphocytes obtained from the spleen 
approximately 30% of pan T and T helper cells, 52% of T suppressor cells, 
and especially the IgA membrane positive B lymphocytes were shown to bind 
fluorescent somatostatin (14). In addition, 87.5% of the primary human 
lymphoblastic leukaemias express somatostatin binding sites of two different 
affinities, compared with 12.5% of the non-lymphocytic leukaemias (13). A 
Jurkat line of human leukaemic T cells and the U-266 IgE producing 
myeloma cells also bind fluorescent labelled and radio labelled somatostatin 
(15). Scatchard analysis of this competitive binding indicated high and low 
affinity binding sites on both cell lines. The human adult T cell leukaemia cell 
line MT-2, the human T cell line Molt-4F, and the Epstein-Barr virus 
transformed B cell line Isk were investigated by Nakamura et al. (16). The 
MT-2 and Isk cell lines showed large numbers of high affinity somatostatin 
receptors (Kd = 0.64 nM and Kd = 1.1 nM, respectively), while the Molt-4F cell 
line possessed less receptors. No receptors were found on the Jurkat cell 
line, which is in contrast with the observations by Sreedharan et al. (15). 
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Summarizing, somatostatin receptors are expressed on normal as well as 
activated monocytes, lymphocytes, lymphocytic leukaemic cells and lymphoid 
cell lines. Normal granulocytes and red blood cells do not possess 
somatostatin receptors. Normal lymphocytes have low affinity receptors, 
activated lymphocytes and leukaemic cells present somatostatin receptors 
with Kd values in the nanomolar range, which suggests that somatostatin 
receptor expression is related to activation and/or proliferation of these cells. 
The greater proportion of somatostatin receptor positive cells in Peyer's 
patches may be related to continuous antigenic stimulation. The expression 
of two types of somatostatin receptors in human lymphocytic leukaemic cells 
may be the result of malignant transformation. These studies further suggest 
that somatostatin receptors are expressed in cells that originate from the 
lymphocytic and monocytic system without a distinct predilection for 
lymphocyte subsets. 
Somatostatin and somatostatin receptors on lymphoid tissue and the 
role of the peripheral nervous system 
Somatostatin has been identified in all brain regions, the highest levels being 
present in the hypothalamus, in the limbic and mesencephalic regions and in 
the basal ganglia (17,18). Somatostatin is also found in peripheral tissues, 
like the endocrine glands, the gastrointestinal system and the peripheral 
nervous system. In the peripheral nervous system, somatostatin is found in C 
fibres and the small myelinated A-delta fibres. The peptide occurs in the 
synaptosomal fraction of axon terminals and is released in vitro upon 
electrical depolarization in the presence of calcium. The somatostatin content 
of primary afferent nerves is not related to the functional differences in 
sensory function, which suggests that somatostatin may serve as a local 
modulator. It has been suggested that local immune responses may be 
mediated by neuropeptides like somatostatin, which is released into the 
microenvironment by sensory nerves (19). 
Lymphoid organs contain autonomic nerve fibres, which are associated with 
blood vessels, lymphocytes, and macrophages. The presence of 
neurotransmitters in these fibres, directly innervating the parenchymal 
elements of lymphoid organs, establishes an anatomical link with the nervous 
system, which provides a route for the translation of central nervous system 
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activity into signals that can influence the functions of specific cells in the 
immune system. Noradrenergic innervation of lymphoid tissue is particularly 
related to the zones of T lymphocytes and thymocytes (20). Somatostatin 
receptors have been detected in mouse spleen and Peyer's patches (14). 
Canine mesenteric lymph nodes express calcitonin gene related peptide and 
substance P receptors but no receptors for substance K, somatostatin and 
bombesin (21). In contrast, human gut associated lymphoid tissues (palatine 
tonsils, ileal Peyer's patches, vermiform appendix, and colonic solitary 
lymphatic follicles) present somatostatin receptors as detected by in vitro 
receptor autoradiography using [1251-Tyr'j-octreotide, somatostatin 14 and 
somatostatin 28 (22). These receptors are preferentially located in the 
germinal centres. The luminal parts of the centres are more strongly labelled 
than the basal parts. This observation suggests that the expression of 
somatostatin receptors is related to the proliferative state of lymphoid cells, 
and that the action of somatostatin takes place in activated lymphoid tissue. 
Germinal centres are sites of intensive B cell lymphoblast proliferation. The 
receptors found in these lymphoid tissues probably correspond best to a 
somatostatin receptor which binds with high affinity to somatostatin 14, 
somatostatin 28, as well as octreotide (22). 
Messenger ribonucleic acid (mRNA) encoding for somatostatin has been 
found in the spleen and thymus of male rats, and in the spleen, thymus and 
bursa of Fabricius of chickens (23,24). The somatostatin concentration in rat 
thymus was higher than in rat spleen. The somatostatin concentration in the 
bursa of Fabricius of the chicken was also higher than in the spleen. In the 
spleen the somatostatin positive cells were located especially in clusters in 
the white pulp, and more dispersed in the red pulp. The somatostatin positive 
cells in the thymus were located in the medulla and around the 
corticomedullary junction. Large clusters of positive cells were observed in 
the medullary portion of the nodules of the bursa of Fabricius. In the rat, 
dispersed spleen B lymphocytes were somatostatin positive, while in the 
thymus a small population of thymocytes contained somatostatin (23). 
Summarizing, peptidergic neurons may contain somatostatin, while 
somatostatin receptors can be found in normal lymphoid tissue. The 
anatomical link between the nervous system and lymphoid tissue suggests 
that the nervous system may directly modulate the immune system via 
somatostatin receptors. In addition, the presence of somatostatin mRNA in 
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lymphoid tissue indicates that lymphocytes are capable of synthesizing 
somatostatin, which may act as an autocrine or paracrine factor. 
The modulation of immune functions by somatostatin 
Somatostatin might modulate the immune response by a variety of 
mechanisms. These include modification of immunoglobulin secretion by 
plasma cells, suppression or enhancement of lymphocyte proliferation, 
cytotoxicity and changes in cytokine production, release of mediators by 
basophils, recruitment of eosinophils, and changes in macrophage function. 
Somatostatin and immunoglobulin production 
The murine IgA secreting plasmacytoma cell line MOPC-315 was found to 
bind fluorescent somatostatin as well as 125 1 labelled somatostatin (25). This 
plasmacytoma cell line presented a high density of high affinity receptors 
(Kd = 1.6 nM). In contrast, another plasmacytoma cell line, J-558, expressed 
no somatostatin receptors. Somatostatin at a concentration of 10 nM 
inhibited the IgA synthesis by MOPC-315 Significantly by 50%, whHe 1 pM of 
the peptide exerted a stimulatory action (+ 50%). Somatostatin inhibited the 
synthesis of IgA and IgM by lymphocytes prepared from Peyer's patches, 
mesenteric lymph nodes and the spleen (26). The synthesis of IgA was more 
inhibited (20-50%) than that of IgM (10-30%) (14,26). 
All three immunoglobulin producing B lymphocyte isotypes in Peyer's patches 
bind somatostatin in a similar fashion (14). So, the inhibition of 
immunoglobulin production by somatostatin cannot be explained on the basis 
of binding to distinct subsets of B lymphocytes. Somatostatin inhibits all three 
classes of immunoglobulin production by unstimulated as well as pokeweed 
mitogen stimulated human peripheral blood lymphocytes. The highest 
percentage of inhibition was observed in the synthesis of IgG and IgA (27). 
Summarizing, plasma cells express somatostatin receptors. Somatostatin 
inhibits immunoglobulin synthesis, and affects in particular the production of 
IgA. In view of this, somatostatin might exert a local regulatory influence on 
IgA synthesis by the gut. 
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The influence of somatostatin on lymphoid cell proliferation 
Somatostatin analogues have direct antiproliferative effects on a variety of 
experimental human solid tumour cell lines (9). These inhibitory effects seem 
to be mediated via specific somatostatin receptors located on the tumour 
cells. Antiproliferative effects were reported on leukaemia cell lines and 
activated white blood cells as well. Plasma obtained from a patient with a 
somatostatinoma was shown to inhibit colony formation and tritiated 
thymidine incorporation by T lymphocytes (28). The somatostatin produced 
by this tumour was identified as somatostatin 14 and was suggested to have 
immunoregulatory properties. The influence of somatostatin on lymphocyte 
and lymphoid cell line proliferation was extensively studied, using cells 
originating from different species (Table 1). In most investigations (10 out of 
16) somatostatin showed a concentration dependent modulation of the 
spontaneous and lectin induced proliferative response of lymphocytes and 
cell lines. At concentrations of 0.01-1 nM an inhibitory effect on the 
proliferation was observed. In three reports a biphasic proliferative response 
of lymphoid cells was observed. This response was antimitotic at low 
somatostatin concentrations, but became stimulatory at concentrations above 
100 nM. At present the pathophysiological meaning of these biphasic 
responses is not known. Different somatostatin receptor subsets may be 
responsible for this phenomenon. We postulate that low numbers of high 
affinity receptors induce an inhibitory and high numbers of low affinity 
receptors mediate a stimulatory proliferative response. In other words, direct 
and indirect effects of somatostatin may have opposite results. 
An interesting observation was the inhibition of lymphocyte proliferation after 
the in vivo administration of somatostatin and the powerful somatostatin 
analogue BIM-23014c (29). Mouse lymphocytes from the spleen and Peyer's 
patches demonstrated a reduction of [3H)-thymidine incorporation by 50% 
and 65%, respectively. After exposure to somatostatin in vivo, and thereafter 
in vitro as well, a further reduction in the proliferative response was 
demonstrated by 85% and 93%, respectively. The higher numbers of 
somatostatin receptors on Peyer's patches might possibly have caused the 
difference in inhibition of proliferation between lymphocytes from Peyer's 
patches and lymphocytes from the spleen (29). 
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0' 
Somatostatin concentration (in nM) Il Cells/cell lines Inhibition Stimulation References 
III 
" IgA secreting plasmacytoma MOPC~315 0.001 - 1 >100 25 Q 
SO 
eenA* stimulated murine lymphocytes >0.001 26,29-31 (J) 
(peyer's patches, mesenteric lymph nodes, spleen) § 
:3 
Human lamina propria lymphocytes " none none 27,32 
" (J) Human peripheral lymphocytes 0.01 - 1000 III 
" PHA* stimulated human T lymphocytes 0.0001 - 1 33 Q 
'" Molt-4 Iymphoblasts 0.0001 - 0.1 >100 III (J) 
GenA* stimulated rat thymocytes 0.01 - 100 34 :3 III 
Spontaneous proliferation of mouse spleen lymphocytes 1 - 10 >100 35 
.g-
o 
iii 
Human thymocytes, guinea pig T lymphocytes, rat B lymphocytes none none 36 ?f 
Rabbit spleen lymphocytes none 100 37 
en 
'0 
Gi 
ConA"'/LPS* stimulated mouse lymph node lymphocytes none none 38 :3 
PHA*/LPS* stimulated rainbow trout lymphocytes 0.1 - 1000 39 
Guinea pig spleen lymphocytes <0.001 - 1000 40 
Mercurous chloride stimulated peripheral T lymphocytes 1 - 1000 41,42 
* GonA = concanavalin A; PHA = phytohaemagglutinin; LPS = lipopolysaccharide 
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The influence of somatostatin on the activation of isolated mononuclear cells, 
obtained from the human intestinal mucosa, were compared with peripheral 
blood lymphocytes (27). The amount of somatostatin required for a 50% 
inhibition of the phytohaemagglutinin induced expression of the interleukin 2 
receptor was 100 to 1000 times lower in the intestinal mucosa population 
than in the peripheral blood lymphocytes. This somatostatin effect occurred 
early after mitogen stimulation, while lymphocytes tended to be partially 
refractory in the late phase of activation (27,40). The affinity of the 
somatostatin receptor on intestinal mucosa lymphocytes was approximately 
500 times higher than on peripheral blood lymphocytes (Kd = 2.1 nM vs. 
Kd = 910 nM). This difference in affinity suggests the existence of two 
subtypes of somatostatin receptors, namely a low affinity receptor in resting 
lymphocytes and a high affinity receptor in activated lymphocytes. Inhibition 
of proliferation by somatostatin was less in peripheral blood lymphocytes 
than in lamina propria lymphocytes, an effect that might be explained by an 
interleukin independent alternative pathway (27). 
The effects of somatostatin in many tissues have been related to the 
inhibition of cyclic adenosine monophosphate (cAMP) production (43-47). 
Somatostatin inhibits adenylate cyclase by a membrane receptor coupled to 
activation of an adenylate cyclase inhibiting G protein complex. Somatostatin 
in physiological doses does not influence the adenylate cyclase activity in 
lymphocytes and leukaemic cells but an inhibition in cAMP generation was 
observed in response to higher concentrations of somatostatin (48). These 
investigations suggest that the lymphocyte modulating effects of somatostatin 
cannot be ascribed to a decrease in intracellular cAMP level. However, in 
another study it was shown that the somatostatin analogue RC-102-2H 
decreases cAMP production in spleen lymphocytes (49). 
Somatostatin receptors have been shown in many tissues to be linked to G 
proteins (50-52). Guanosine triphosphate (GTP) can reduce agonist binding 
to somatostatin receptors by uncoupling G proteins from the receptors, 
thereby converting the receptors to a low affinity state for agonists (50-52). 
GTP is able to inhibit the binding of [, 25 I-Tyr3 ]-octreotide in the germinal 
centres of gut associated lymphoid tissues. Summarizing, most studies so far 
suggest that the somatostatin receptor in lymphoid tissue is coupled to a G 
protein, representing a true membrane somatostatin receptor. 
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The influence of somatostatin on cytotoxicity and cytokine production. 
In vivo administration of somatostatin and the somatostatin analogue BIM-
23014c affects the natural killer activity in vitro of lymphocytes from the 
mouse spleen and Peyer's patches (29). The inhibition of the killer activity 
was significantly higher in lymphocytes prepared from Peyer's patches than 
from the spleen. Krco et al. observed no influence of somatostatin on 
lymphocyte proliferation. However, at nanomolar concentrations an inhibitory 
effect was found on the mixed lymphocyte reaction (38). Somatostatin had 
no effect on the cytotoxic response against K-562 and CaCo-2 colon 
carcinoma target cells (53). 
Apart from the influence of somatostatin on cellular cytotoxicity, the influence 
of somatostatin on the production of cytotoxic cytokines was also studied 
(54). The destruction of mitomycin C treated murine L-929 cells, induced by 
Iymphotoxin and tumour necrosis factor, was enhanced by somatostatin 14 
and especially by somatostatin 28. The observed cytotoxic effects in these 
experiments significantly increased over a narrow concentration range of 
somatostatin. The authors hypothesized that somatostatin promotes cell 
injury by inhibiting the repair mechanism of the affected cells. 
Somatostatin and somatostatin analogues inhibit the secretion of hormones 
produced by normal endocrine cells as well as by neuroendocrine tumours. 
The release of both Iymphotoxin and tumour necrosis factor by peripheral 
mononuclear cells was significantly decreased by 10-100 nM somatostatin 
(54). In another study it was shown that somatostatin and octreotide inhibit 
the secretion of interferon y but not interferon ex by mononuclear cells at 
concentrations higher than 1 11M (55). It seems unlikely that this effect occurs 
at physiological conditions because of the very high somatostatin 
concentration applied in these experiments, while somatostatin is also unable 
to decrease t~e interferon production induced by natural antigens (53). In 
contrast, somatostatin (10 nM) was shown to inhibit the mitogen induced 
production of interferon y by schistosoma induced granulomas and splenic T 
lymphocytes by as much as 75% (56,57). This suggests a regulatory function 
of somatostatin in the granuloma response. 
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Summarizing, controversial reports have been published concerning a 
possible enhancement of cytotoxicity by somatostatin. Modification of 
cytokine production by somatostatin or somatostatin analogues may be a 
regulatory factor in the inflammatory response. 
The influence of somatostatin on basophils and eosinophils 
Somatostatin has been reported to suppress the antihuman myeloma IgE 
induced histamine and leukotriene release by human basophils, mouse bone 
marrow derived mast cells and rat leukaemic basophils at pico- to nanomolar 
concentrations (58,59). The rat leukaemic basophils released a somatostatin-
like peptide, which suggests a role in the feedback regulation of basophil 
activity (60). In contrast to these results somatostatin 14 and other 
somatostatin analogues at much higher concentrations enhanced histamine 
release by mast cells (61). Such a histamine releasing effect of high 
concentrations (5 JlM) of somatostatin 14 and somatostatin 28 was also 
described in white blood cells prepared from patients with allergic 
hyperreactivity (62). The pattern of histamine release suggests a biphasic 
effect with inhibition in the lower (nM) concentrations of somatostatin, as also 
described in the proliferation experiments mentioned above. 
The hypereosinophilia in rat which can be induced by administration of 
cyclophosphamide or sephadex 48 hours before immunization with complete 
Freund's adjuvant, is significantly decreased by the somatostatin analogue 
BIM-23014c (63,64). Somatostatin has been shown to enhance the formation 
of human leucocyte migration inhibiting factor (65). This activity may account 
in part for its depressive effect on eosinophils. 
Summarizing, somatostatin may be involved in hyperreactivity by regulation 
of mediator release by basophils and the recruitment of eosinophils. At low 
somatostatin concentrations an inhibitory effect was observed. 
Somatostatin and macrophages 
Circulating monocytes present low numbers of somatostatin receptors (12). 
Macrophages are able to destroy tumour cells. The tumoricidal capacity is 
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greatly enhanced after exposure to recombinant interferon. Peck showed that 
this effect was abolished in the presence of somatostatin (66). 
Concentrations of somatostatin needed to obtain this effect were above 1 nM 
with a maximal concentration at 10 11M. The author hypothesized that these 
high concentrations of somatostatin are needed because of protease activity 
in the culture medium and the rapid degradation of the peptide. In this study, 
the inhibitory effects of somatostatin could be reversed by substance P (66). 
In another experiment, the chemotactic activity of monocytes was 
investigated (67). Chemotaxis was enhanced by octreotide but not by 
somatostatin 14. Patients with acromegaly, who were chronically treated with 
octreotide, showed an impaired chemotactic response, suggesting down 
regulation of somatostatin receptors (67). Octreotide also increases the 
phagocytic activity of monocytes from patients with cirrhosis of the liver (68). 
Somatostatin at concentrations of 1-100 nM stimulated the lysis and inhibited 
the incorporation of IgG coated 51Cr labelled sheep red blood cells by rat 
peritoneal macrophages (69). Higher concentrations resulted in an opposite 
effect, which again suggests a biphasic effect. 
Summarizing, somatostatin and somatostatin analogues influence 
macrophage function. An interesting phenomenon is the difference between 
octreotide and somatostatin 14 affecting the chemotactic response, which 
suggests the presence of different receptor subtypes on monocytes. 
Summary 
Somatostatin and somatostatin receptors have been demonstrated in non-
pathological and pathological lymphoid tissue and may play a regulatory, 
mostly inhibitory, role in the immune response. Somatostatin is produced by 
lymphocytes and monocytes which suggests an autocrine or paracrine 
regulatory role, but somatostatin may be released as well by nerve endings. 
It can therefore be hypothesized that apart from a role of somatostatin in 
local immunomodulation of cells belonging to the immune system, a second 
pathway exists in which this peptide exerts its effects via neuroendocrine 
modulation of the immune response. This might represent a direct regulatory 
relation between the nervous and the immune system. 
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SOMATOSTATIN RECEPTOR AUTORADIOGRAPHY 
IN MALIGNANT LYMPHOMAS 
Somatostatin receptor autoradiography in malignant lymphomas 
Abstract 
A wide variety of primary and metastatic human neoplasms express 
somatostatin receptors. We evaluated the somatostatin receptor status of 
malignant lymphomas that had been surgically removed from 31 patients. 
Somatostatin receptors were visualized by in vitro somatostatin receptor 
autoradiography with the somatostatin analogue [, 25I-Tyr3]-octreotide as 
radioligand. Of eleven low grade malignancy B cell non-Hodgkin's lymphomas, 
ten were somatostatin receptor positive, with a high receptor density restricted 
to the neoplastic follicles. All of the eight intermediate grade non-Hodgkin's 
lymphomas were somatostatin receptor positive. Seven out often non Hodgkin's 
lymphomas of high grade malignancy were somatostatin receptor positive, often 
with a high density of receptors. One T cell lymphoma and one Hodgkin's 
lymphoma were also positive. Somatostatin receptors were of high affinity 
(K, = 1.2 nM) and specific for bioactive somatostatin analogues. 
Introduction 
Somatostatin receptors have been observed not only in normal somatostatin 
target tissues, but also in several types of human cancer (1). The receptors 
occur in most neuroendocrine neoplasms (2,3), but also in tumours of the 
central nervous system (4,5), breast (6,7) and lung (8). The presence of 
somatostatin receptors may be, for certain tumour types, a pathobiochemical 
marker of predictive value for the efficacy of somatostatin analogue therapy 
(3,9), while it may also be of prognostic significance (10). Moreover, these 
somatostatin receptors can be visualized in vivo with gamma camera scanning 
techniques, enabling the precise localization of primary and metastatic tumour 
sites (11-13). 
It has been known for several years that the lymphopoietic system may be a 
target for somatostatin. Indeed, somatostatin affects various lymphocytic 
functions in non-neoplastic and neoplastic murine or human lymphoid cells in 
vitro (14,15). For instance, somatostatin has been shown to inhibit lymphocyte 
proliferation (16-20), forskolin stimulated adenylate cyclase (21,22), as well as 
IgA synthesis in lymphocytes (20). In addition, somatostatin antagonizes actions 
of vasoactive intestinal peptide and substance P in lymphoid tissues (14). These 
effects may be mediated via specific receptors, since somatostatin receptors 
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have been found in several types of non-neoplastic lymphocytes in mice (23), 
in various lymphoid cell lines, such as the Jurkat line of human leukaemic T 
cells, in IgE producing U-266 myeloma cells (24) and in the MT-2, Isk and 
Molt-4F cell lines (25). Peripheral resting human lymphocytes also possess 
somatostatin receptors, albeit of lower affinity (26). The biochemical processes 
mediated by somatostatin through its receptors are likely to be the molecular 
basis for a wide range of somatostatin actions affecting the immune system 
(14,15,27,28). 
The aim of the present study was to investigate, using in vitro receptor 
autoradiography, whether human malignant lymphomas, mostly non-Hodgkin's 
lymphomas, express somatostatin receptors. 
Materials and methods 
Patients 
Thirty-four surgical biopsies from 31 patients with lymphoma were obtained from 
the Institutes of Pathology of Berne and Lucerne, Switzerland, and from the 
Department of Internal Medicine, Erasmus University Hospital Rotterdam, the 
Netherlands. One part of the material was fixed in neutral buffered formalin and 
used for histopathological and immunohistochemical study. Another part was 
frozen and used for somatostatin receptor autoradiography. Tumours were 
classified in accordance with either the International Working Formulation 
system (29) or the Kiel classification (30). Low grade lymphoma tissue was 
obtained from 12 patients (13 samples), lymphomas of intermediate grade from 
8 patients (9 samples), and high grade lymphomas from 10 patients (11 
samples). One sample from a patient with Hodgkin's disease was included. 
Non-neoplastic lymphoid tissues, including lymph nodes with minor 
histopathological changes and lymph nodes bearing non-lymphomatous 
metastatic tumours, were also examined. 
Somatostatin receptor autoradiography 
Receptor autoradiography was done on cryostat sections (10 11m and 20 11m) 
of the tumour samples, using [, 25 I-Tyr3]-octreotide as radioligand, as described 
previously (2,3). Briefly, the sections were mounted on pre-cleaned microscope 
slides and stored at -20°C for at least 3 days to improve adhesion of tissue to 
the slide. Sections were then incubated for 2 hours at room temperature in the 
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presence of the iodinated ligand (0.15-0.30 x 106 dpmlml, about 80-160 pM). 
The incubation solution was 170 mM Tris-HCI buffer, pH 7.4, containing 1 % 
bovine serum albumin (BSA), bacitracin (40 ;tg/ml), and MgCl, (5 mM) to inhibit 
endogenous proteases. Non-specific binding was determined by adding 1 ;tM 
solution of the unlabelled peptide [Tyr'J-octreotide. Incubated sections were 
washed twice for 5 minutes in cold incubation buffer containing 0.25% BSA, 
then in buffer alone, and dried quickly. Compared to previous procedures of 
washing in distilled water (4,5,7), the present method of washing in buffer 
resulted in a much better histological preservation of the lymphoid tissues. 
Finally, the sections were apposed to 'H labelled ultrafilms (Cambridge 
Research, Nussdorf, Germany) and exposed for one week in X-ray cassettes. 
In selected cases displacement experiments were done in successive sections 
of a tumour by increasing the concentration of various biologically active or 
inactive peptides (3). In addition, saturation experiments using increasing 
concentrations of [125 1_ Tyr'J-octreotide were performed on tumour tissue sections 
(3). The autoradiograms were quantified using a computer assisted image 
processing system (3). Tissue standards for iodinated compounds (Amersham, 
Aylesbury, United Kingdom) were used for this purpose. A tumour was defined 
as somatostatin receptor positive when the optical density measured over a 
tumour area in the 'total binding' section was at least twice the optical density 
of the 'non-specific' binding section. 
Immunohistochemistry 
Paraffin sections, 5-7 flm thick, were mounted on glass slides coated with 
pOlyvinyl-acetate glue, de-paraffinized, hydrated and, if required, treated with 
0.1 % trypsin for 10 minutes at 37°C. Sections were then washed and incubated 
for 18-24 hours at room temperature with specific antibodies directed against 
CD antigens of lymphocytes: (a) lymphoid cells: CD45 (antibody LC); (b) B 
lymphocytes: CD20 and 45R (antibodies L26, 4KB5, KiN3, MB1); (c) T 
lymphocytes: CD4, CD5 and 45RO (antibodies T1, T4, UCHL 1); (d) CD30 
(antibody: Ber-H2); and (e) immunoglobulin light chains (antibodies kappa, 
lambda). Incubations without specific antibodies served as negative controls. 
The avidin-biotin-peroxidase complex technique was used (31). 
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Results 
Table 1 describes the results of the somatostatin receptor determination in the 
three different groups of non-Hodgkin's lymphoma. In lymphomas of low grade 
malignancy 11 out of 12 cases (92%) were somatostatin receptor positive. All 
lymphomas of intermediate grade malignancy were positive. Among ten 
lymphomas of high grade malignancy, seven were positive for somatostatin 
receptors (70%). In addition, a tissue sample of Hodgkin's disease with nodular 
sclerosis was somatostatin receptor positive. Overall, a low to moderate density 
of receptors was observed, but several samples, particularly lymphomas of high 
grade malignancy, expressed a high somatostatin receptor density. 
Figure 1 shows a low grade follicular lymphoma, in which the follicles were 
preferentially and heavily labelled, whereas the surrounding cells and 
interfollicular cells had a low receptor density, or no demonstrable somatostatin 
receptors. As seen in Figure 2, the follicles displaying somatostatin receptors 
in this tumour sample contained mainly B lymphoid cells, with monotypic 
cytoplasmic immunoglobulin (not shown). Figure 3 shows an example of a high 
grade lymphoma with diffusely distributed somatostatin receptors. The 
somatostatin receptors in lymphoma tissues had high affinity for and were 
specific to somatostatin analogues, since unrelated peptides such as luteinizing 
hormone-releasing hormone did not influence the radioligand binding (Figure 4). 
Scatchard analysis of data obtained in saturation experiments using 
[ '251_ Tyr'J-octreotide gave a dissociation constant (Kd ) of 1.2 nM in a B cell 
non-Hodgkin's malignant lymphoma. For comparison and control, non-
lymphomatous lymphoid tissues, such as lymph nodes without neoplastic 
changes, lymph nodes with foci of non-lymphomatous metastatic tumours, or 
gastrointestinal lymphoid tissues, were also investigated. Whereas small 
lymphocytes and primary lymphatic follicles were usually somatostatin receptor 
negative, the central part of larger, non-neoplastic germinal centres was 
somatostatin receptor positive. This suggests that lymphoid cells expressing 
somatostatin receptors are frequently in a proliferative and/or stimulated stage. 
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:3 
Classification t Autoradiography:!: '" Patient Sex* Age Therapy Site of lymphoma C 
'" Low grade malignancy iii S-
M 38 Small lymphocytic Leg + Diffuse OJ 
() 
<D 
2 F 52 Follicular, predominantly small cleaved cell Thorax +++ Follicular 1:J C 
.., 
3 M 57 Follicular, predominantly small cleaved cell Neck ++ Follicular 
'" c:: 
4 M 54 Follicular, mixed small cleaved 1 large cell Chemotherapy Groin, axilla + Follicular C OJ 
5 F 43 Follicular, predominantly small cleaved cell Neck + Follicular ~ 
to 
6 M 75 Follicular, predominantly small cleaved cell Neck + Follicular OJ 1:J ;:,-
M 67 Follicular, predominantly small cleaved cell Neck Follicular '<: 7 + 
Follicular, mixed small cleaved 1 large cell S· 
:3 
8 F 40 Follicular, predominantly small cleaved cell Groin '" + cZ' 
" 9 M 60 Follicular, mixed small cleaved 1 large cell Supraclavicular + 
'" 
" Diffuse, mixed small cleaved 1 large cell ~~ 
10 F 79 Follicular, mixed small cleaved 1 large cell Neck + Diffuse :3 1:J 
Diffuse, mixed small cleaved 1 large cell ;:,-0 
:3 
11 M 78 Follicular, mixed small cleaved 1 large cell Upper arm '" 
'" Diffuse, mixed small cleaved 1 large cell 
12 M 77 T cell, angioimmunoblastic§ Supraclavicular + 
Continued .. 
en 
~ 
Table 1. (cont.) 
Patient Sex" Age Classification t 
Intermediate grade malignancy 
13 F 45 Diffuse, mixed small cleaved IIarge cell 
Diffuse, large cell: cleaved or noncleaved 
14 M 63 Diffuse, large cell: cleaved or noncleaved 
15 F 72 Diffuse, large cell: cleaved or noncleaved 
16 M 29 Diffuse, mixed small cleaved IIarge cell 
17 F 62 Diffuse, mixed small cleaved 1 large cell 
18 F 90 Diffuse, mixed small cleaved 1 large cell 
19 M 63 Follicular, predominantly large cell 
Diffuse, large cell: cleaved or noncleaved 
20 M 62 Diffuse, mixed small cleaved IIarge cell 
Therapy Site of lymphoma 
Chemotherapy Lymph node 
Supraclavicular 
Chemotherapy Axilla 
Liver hilus 
Radiotherapy Axilla 
Tonsil, palatinum 
Abdomen 
Neck 
Autoradiography:): 
+++ Diffuse 
+++ Diffuse 
++ Diffuse 
+ Diffuse 
+ Diffuse 
+ Diffuse 
+ 
+ Diffuse 
Continued .. 
9 
~ (j) 
.., 
o 
~ 
'" "-' 
Table 1. (cont.) 
Patient Sex* Age Classification t Therapy Site of lymphoma Autoradiography+ 
High grade malignancy 
21 F 30 Diffuse, large cell: cleaved or noncleaved Small intestine +++ Diffuse 
Diffuse, large cell immunoblastic 
22 M 56 B cell, centroblastic§ Chemotherapy Kidney ++ 
Radiotherapy 
23 M 13 Small non-cleaved cell: Burkitt's Supraclavicular ++ 
24 F 77 Diffuse, mixed small cleaved 1 large cell Neck ++ 
Diffuse, large cell immunoblastic 
25 M 81 B cell, centroblastic§ Neck + 
26 F 37 Diffuse, large cell immunoblastic Chemotherapy Neck + 
27 F 76 B cell, centroblastic§ Skin + Diffuse 
28 F 62 B cell, centroblastic§ Axilla 
29 F 5 Small non-cleaved cell: Burkitt's Small intestine 
30 M 3 Small non-cleaved cell: Burkitt's Ileum 
M = male; F = female 
International Working Formulation system 
+++ = high density of somatostatin receptors; ++ = moderate density of somatostatin receptors; + = low density of somatostatin 
receptors; - = no somatostatin receptors detectable 
Kiel classification 
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Figure 1. Visualization of somatostatin 
receptors in a low grade B cell lymphoma 
(patient 2, see Table 1). (A) Haematoxylin~eosin 
stained section. (8) Autoradiogram showing 
total binding of C251-Tyr31-octreotide. (C) 
Autoradiogram showing non-specific binding of 
C251-Tyr3]-octreotide in the presence of 1 IlM 
[Tyr]-octreotide. Bar represents 1 mrn. 
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Figure 2. Low grade B cell lymphoma (patient 
2, see Table 1). (A) Immunohistochemical 
staining for B cell type lymphoid cells. (8) 
Somatostatin distribution. Bars represent 1 mm. 
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Discussion 
Figure 3. Somatostatin receptors in a high 
grade non-Hodgkin's lymphoma (patient 22, see 
Table 1). (A) Haematoxylin-eosin stained 
section. (8) Autoradiogram showing total 
.,,' binding of [1251_Tyr3]_octreotide. (C) 
Autoradiogram showing non-specific binding of 
C25 /-Tyr3]-octreotide in the presence of 1 11M 
[Tyr3J-octreotide. Bar represents 1 mm. 
This study describes the presence of somatostatin receptors in most of the 
non-Hodgkin's human lymphoma tissues examined in vitro by receptor 
autoradiographic techniques. These receptors have high affinity for and are 
pharmacologically specific to somatostatin. They have been found in lymphomas 
of low, intermediate and high grade malignancy. 
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Figure 4. Somatostatin receptors in non-Hodgkin's lymphoma of intermediate grade (patient 13, see 
Table 1). Displacement curve of C25 1-Tyr3]-octreotide in tumour tissue sections incubated with 
radioligand (30,000 counts per minutel100 ).tI) and increasing concentrations of unlabelled [Tyr31-
octreotide (e) or 100 nM luteinizing hormone-releasing hormone (.6.). 
Various types of cells may express somatostatin receptors, depending on the 
lymphoma type and grade of malignancy. For instance, in low grade B cell 
lymphomas with a follicular pattern, the somatostatin receptor distribution was 
clearly non-homogeneous. The follicular structures consisted mainly of B cells 
rich in somatostatin receptors, whereas the interfollicular areas with many cells 
of the T phenotype displayed fewer somatostatin receptors. However, one high 
grade T cell lymphoma in the present series was also clearly positive for 
somatostatin receptors. Thus, neoplastic Band T lymphocytes have the 
potential of expressing somatostatin receptors under certain conditions .. 1 n most 
high grade lymphomas of the B cell type, the relatively homogeneous 
distribution of the somatostatin receptors reflected the diffuse histopathological 
pattern of these tumours. 
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The relatively frequent occurrence in high grade lymphomas of a moderate to 
high density of somatostatin receptors contrasts partially with previous 
somatostatin receptor studies of other neoplasms, such as glial tumours (5,32), 
or carcinoids (3). The expression of somatostatin receptors in these tumours 
was inversely related to their differentiation grade; most neuroendocrine tumours 
that displayed somatostatin receptors were usually well differentiated. 
Few lymphomas examined in vitro lacked somatostatin receptors. Since these 
were mainly tumours with a high malignancy grade, the absence of somatostatin 
receptors may relate to analogous observations made in other tumour types 
(3,5,9). However, it may be due to other causes: (a) accidental causes, 
inadequate handling of materials (e.g. thawing of tissues before 
autoradiography), or (b) previous chemo- or radiotherapy. However, none of the 
somatostatin receptor negative tumour samples were acquired from patients 
treated by irradiation or given cytotoxic drugs. Moreover, the tumours of six 
patients given either chemo- or radiotherapy, or both, displayed somatostatin 
receptors. 
The significance of somatostatin receptors in human malignant lymphoma is 
unknown. Some links between somatostatin, somatostatin receptors and 
characteristics of neoplastic lymphoid cells have been demonstrated in animals 
and humans. Studies in murine and human lymphoid cells and tissues have 
described various cellular actions of somatostatin, such as inhibition of cell 
proliferation (16-18,20), of IgA synthesis (20) and of forskolin stimulated 
adenylate cyclase production (21,22), and antagonism of the actions of 
vasoactive intestinal peptide and substance P in lymphatic tissues (14). It can 
therefore be expected that lymphocytes treated with somatostatin will undergo 
changes in their immunomodulatory characteristics (14,15,27). Since these 
actions are mediated by specific somatostatin receptors on the cell membrane 
(22,24,27), it can be speculated that similar actions of somatostatin might occur 
in human malignant lymphomas via the somatostatin receptors described. The 
potential therapeutic relevance of direct effects of somatostatin on malignant 
lymphoma could be evaluated using somatostatin analogues such as octreotide. 
In addition, indirect effects, i.e. more general consequences of somatostatin 
analogues on the normal immune system, should be considered (27,28). 
The present study shows that somatostatin receptors may represent a general 
pathobiochemical marker for malignant lymphomas in vitro. Somatostatin 
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receptors may have useful diagnostic functions in vivo. We have already shown 
that several somatostatin receptor containing human tumours can be visualized 
in vivo by means of gamma camera scintigraphy after injection of 123 1_ or 111ln 
labelled octreotide analogues (11,12,33). The in vivo labelling may be 
diagnostically helpful for a more sensitive staging of disease, and might be 
instrumental in improving the choice of therapy for various stages of disease in 
patients with malignant lymphomas. 
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CHAPTER 3.2 
SOMATOSTATIN RECEPTOR SCINTIGRAPHY 
IN MALIGNANT LYMPHOMAS 
Somatostatin receptor scintigraphy in malignant lymphomas 
Abstract 
Normal as well as activated lymphocytes, macro phages and leukaemic cells 
have previously been shown by radio receptor analysis to express receptors 
for somatostatin. An '''In labelled somatostatin analogue was already used 
successfully in the visualization of a variety of neuroendocrine tumours. We 
investigated ten consecutive patients with malignant lymphomas (Hodgkin's 
disease and non-Hodgkin's lymphomas). In all patients the lymphoma 
deposits could be visualized with somatostatin receptor imaging. In four 
patients additional tumour localizations were observed as compared to the 
results of combined physical and radiological examinations (computed 
tomography and ultrasonography). In three cases tissue biopsies were taken 
and confirmed by autoradiography to be somatostatin receptor positive. 
These data indicate that malignant lymphomas may express somatostatin 
receptors in sufficient numbers and density to allow in vivo tumour 
visualization with a radiolabelled somatostatin analogue. 
Introduction 
In the literature several reports have been published concerning the presence 
of somatostatin receptors on a variety of white blood cells (1-3). Receptors 
for somatostatin were also identified on human leukaemic cells in 
lymphoblastic leukaemia and in non-lymphocytic leukaemia. Most 
lymphocytic leukaemia cells were found to express two classes of binding 
sites, high and low affinity receptors, in contrast to the single class low 
affinity receptors in activated lymphocytes (4). Somatostatin exerts in certain 
conditions an inhibitory effect on lymphocyte proliferation, immunoglobulin 
synthesis as well as on the production of growth factors (5-11). In previous 
studies we have shown that the localization of a number of somatostatin 
receptor positive endocrine tumours like carcinoids, endocrine pancreatic 
tumours and paragangliomas, can be visualized after the intravenous 
application of a radiolabelled somatostatin analogue (12-16). 
In the present study we examined somatostatin receptor imaging of tumour 
tissue in vivo in patients with Hodgkin's disease and non-Hodgkin's 
lymphomas. 
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Materials and methods 
Patients 
Ten patients with non-Hodgkin's lymphoma or Hodgkin's disease were 
included. The major pathological and clinical features of these cases are 
listed in Table 1. Patients were classified according to both the International 
Working Formulation system (17), and the Kiel classification (18). 
Somatostatin receptor scintigraphy 
For in vivo somatostatin receptor imaging [DTPA-D-Phe ']-octreotide was 
obtained from Sandoz (Basel, Switzerland). The preparation of ['11ln_DTPA_ 
D-Phe' ]-octreotide, the dose administered (200-250 MBq), the technique of 
scintigraphy with the gamma camera, as well as with single photon emission 
computed tomography (SPECT) have been described previously (12,16). The 
ideal imaging time was 24 hours after administration. The scintigram was 
repeated at 48 hours in cases with radiopharmaceutical radioactivity in the 
intestinal tract. The scintigrams were scored by two investigators from the 
Department of Nuclear Medicine, Erasmus University Hospital Rotterdam, the 
Netherlands, independently of the evaluation of the clinical, pathological, 
radiological and haematological parameters. In normal individuals 
physiological accumulation of radioactivity is seen 24 hours after 
administration of ['11ln_DTPA_D_Phe' ]-octreotide in the pituitary and thyroid 
gland, the liver, spleen, kidneys, as well as the urinary bladder. Radioactivity 
at other sites was considered to be suspect for the presence of somatostatin 
receptor positive tissue. Tumour localization in the liver was considered to be 
present in case of heterogenous hepatic accumulation of the radioligand. 
Somatostatin receptor autoradiography 
The presence of somatostatin receptors was investigated by autoradiography 
on 10 11m thick frozen sections of lymphoma tissue, as described in detail for 
various types of tumorous and non-tumorous tissues (19-22). [1251_Tyr3]_ 
octreotide was used as radioligand, as it had been shown previously to 
specifically label somatostatin receptors (19). 
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Results 
In Table 1 the results of the comparison between tumour localizations found 
with initial radiological investigations (chest X-ray, computed tomography 
(CT) and ultrasonography) and 1111n labelled somatostatin analogue scanning 
are presented in seven patients with untreated lymphomas and three patients 
(patient 4, 5 and 6) with recurrent lymphomas of different types. 
In patient 1 mediastinal lymphomas, which had been missed on the chest X-
ray and CT scan, were apparent with 1111n labelled somatostatin analogue 
scanning (Figure 1). On repeated evaluation of the CT scan mediastinal 
localizations of lymphoma were seen and the assessment 'negative' was 
revised. The lalter metastasis of lymphoma tissue were later confirmed at 
autopsy. Autoradiographic investigation (Figure 2) also confirmed the 
presence of specific somatostatin receptors in the lymphoma tissue of this 
patient, mainly in the central lymphoblastic areas of the lymphoma. In patient 
2 the deep ulcerative lesions in the lower part of the right leg were positive at 
somatostatin receptor imaging (Figure 3). The mediastinal lymphoma in 
patient 2 (Figure 4), had been missed on the X-ray and CT scans of the 
thorax, also after retrospective survey of the CT scan. This patient indeed 
developed a radiologically evident mediastinal lymphoma six months later. 
Unfortunately, we did not repeat somatostatin receptor scintigraphy at that 
stage in order to see whether a clearer visualization was present. Mediastinal 
involvement of lymphoma was confirmed to be present later at autopsy. 
Autoradiography of these lesions again demonstrated somatostatin receptors 
in the lymphoma tissue. Also in patients 6 and 8 additional tumour 
localizations were detected at scintigraphy as compared with radiological 
techniques (Figure 5). Additional ultrasound andlor CT examinations 
confirmed the presence of tumour tissue at sites with high radioactivity in 
both patients. Tissue biopsies at the tumour sites in patients 1, 2, and 7 
confirmed the presence of lymphoma tissue, which was in all instances 
somatostatin receptor positive at autoradiography. Patients 9 and 10, who 
had Hodgkin's disease, also showed in vivo somatostatin receptor positivity 
of the lymphoma tissue. In patients 3,4, 5, 7, 9, and 10 tumour localizations 
indicated by ultrasound andlor CT examinations completely paralleled the 
investigations with 111ln labelled somatostatin analogue. Moreover, in none of 
the patients the conventional staging procedure indicated lymphoma sites 
that had been missed by somatostatin scintigraphy. 
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Table 1. Somatostatin receptor scintigraphy with ['l'ln-DTPA-D-Phe l]-octreotide in patients with malignant lymphomas. 
Site of lymphoma 
Patient Diagnosis Classification* Stage Radiology Scintigraphy Autoradiography 
non-Hodgkin (a) centroblastic II pancreas, truncus supraclavicular, positive 
centrocytic coeliacus and para- mediastinal, liver 
aortal hilus, pancreas, 
(b) diffuse, mixed small lower abdomen 
cleaved 1 large cell 
2 non-Hodgkin (a) centroblast localization visible at skin right leg, skin positive 
physical examination above liver region 
(b) diffuse, large cell and mediastinal 
3 non-Hodgkin (a) polymorph brain brain not done 
(immunocytoma) 
(b) diffuse, mixed small 
cleaved IIarge cell 
4 non-Hodgkin (a) centrocytic II left: pleura and left rib lung on left side not done 
(b) diffuse, small 
cleaved 
5 non~Hodgkin (a) lymphopJasmacytic right upper leg right upper leg not done 
lymphopJasmacytoid Ii (b) small, plasmacytoid 
Cii 
Continued .. I~ (J) 
'" 
CJ) Ig> CJ) 
'" III Table 1. (con!.) Ig 
iii 
Site of lymphoma S 
Patient Diagnosis Classification* Stage Radiology Scintig raphy Autoradiography Cil C) 
'" 6 non~Hodgkin (a) centroblastic IV cervical, cervical, not done "0 8" 
centrocytic diffuse supraclavicular, right supraclavicular, right 
.., 
'" 
(b) diffuse, large cell 
kidney, para~aortal, kidney, para-aortal, ~. 
lung hilum left side both lung hila <5-
OJ 
7 non-Hodgkin (a) anaplastic II submandibular, submandibular, positive "0 ::>-
centrocytic diffuse parapharyngeal right supraclavicular right '<: 
side side 5' 
(b) diffuse, large cell 
'" 
III 
8 non-Hodgkin Lennert's III stomach, truncus neck, not done c& 
'" lymphoma, large coeliacus, para- supraclavicular, lung III ~ 
cell aortal, hila, upper abdomen, 
'< 
supraclavicular right liver hilum, para-
'" side aortal 
"0 
::>-
0 
9 Hodgkin nodular sclerosis II mediastinal, retro- med iastinal, not done I~ 
and parasternal, supraclavicular 
paratracheal 
10 Hodgkin nodular sclerosis supraclavicular supraclavicular not done 
(a) Kiel classification; (b) International Working Formulation system 
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Figure 1. Visualization of the mediastinal, and supraclavicular lymph nodes (A), and lymphoma 
localizations in the pancreas and liver hilus (8) in a non-Hodgkin's lymphoma (patient 1, see 
Table 1) by 111ln labelled somatostatin analogue scintigraphy (anterior views, 48 hours after 
injection). 
Discussion 
I n the present study we report the presence of somatostatin receptors on the 
lymphoma tissue of a variety of types of non-Hodgkin's as well as Hodgkin's 
lymphomas. The localization of somatostatin receptors is mainly in the 
lymphoblastic areas of the lymphomas, representing the most active central 
part of these tumours. The affinity and/or the density of somatostatin 
receptors on these previously untreated or recurrent lymphomas was so high 
that in vivo visualization of these receptors with the 1111 n labelled 
somatostatin analogue was possible. In previous studies the use of this 
scintigraphic technique was shown to be successful in visualizing endocrine 
tumours like carcinoids, endocrine pancreatic tumours and paragangliomas, 
which contain high numbers of somatostatin receptors (13,14,22). 
In the present study the lymphoma tissue of the ten patients investigated 
could be visualized. In four of these patients additional tumour localizations, 
which had been missed initially at physical examination and routine 
radiological and ultrasound examination, were detected by somatostatin 
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Figure 2. Visualization of somatostatin 
receptors in a supraclavicular lymphoma of a 
patient with non-Hodgkin's lymphoma (patient 
1, see Table 1). (A) Haematoxylin-eosin 
stained section. (B) Autoradiogram showing 
total binding of [1251_Tyr3j_octreotide. (C) 
Autoradiogram showing non-specific binding 
of [1251-Tyr3]_octreotide in the presence of 1 
11M [Tyr3]-octreotide. Bar represents 1 mm. 
receptor scintigraphy. Visualization of tumour tissue by somatostatin receptor 
scintigraphy is not specific for lymphomas. A variety of granulomatous 
diseases like sarcoidosis, aspergillosis, and tuberculosis can also be 
visualized. The additional sites of radioactivity in our patients indeed 
represented lymphoma tissue, as was confirmed by biopsies or post-mortem 
pathology. In six patients the results of radiological examinations and l1lln 
labelled somatostatin receptor scintigraphy were parallel, i.e. the same 
tumour localizations were visualized. Therefore no false negative results 
were obtained in this group of lymphoma patients studied. 
Previous studies have shown that monocytes and lymphocytes as well as 
Iymphoblasts express somatostatin receptors (1,3-5). Functional studies 
indicate that somatostatin may inhibit ['Hj-thymidine incorporation of 
phytohaemagglutinin and concanavalin A stimulated lymphocytes in vitro 
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Figure 3. Somatostatin receptor positive 
lymphoma tissue in the lower right leg of 
patient 2 (see Table 1), visualized with 111ln 
labelled somatostatin analogue scintigraphy 
(anterior view, 24 hours after injection). 
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Figure 4. Visualization of the somatostatin 
receptor positive mediastinal lymphoma in 
patient 2 (see Table 1) by l11ln labelled 
somatostatin analogue scintigraphy (anterior 
view, 48 hours after injection). 
(5-9,11). Somatostatin may also suppress the synthesis of immunoglobulins 
in an IgA secreting plasmacytoma cell line (10). Our current observations 
represent evidence of the presence of somatostatin receptors in human 
lymphomas of variable histology. 
The scintigraphic technique described in this study is an easy, harmless 
procedure which might add to optimize staging procedures in this type of 
patient. At present staging in non-Hodgkin's lymphoma has become less 
important as more intensive chemotherapy regimens are used for most 
grades of disease. Possibly, this form of imaging could also be of benefit 
when assessing patients for autologous bone marrow transplantation, where 
the best results are seen when the patient is in complete remission. Further 
studies are obviously needed to define more precisely the value and 
limitations of somatostatin scintigraphy in lymphoma patients. For instance, 
the physiological uptake of radioactivity in the liver and spleen after 
intravenous administration of '''In labelled somatostatin analogue might 
hamper optimal tumour detection in these areas, even if a subtraction 
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Figure 5. Visualization of the somatostatin 
receptor positive supraclavicular lymph nodes 
in patient 8 (see Table 1) by 1111n labelled 
somatostatin analogue scintigraphy (anterior 
view, 24 hours after injection). 
technique with [99mTcj-colioid scanning is used. Apart from a role of 111ln 
labelled somatostatin analogue scintigraphy in lymphoma staging, it is 
tempting to hypothesize about the potential use of such a somatostatin 
analogue coupled to a B emitting radionuclide in radiotherapy of these 
diseases. 
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CHAPTER 3.3 
SOMATOSTATIN RECEPTORS IN MALIGNANT LYMPHOMAS 
Somatostatin receptors in malignant lymphomas 
Somatostatin receptors in malignant lymphomas 
Somatostatin receptors have been identified in Hodgkin's disease and non-
Hodgkin's lymphomas as described in Chapter 3.1 and Chapter 3.2. In vitro 
autoradiography demonstrated somatostatin receptors to be predominantly 
present in the lymphoblastic areas of the lymphomas, which represent the most 
active central part of these tumours. Unfortunately, somatostatin receptor 
autoradiography is not suitable for the identification of the somatostatin receptor 
expressing single cell types. Moreover, no reproducible technique is available 
at the moment to analyze single cells. In our studies fluorescent labelled 
somatostatin analogues did not sufficiently identify somatostatin receptors on 
mononuclear cells. Even on endocrine cells the receptor density was too low to 
allow the successful application of this technique at the level of single cells (data 
not shown). These observations are in contrast with the findings presented by 
others (1-3). 
Recently, expression of messenger ribonucleic acid (mRNA) for somatostatin 
receptors has been found in two patients with non-Hodgkin's lymphoma 
(receptor subtypes 2 and 3) and one patient with Hodgkin's disease (receptor 
subtype 2) (4). Besides, somatostatin receptor expression has also been 
described on the veins in the immediate vicinity of non-Hodgkin's lymphoma, 
even when tumour cells lacked somatostatin receptors. This suggests that 
somatostatin receptors may also have a role in the haemodynamic tumour-host 
interactions (4). In low grade B cell lymphomas with follicular histology a non-
homogeneous distribution of somatostatin receptors was observed, comparable 
with the observation in normal gastrointestinal associated lymphoid tissue. In 
most high grade lymphomas of the B cell type the homogeneous distribution of 
somatostatin receptors reflected the diffuse histopathology of these tumours. 
Use of somatostatin receptor scintigraphy in staging of lymphomas 
The presence of somatostatin receptors on malignant cells of lymphoid origin 
allows the in vivo visualization of malignant lymphomas by somatostatin 
receptor scintigraphy, using ["'In-DTPA-D-Phe']-octreotide as radioligand 
(Figure 1 and 2). 
74 
Figure 1. Visualization of mediastinal and 
supraclavicular lymphoma localizations in a 
patient with Hodgkin's disease by l111n labelled 
somatostatin analogue scintigraphy (anterior 
view, 24 hours after injection). 
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Figure 2. Visualization of an intracranial nonR 
Hodgkin's lymphoma in a patient with the 
acquired immunodeficiency syndrome (AIDS) 
by l111n labelled somatostatin analogue 
scintigraphy (anterior view, 24 hours after 
injection). 
Recently, 40 consecutive, previously untreated, patients with histologically 
proven Hodgkin's disease were studied (5,6). The results of the initial 
conventional staging methods, i.e. physical examination, computed tomography 
of the chest and abdomen, bone marrow biopsy and lymphangiography, were 
blindly compared with those of somatostatin receptor scintigraphy, using ['"In_ 
DTPA-D-Phe' ]-octreotide (Table 1). In 39 patients (97.5%) somatostatin receptor 
positive lesions were detected at scintigraphy. In 17 patients somatostatin 
receptor scintigraphy was in agreement with the conventional staging methods. 
In 18 patients more lesions were found with scintigraphy, in five patients more 
lesions were found with the conventional staging methods. When somatostatin 
receptor scintigraphy was added to the conventional staging methods, the 
clinical stage was upgraded in six patients with Hodgkin's disease (Table 2). 
Somatostatin receptor scintigraphy, using ['"In-DTPA-D-Phe' ]-octreotide, was 
performed in 62 consecutive, previously untreated, patients with histologically 
proven non-Hodgkin's lymphoma (5,6). Of these, 53 (85%) were positive at 
scintigraphy. In 31 patients concordance between the results of conventional 
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Table 1. Comparison of somatostatin receptor scintigraphy (SRS) and conventional staging 
methods (CSM) in patients with Hodgkin's disease or non-Hodgkin's lymphoma (5,6). 
SRS in agreement SRS superior SRS inferior 
Diagnosis with CSM to CSM to CSM Total 
Hodgkin's disease 17 18 5 40 
Non-Hodgkin's lymphoma 31 17 14 62 
Table 2. Change in clinical stage in Hodgkin's disease and non-Hodgkin's lymphoma with 1111n 
labelled somatostatin analogue scintigraphy (5,6). 
Diagnosis 
Hodgkin's disease 
Non-Hodgkin's lymphoma 
Total number of patients 
40 
62 
Upgrade 
6 
13 
staging methods and somatostatin receptor scintigraphy was found (Table 1). 
In 17 patients somatostatin receptor scintigraphy disclosed additional lymphoma 
localizations. Somatostatin receptor scintigraphy failed to demonstrate selected 
sites of non-Hodgkin's lymphoma in five patients. When somatostatin receptor 
scintigraphy and the conventional staging methods were combined, the clinical 
stage was upgraded in 13 patients with non-Hodgkin's lymphoma (Table 2). 
Several other studies, using '''In labelled somatostatin analogue scintigraphy, 
reported lower sensitivity rates for the detection of malignant lymphomas than 
the rates we found (7-11) (Table 3). One explanation for the difference in the 
observed sensitivity rates may be a different composition of the patient groups. 
For example, in the study of Bong et aI., the exclusion of patients with low grade 
non-Hodgkin's lymphoma or chronic lymphocytic leukaemia resulted in a higher 
sensitivity (72% vs. 39%). Moreover, the specific activity of the ligand used was 
lower than in our studies (100-200 MBq/10 I1g vs. 200-250 MBq/10 I1g). 
Differences in sensitivity rates may also be explained by differences in the 
preset counting time and the specifications of the gamma camera used. 
Unfortunately, these data were not available from all studies. Finally, in our 
studies we consequently performed single photon emission computed 
tomography (SPECT) of the abdomen. In none of the other studies SPECT 
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Table 3. Reported sensitivity rates of 1111n labelled somatostatin analogue scintigraphy in 
Hodgkin's disease and non-Hodgkin's lymphoma (7-11). 
Sensitivity 
Authors Hodgkin's disease Non-Hodgkin's lymphoma 
Bong et at (8)' 92% 39% 
Sarda et al. (10)' 58%"" 58%** 
Bares et al. (7)' 78% 63% 
Ivancevic et a1. (11 ) 86% 82% 
Lipp et al. (9) 70% 35% 
Sensitivity based on the number of lesions detected. 
** Combined sensitivity. No separate data for Hodgkin's disease and non-Hodgkin's 
lymphoma were reported. 
imaging of the abdomen was performed consequently. Therefore, the low 
sensitivity rates reported in these studies may have been caused by the failure 
to detect tumour localizations in the abdominal region (7). In our opinion, 
SPECT imaging, using 200-250 MBq of ["'In-DTPA-D-Phe' J-octreotide, is an 
important additional technique in the detection of abdominal tumour localizations 
in patients with Hodgkin's disease or non-Hodgkin's lymphoma. 
Octreotide does not specifically visualize lymphoma tissue. A variety of 
granulomatous diseases like sarcoidosis, aspergillosis and tuberculosis can also 
be visualized. The additional sites of accumulation of radioactivity in our 
lymphoma patients, however, did represent malignant lymphoma tissue, as was 
investigated in almost all patients by biopsies or post-mortem examination. The 
in vitro identification of somatostatin receptors in biopsies of the malignant 
lymph nodes confirmed that the activity seen in vivo actually represented 
somatostatin receptor positive tumour tissue (12). 
Somatostatin receptor scintigraphy is an easy and harmless procedure that may 
contribute to the optimization of staging procedures in patients with malignant 
lymphoma's. It offers a number of distinct advantages when compared with 
conventional staging methods. Firstly, the whole body is imaged, enabling the 
detection of tumour localizations in areas not under clinical suspicion, and 
herewith the accurate documentation of the extent of the disease. Secondly, 
scintigraphy may distinguish malignant disease from non-malignant disease. 
77 
Somatostatin receptors in malignant lymphomas 
Table 4. Responses to octreotide treatment in lymphoproliferative disorders (13). 
Diagnosis Partial remission Stable Progression 
Low grade non·Hodgkin's lymphoma 10 14 4 
Chronic lymphocytic leukaemia 0 15 4 
Cutaneous T cell lymphoma 4 2 3 
This may be of value in the management of residual masses, for example with 
the notoriously difficult mediastinal localizations. Somatostatin receptor 
scintigraphy may also be useful in the avoidance of overtreatment in already 
cured patients. A shortcoming of this scintigraphic technique is the uptake of 
radioactivity in the liver and spleen after intravenous administration of ["'In_ 
DTPA-D-Phe'l-octreotide, which may hamper optimal tumour detection in these 
areas, even if a subtraction technique with [99mTcl-colioid scanning is used. 
Therefore, SPECT imaging is an important additional technique in the detection 
of tumour localizations in the upper abdomen, as mentioned above. 
Further studies are obviously needed to define more precisely the possibilities 
and limitations of ['"In-DTPA-D-Phe' l-octreotide scintigraphy in patients with 
malignant lymphomas. 
Octreotide in the treatment of malignant lymphomas 
Apart from the role of octreotide in the staging of disease, evaluation of the 
somatostatin receptor status may be of value in the treatment of patients with 
malignant lymphomas with somatostatin analogues. The efficacy of the 
somatostatin analogue octreotide (Sandostatin"j, 150 fig tid, has been 
demonstrated in 56 patients with Iymphoproliferative disorders (Table 4) (13). 
Partial remissions were found in patients with low grade non-Hodgkin's 
lymphoma and cutaneous T cell lymphoma. No remissions were found in 
patients with chronic lymphocytic leukaemia, which is in agreement with the 
observation that somatostatin receptor scintigraphy is negative in this disease 
(unpublished data). The somatostatin receptor status of patients with malignant 
lymphomas will become particularly important when somatostatin analogues 
coupled to a B emitting radionuclide will become available for radiotherapy of 
these diseases. 
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CHAPTER 4.1 
SOMATOSTATIN RECEPTORS IN GRANULOMATOUS DISEASES 
Somatostatin receptors in granulomatous diseases 
Granulomatous inflammation 
Granulomatous inflammation is manifested in chronic inflammatory diseases that 
often result in tissue destruction and end-stage fibrosis. The common 
histological feature of granulomatous inflammations is the infiltration of 
mononuclear leucocytes. A variety of granulomatous diseases are caused by 
infectious agents (tuberculosis, histoplasmosis) or non-infectious agents 
(silicosis, berylliosis). Others are of unknown origin (sarcoidosis, Wegener's 
granulomatosis). Within the group of granulomatous diseases there is 
heterogeneity with regard to the cellular infiltrate and the intensity of specific 
lesions. Granulomatous inflammations can roughly be classified as either a 
hypersensitivity type response (immunological) or a foreign body type response 
(non-immunological). This classification is based on the degree of antigen 
specific lymphocytes in the developing lesion. In both granuloma types, 
macrophages and their derivatives, epithelioid cells and giant cells, are constant 
components of the lesion. 
The pathogenetic mechanism of granuloma formation starts with the 
presentation of an antigen by an antigen presenting cell in concordance with 
HLA class II molecules. Antigen presentation activates T helper 1 cells to 
produce interferon yand interleukin 2. Interferon y is an important cytokine in the 
induction of granuloma formation, because it enhances the expression of HLA 
class II molecules, Macrophages are producers of the Iymphokines interleukin 
1 and tumour necrosis factor a, which have overlapping and related biological 
activities, but are encoded by unique gene sequences. In particular, interleukin 
1 can induce the production of interleukin 2 by T lymphocytes. Interleukin 1 
dependent interleukin 2 stimulation has been shown to be an important signal 
for growth and clonal expansion of effector T cell populations. Experimental data 
suggest that interleukin 1 plays a key role in the development of granulomatous 
inflammations (1). Granuloma macrophages are able to produce tumour 
necrosis factor a as well. This cytokine has a role in the maintenance of 
established granuloma lesions. 
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Somatostatin receptors in granulomas 
A well known model for granulomas of the hypersensitivity type response is the 
Schistosoma mansoni egg induced antigen specific granuloma (2). This delayed 
type hypersensitivity reaction is a rapidly progressing, florid, granulomatous 
response, characterized by activated macro phages, sensitized T lymphocytes 
and antibody secreting 6 cells. The Schistosoma mansoni egg induced 
granuloma model was studied extensively in relation to neuropeptides and 
neuropeptide receptor expression (3-7). T lymphocytes, isolated from hepatic 
granulomas and predominantly CD4 positive, have a high affinity for 
somatostatin 14 (K, = 4.3 nM) and octreotide (K, = 0.1 nM) (8). 60th 
somatostatin 14 and octreotide suppress interferon y synthesis by stimulated 
CD4 positive lymphocytes (8). Further, somatostatin 14 reduces the production 
of IgG2 by granuloma 6 cells, probably by decreasing the secretion of interferon 
y (9). Continuous infusion with octreotide was found to decrease the hepatic 
granuloma size in vivo (10). Granuloma macrophages secrete somatostatin 14. 
This may be a feedback counter mechanism in the regulation of the 
granulomatous inflammatory response (11). 
Recently, messenger ribonucleic acid (mRNA) for somatostatin receptor subtype 
2 was isolated from hepatic murine granulomas by using the polymerase chain 
reaction technique. Also, purified CD4 positive granuloma T cells and granuloma 
T cell lines were shown to contain mRNA for the somatostatin receptor subtype 
2 (12). 
Our results on somatostatin receptor expression in human granulomatous 
diseases are presented in Chapter 4.2. 
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Somatostatin receptor scintigraphy in granulomatous diseases 
Abstract 
Normal as well as activated lymphocytes and macrophages have previously 
been shown by radioreceptor analysis to express somatostatin receptors. The 
somatostatin analogue ["'In-DTPA-D-Phe' J-octreotide has already been used 
successfully in the visualization of a variety of neuroendocrine tumours and 
malignant lymphomas. In the present study 20 consecutive patients are 
investigated; 12 patients with sarcoidosis, one patient with both sarcoidosis and 
aspergillosis, four patients with tuberculosis and three patients with Wegener's 
granulomatosis. For in vivo somatostatin receptor imaging, total body 
scintigraphy was performed 24 and 48 hours after the administration of ['"1 n-
DTPA-D-Phe'j-octreotide. Granuloma localizations could be visualized in all 
patients studied; additional sites were found in nine patients with sarcoidosis 
and in two patients with tuberculosis. In vitro autoradiography of fresh tissue 
biopsies, using the somatostatin analogue [' 25I-Tyr3J-octreotide, showed binding 
at sites that were microscopically identified as granulomatous inflammation. 
These observations demonstrate the expression of somatostatin receptors by 
human granulomas. This scintigraphy procedure may contribute to a more 
precise staging and evaluation of granulomatous diseases. More importantly, it 
may be a sensitive indicator of the efficacy of glucocorticoid and/or 
immunosuppressive therapy. 
Introduction 
Granulomas may be defined as small collections of modified macro phages 
(epithelioid cells, multinucleated giant cells) and lymphocytes, but fibroblasts 
and granulocytes can also be present. Aggregated granulomas often result in 
pseudotumorous lesions. In more advanced stages, they may become enclosed 
by fibrous tissue and eventually be replaced by hyaline scars. Granulomas are 
manifestations of the response to a variety of antigens. They occur in 
mycobacterial, parasitic, fungal and other infectious diseases, as a reaction to 
non-infectious poorly digestible agents, and in diseases of obscure origin such 
as sarcoidosis, Crohn's disease and Wegener's granulomatosis. 
Recently, we developed a technique in which the administration of radionuclide 
labelled somatostatin analogue successfully visualizes endocrine tumours and 
malignant lymphomas (1-3). Experimental murine Schistosoma mansoni induced 
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granulomas express somatostatin receptors and synthesize somatostatin as well 
(4-6). This observation led to the present study, in which we investigated the 
value of['11ln-DTPA-D-Phe' J-octreotide scintigraphy in patients with sarcoidosis 
(one of whom also had aspergillosis), tuberculosis orWegener's granulomatosis. 
Materials and methods 
Patients 
Twenty consecutive patients were included; 13 patients with sarcoidosis, one 
of them having aspergillosis as well, four patients with active tuberculosis, and 
three patients with Wegener's granulomatosis. The diagnosis of sarcoidosis was 
based on the appearance of hilar lymphadenopathy, the presence of an 
alveolitis, as demonstrated by an increased percentage CD3 positive 
lymphocytes (>40%) and an increased CD4/CD8 ratio (>4) in the 
bronchoalveolar fluid, and the presence of epithelioid cells in transbroncheal 
biopsies. In six patients the diagnosis was based on biopsies taken from 
affected bones (patients 2 and 4), lymph nodes (patients 7,8 and 11), and liver 
(patients 4 and 10). The presence of aspergillosis infection of the lung in one 
patient and of active pulmonary tuberculosis in four patients was diagnosed on 
the basis of cultures of the sputum as well as direct microscopic investigation 
using special stains. The diagnosis Wegener's granulomatosis was based on 
the clinical findings, the demonstration of necrotizing granulomatous vasculitis 
in biopsies of the upper respiratory tract, and the presence of antineutrophil 
cytoplasmic antibodies. 
Somatostatin receptor scintigraphy 
The somatostatin analogue [DTPA-D-Phe'J-octreotide was obtained from 
Mallinckrodt (petten, the Netherlands). [DTPA-D-Phe 'J-octreotide was coupled 
to 111ln as described previously (2). ['11ln-DTPA-D-Phe' j-octreotide is excreted 
mainly via the kidneys, 90% of the dose being present in the urine 24 hours 
after injection. Because of its relatively long effective half-life, ['"In-DTPA-D-
Phe' J-octreotide is a radionuclide coupled somatostatin analogue that can be 
used to visualize somatostatin receptor bearing tumours and inflammation 
localizations efficiently after 24 and 48 hours, when the interfering background 
radioactivity is minimized by renal clearance (2,7,8). ['11ln_DTPA_D_Phe' J-
octreotide (200-250 MBq) was injected and planar images were obtained with 
a large-field-of-view gamma camera (Counterbalance 3700 and ROTA II, 
89 
Somatostatin receptor scintigraphy in granulomatous diseases 
Siemens Gammasonics, Erlangen, Germany), equipped with a medium energy 
collimator. Static images were obtained 24 and 48 hours after injection of ['"In_ 
DTPA-D-Phe' ]-octreotide, because of the low background radioactivity at that 
time. Preset counts for images obtained 24 hours after injection of the 111ln 
labelled octreotide, was 300,000 for the head and neck, and 500,000 for the 
remainder of the body; the preset counting time for images obtained 48 hours 
after injection of ['11ln-DTPA-D-Phe' ]-octreotide, was 15 minutes (8). To define 
the granulomas as visualized during this scintigraphic procedure, we used a 
simple yes-or-no system. As a rule, and especially in the abdomen, 
accumulation of radioactivity at an abnormal site was considered to represent 
somatostatin receptor binding only if it was present on the sCintigrams of both 
standard imaging time points. The scintigrams of all 20 patients were studied 
independently by two investigators, without knowing the patient's identity, 
medical history, or outcomes of other investigations. In order to compare the 
number of lesions demonstrated with conventional imaging techniques with 
those visualized during ['11ln-DTPA-D-Phe' ]-octreotide scintigraphy, the images 
were divided in parts easily recognizable on scintigrams, i.e. the head and neck, 
chest, upper abdomen, lower abdomen (division line: lower edges of the 
kidneys), and extremities. 
Somatostatin receptor autoradiography 
The presence of somatostatin receptors in granuloma tissue was investigated 
by autoradiography on 10 flM thick frozen sections of tissue. [1251_Tyr']_ 
octreotide, which has previously been show to specifically label somatostatin 
receptors, was used as radioligand. This technique has been described in detail 
for various types of tumorous and non-tumorous tissues (9-12). 
Results 
After intravenous injection of ['11ln-DTPA-D-Phe' ]-octreotide, physiological 
uptake of radioactivity was seen in all patients in the pituitary gland, the thyroid 
gland, the liver, the spleen, the kidneys and the bladder, as described previously 
(2,7,8). 
The comparison of tumour localizations found with conventional imaging 
techniques and ['''In_DTPA_D_Phe' ]-octreotide scintigraphy is presented in 
Table 1. Patients 1-13 had sarcoidosis. In all 13 patients the known localizations 
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Figure 1. Bilateral uptake of Cl1In~DTPA-D­
Phe1]-octreotide in the hila of the lungs in a 
patient with sarcoidosis (patient 1, see Table 1) 
(posterior view, 48 hours after injection). The 
carotid paraganglioma is indicated by an arrow. 
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Figure 2. Visualization of the hila of the lung, 
supraclavicular lymph nodes and lymph nodes 
in the neck of a patient with sarcoidosis (patient 
2, see Table 1) by l111n labelled somatostatin 
analogue scintigraphy (anterior view, 24 hours 
after injection). 
of sarcoidosis could be visualized after the administration of the '''In labelled 
octreotide, with the exception of a granuloma in a phalanx and in the liver of 
patient 4 and a granuloma in the left axilla of patient 7. In patient 1 a carotid 
paraganglioma was visualized in addition to the hila of the lung (Figure 1). A 
lesion in the cerebellum of patient 10, only detected by magnetic resonance 
imaging, could have been a granuloma, but was negative at scintigraphy. In 
nine of these patients, however, more granulomas were detected with whole 
body scintigraphy than with conventional imaging techniques (patients 2-8, 10 
and 13). In all these cases the presence of 'new' granuloma sites was confirmed 
by additional computer tomography, ultrasound and X-ray investigations and/or 
biopsies of the tissue. In patient 2 the spread of granulomas in the hilar region 
of the lung (Figure 2) and in the bones of the hands and feet (Figure 3) was 
considerably more extensive than previously suspected. In patients 2, 5 and 13 
additional granuloma localizations were detected in the salivary glands (normal 
salivary glands are not visualized with ['''In-DTPA-D-Phe' ]-octreotide 
scintigraphy). In patient 9, aspergillosis of the right lung was visualized, in 
addition to the affected lymph nodes in the inguinal region. 
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Table 1. Somatostatin receptor scintigraphy with [111In_DTPA_D_Phe l]-octreotide in patients with granulomatous diseases. '-l OJ 
0 
Patient Sex* Age Diagnosis Therapy Known sites of Scintigraphy OJ Oi 
inflammation 5-
M 43 Sarcoidosis None Lung hila Lung hila co co 
Paraganglioma {'l 
0 
2 F 37 Sarcoidosis Corticosteroids Submandibular, Nose, salivary glands, neck, 
.., 
OJ 
supraclavicular, lung hila, supraclavicular, lung hila, co S· 
liver, fingers, toes right knee, fingers, toes g 
3 M 37 Sarcoidosis None Left lung hilus Lung hila OJ 
-C 
::>-
'<:: 
4 F 33 Sarcoidosis Corticosteroids Brain (parietal, right side), Brain, lunghila, nose S· 
nose, hand, liver CQ 
OJ 
5 F 18 Sarcoidosis None Erythema nodosum, Right lung hilus, lacrimal 
" <:: paratracheal, carina glands, parotid glands 0 
'-l 
6 F 46 Sarcoid isis None Lung hila Lung hila, supraclavicular, OJ 0 
mediastinum 1ii 
7 F 66 Sarcoidosis None Supraclavicular, right lung Lung hila, supraclavicular ~ 
hilus, left axilla <D 
'" OJ 
8 M 46 Sarcoidosis Corticosteroids Lung hila Lung hila, supraclavicular, <D OJ 
abdomen 
9 M 40 Sarcoidosis None Right lung, inguinal Right lung, inguinal 
Aspergillosis 
Continued .. 
Table 1. (cont.) 
Patient Sex* Age Diagnosis Therapy Known sites of Scintigraphy 
inflammation 
10 F 46 Sarcoidosis None Cerebellum, left maxillary Nose, left maxillary sinus, 
sinus, liver supraclavicular, lung hila, 
spleen (enlarged), liver 
(enlarged) 
11 F 41 Sarcoidosis None Neck, supraclavicular, Neck, supraclavicular, 
mediastinal mediastinal 
12 F 52 Sarcoidosis None Lung hila Lung hila 
13 M 45 Sarcoidosis None Lungs Lungs, parotid glands 
14 M 32 Tuberculosis None Right lung Right lung, left lung hilus 
15 M 21 Tuberculosis None Left lung Left lung 
16 M 35 Tuberculosis None Left lung Left lung, pericard 
17 M 41 Tuberculosis None Lungs, peri-aortal Lungs, upper abdomen 
18 F 67 Wegener's granulomatosis Corticosteroids Nose, larynx, lungs Nose, throat, lungs 
Cydophosphamide 
19 M 66 Wegener's granulomatosis Corticosteroids Nose, lungs, kidneys Nose, lungs, kidneys 
20 M 45 Wegener's granulomatosis Corticosteroids Nose, urethra Nose, urethra I~ 
"0 
M = male; F = female I~ <D 
'" 
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Figure 3. Bone involvement of the fingers (A) and toes (8) of a patient with sarcoidosis (patient 2, 
see Table 1), visualized by l111n labelled somatostatin analogue scintigraphy (48 hours after 
injection). 
Scintigraphy was repeated in two patients, one month (patient 6) and four 
months (patient 13) after the start of therapy with prednisone; the initial dose 
was 30 mg per day, and was progressively reduced over a period of one month. 
Both patients had responded well to this therapy, as indicated by the clinical 
picture (general well being, decreasing size of lymphomas by physical 
examination) and normalization of radiological findings. Visualization of the 
lesions in the hila of the lung disappeared completely in both patients. In three 
other patients (patient 2,4 and 8), who were also treated with prednisone 
therapy for one month (30 mglday in patient 2 and 60 mg/day in patients 4 and 
8) only minor changes were noted, clinically and radiologically. The granulomas 
of these patients remained positive at scintigraphy. 
Patients 14-17 were diagnosed with active lung tuberculosis. ['"In-DTPA-D-
Phe'J-octreotide scintigraphy visualized the pulmonary lesions clearly. In patient 
14, the right lung and a small spot in the left lung were visualized, while the 
chest X-ray had suggested the presence of active tuberculosis in the right lung 
only (Figure 4). In patient 16 we observed tuberculous involvement of the 
pericardium by the uptake of ['"In-DTPA-D-Phe' J-octreotide in the pericardium 
(Figure 5). 
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Figure 4. Imaging of the chest of a patient with 
tuberculosis of the right lung (patient 14, see 
Table 1) by 1111n labelled somatostatin analogue 
scintigraphy (anterior view, 24 hours after 
injection). In the left lung a small spot is 
detectable. 
Patients 18-20 had Wegener's granulomatosis. In patient 18 only a slight uptake 
of ["1 I n-DTPA-D-Phe' J-octreotide was observed, possibly because this patient 
was already treated with prednisone and cyclophosphamide. Patient 20 was 
treated with prednisone (initial dose 60 mg/day) and azathioprine (150 mg/day). 
This patient did not respond very well to therapy (general well being, urethra 
obstruction, sinusitis and persistent positive antibodies against neutrophil 
cytoplasmic antigens). The ['l1ln-DTPA_D_Phe' J-octreotide scintigraphy repeated 
after 2 months of therapy remained positive. 
To validate the specificity of the visualization by ['l1ln-DTPA-D-Phe' J-octreotide 
scintigraphy, in vitro autoradiography with [, 25 I-Tyr3J-octreotide was performed 
on biopsies of granulomatous tissue. In vitro somatostatin receptor expression 
was shown in a lymph node from patient 11. The somatostatin receptors were 
localized in the region of epithelioid and giant cells of the granulomas. 
Unfortunately, we did not obtain biopsies of granulomatous tissues from the 
other patients included in our study. Most interestingly, however, tissue biopsies 
of two patients with sarcoidosis (not scanned in vivo), obtained from the 
Institutes of Pathology in Berne and Lucerne, Switzerland, were tested with in 
vitro somatostatin receptor autoradiography. The first tissue specimen, from a 
patient with active sarcoidosis, displayed multiple confluent typical granulomas 
(Figure 6). This lesion was strongly somatostatin receptor positive. The 
receptors were preferentially located in the areas containing epithelioid cells and 
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Figure 5. Three-dimensional representation of the heart in a patient with tuberculous pericarditis 
(patient 16, see Table 1) by 11I1n labelled somatostatin analogue scintigraphy (24 hours after 
injection). 
not in the zone of surrounding lymphocytes. The second patient was 
successfully treated with glucocorticoids. The biopsy showed complete sclerosis 
of the granulomatous lesions and no somatostatin receptors were detectable 
(Figure 7). Lymph nodes of two other patients with tuberculosis also expressed 
somatostatin receptors throughout the granulomatous tissue at in vitro 
autoradiography. 
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Figure 6. Visualization of somatostatin 
receptors in active sarcoidosis. (A) 
Haematoxylin-eosin stained section. (8) 
Autoradiogram showing total binding of [1251_ 
Tyr3]-octreotide. The pale granuloma tissue is 
labeUed, but not the darker lymphocytes. (C) 
Autoradiogram showing non-specific binding of 
[ 1251-Tyrj-octreotide in the presence of 1 ).lM 
[Tyr3]-octreotide. (0) Somatostatin receptor 
positive granuloma shown at higher 
magnification. Bars represent 1 mm. 
Chapter 4.2 
97 
Somatostatin receptor scintigraphy in granulomatous diseases 
98 
Figure 7. Absence of somatostatin receptors in 
a successfully treated sarcoidosis. (A) 
Haematoxylin-eosin stained section. (8) 
Autoradiogram showing total binding of [125 1_ 
Tyr31-octreotide. (C) Autoradiogram showing 
non-specific binding of [125J_Tyr3]_octreotide in 
the presence of 1 i-lM [Tyr3]-octreotide. (0) 
Largely sclerosed sarcoidosis shown at high 
magnification. Bars represent 1 mm. 
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Discussion 
We report that granulomatous tissue of patients with active sarcoidosis, 
tuberculosis, aspergillosis and Wegener's disease expresses somatostatin 
receptors in sufficient numbers to allow in vivo visualization using an 111ln 
labelled somatostatin analogue. In all 13 patients with sarcoidosis, pulmonary 
as well as extra-pulmonary lesions could be visualized with ['"In-DTPA-D-Phe' ]-
octreotide. In virtually all patients more granuloma localizations were detected 
than previously known on the basis of physical examination and routine 
radiological investigations. Our study also presents preliminary evidence for a 
role of ['l1ln-DTPA-D-Phe' ]-octreotide scintigraphy in the evaluation of the effect 
of glucocorticoid therapy of sarcoidosis. The scintigram became negative during 
successful therapy in two patients, while the granuloma sites remained positive 
at scintigraphy during unsuccessful therapy with prednisone in three patients. 
The results of the in vitro study suggest that the disappearance of somatostatin 
receptors in sarcoidosis lesions upon corticosteroid therapy could be due to the 
sclerosis of granulomas and their replacement by hyaline fibrous tissue. 
Granulomas in tuberculosis, aspergilloSiS and in Wegener's granulomatosis were 
also shown to be positive at ['111 n-DTPA-D-Phe ']-octreotide scintigraphy. 
Specific binding was observed in tuberculous granulomas at in vitro 
autoradiography as well. Unfortunately no tissue was obtained for in vitro 
autoradiography from patients with Wegener's granulomatosis. Generally, 
granulomas seem to express somatostatin receptors. 
Experimentally, granulomas in murine schistosomiasis have been shown to 
express somatostatin receptors and synthesize and store somatostatin in the 
granules of (modified) macrophages within the granuloma. The (modified) 
macrophages (epithelioid cells) release somatostatin when stimulated by 
physiological and pharmacological agents (4-6). Synthesis of somatostatin by 
granuloma cells, as well as the presence of somatostatin receptors within 
granuloma cells, might indicate that somatostatin participates in regulating the 
intensity of the granulomatous response to specific microorganisms 
(tuberculosis, aspergillosis, schistosomiasis) or unknown stimuli (sarcoidosis). 
Since somatostatin seems to inhibit proliferative and other functions of lymphoid 
cells (13-17), it is conceivable that similar effects may take place in granulomas. 
In accordance with this hypothesis, it was shown that octreotide therapy 
decreases the intensity of the granuloma response by approximately 45% in 
murine schistosomiasis (6). However, granulomas are not the only lesions of the 
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mononuclear phagocytic and Iymphoreticular system that may yield positive 
scintigrams. Recently, we have observed that neoplastic tissues of virtually all 
patients with Hodgkin's disease or non-Hodgkin's lymphoma are somatostatin 
receptor positive and that their localization can be shown with this technique as 
well (3). A possible shortcoming of somatostatin receptor visualization in 
granulomatous disease lies in the difficulty of detecting liver and spleen 
abnormalities (apparent in patient 10), while microscopically granulomas have 
been reported to be present in the liver in 60-90 % of all cases (18). It is 
conceivable that the sensitivity of this method is not sufficient for the 
visualization of small lesions such as those present in the liver and spleen. 
In summary, we present evidence for the successful visualization of 
granulomatous diseases in humans, mainly of sarcoidosis, with ['"In-DTPA-D-
Phe' ]-octreotide scintigraphy. These prelimin~ry findings suggest that the 
scintigraphy procedure may contribute to a more precise staging and a better 
evaluation of the fairly unpredictable spontaneous course of sarcoidosis and 
Wegener's granulomatosis, and to an optimal choice of biopsy sites in 
granulomatous diseases. More importantly, it may be a sensitive indicator of the 
activity of disease and of the efficacy of glucocorticoid and/or 
immunosuppressive therapy. However, more investigations are necessary to 
understand the pathophysiology of somatostatin receptor expression in 
granulomatous diseases. 
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Somatostatin receptor scintigraphy in rheumatoid arthritis 
Abstract 
I n this study the expression of somatostatin receptors on synovial 
membranes was investigated in vivo and in vitro in patients with rheumatoid 
arthritis. The joints of 14 consecutive patients with active rheumatoid arthritis, 
four patients with severe osteoarthritis, and 30 control patients were studied. 
The somatostatin analogue ['"In-DTPA-D-Phe' J-octreotide was used for in 
vivo somatostatin receptor scintigraphy and the somatostatin analogue [1251_ 
Tyr3J-octreotide was used for in vitro somatostatin receptor autoradiography. 
Seventy-six percent (220 of 290) of the painful joints and 76% (207 of 274) of 
the swollen joints of the patients with rheumatoid arthritis were visualized by 
somatostatin receptor scintigraphy. The degree of pain and swelling 
correlated well with positive scintigraphic findings in the joints (p<O.0001). In 
two patients with rheumatoid arthritis who underwent scintigraphy, as well as 
in four of five other patients, in vitro studies of the synovial membranes 
showed the presence of specific somatostatin receptors. In patients with 
osteoarthritis the uptake of radioactivity in the affected joints was significantly 
lower than that in patients with rheumatoid arthritis. None of the joints of the 
control patients demonstrated uptake of radioactivity. We conclude that 
somatostatin receptors are present in the synovial tissue of patients with 
active rheumatoid arthritis, as demonstrated by both in vivo and in vitro 
techniques. The potential value of somatostatin receptor scintigraphy in the 
clinical evaluation of patients with active rheumatoid arthritis is presently 
unknown. 
Introduction 
Somatostatin is a small peptide, known as a potent inhibitor of growth 
hormone release (1,2). It has recently been suggested that this neuropeptide 
is also involved in haematological and granulomatous diseases such as 
malignant lymphomas, sarcoidosis and human tuberculosis (3,4). Specific 
receptors for somatostatin have been found in activated lymphocytes, 
monocytes, and malignant lymphoid cells, by classic ligand binding 
techniques as well as by in vitro autoradiography (4-8). 
The somatostatin analogue ['11ln_DTPA_D_Phe' J-octreotide has been used 
successfully for in vivo visualization of a variety of neuroendocrine tumours, 
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as well as malignant lymphomas and granulomas (3,4,9,10). In one patient 
with sarcoidosis and arthralgia we observed a high uptake of ['"In-DTPA-D-
Phe'J-octreotide in the affected joints. This observation led us to investigate 
the possible use of somatostatin receptor scintigraphy of affected joints in 
rheumatoid arthritis. 
Rheumatoid arthritis is characterized by synovitis. The histopathological 
features lack uniformity, especially in more established disease, but diffuse 
lymphocytic infiltration (predominantly CD4 positive lymphocytes) and/or 
lymphocytic aggregates positioned around postcapillary venules are present 
in most cases. We postulated that these activated lymphocytes and 
monocytes in the synovial membranes express somatostatin receptors in 
sufficient numbers to allow in vivo visualization, as was the case in the 
disorders mentioned above. Herein we report our first results of somatostatin 
receptor scintigraphy of the joints in 14 consecutive patients with active 
rheumatoid arthritis and four selected patients with severe osteoarthritis 
resembling rheumatoid arthritis. The synovial tissues of two of these patients 
with rheumatoid arthritis as well as of five other patients were investigated for 
the presence of specific somatostatin receptors in vitro by using binding 
assays. 
Materials and methods 
Patients 
Fourteen consecutive patients with rheumatoid arthritis, fulfilling the criteria of 
the American College of Rheumatology (formerly, the American Rheumatism 
Association) (11), and four selected patients with severe osteoarthritis, all 
from the Department of Rheumatology at Dr. Daniel den Hoed Clinic, 
Rotterdam, the Netherlands, were enrolled in the study after giving informed 
consent. Demographic and clinical characteristics of the patients are shown 
in Table 1. Clinical evaluation of the joints was performed by a 
rheumatologist. The joints were scored for pain and swelling on a 0-3 scale, 
with 0 representing no swelling or pain and 3 representing extensive pain 
and swelling. Twenty patients with ophthalmic Graves' disease, five with 
neuroendocrine tumours, and five with malignant lymphomas were used as 
control patients. None of these patients had signs of arthritis, except for one 
patient with ophthalmic Graves' disease who had severe generalized joint 
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pains but no objective abnormalities found on physical examination. The 
joints of these control patients were scored according to their uptake of 
radioactivity, similar to the procedure in the patients with rheumatoid arthritis 
and osteoarthritis. 
Somatostatin receptor scintigraphy 
The somatostatin analogue [DTPA-D-Phe' ]-octreotide was obtained from 
Mallinckrodt (petten, the Netherlands). [DTPA-D-Phe ']-octreotide was 
coupled to 111ln as described previously (12). ['11ln_DTPA_D_Phe' ]-octreotide 
is excreted mainly through the kidneys, 90% of the dose being present in the 
urine 24 hours after injection. Because of its relatively long effective half-life, 
C"ln-DTPA-D-Phe' ]-octreotide can be used to efficiently visualize 
somatostatin receptor bearing lymphomas, granulomas, and neuroendocrine 
tumours after 24 hours when interfering background radioactivity is minimized 
by renal clearance (13,14). ['11ln-DTPA-D-Phe' ]-octreotide (200-250 MBq) 
was injected, and planar images were obtained with a large-field-of-view 
gamma camera (Counterbalance 3700 and ROTA II; Siemens Gammasonics, 
Erlangen, Germany) equipped with a medium energy collimator. Scanning 
was done for a preset time of 15 minutes, 24 hours after injection of the 111ln 
coupled somatostatin analogue (14). In normal individuals, physiologic 
accumUlation of radioactivity is seen 24 hours after administration of ['"In_ 
DTPA-D-Phe' ]-octreotide in the pituitary and thyroid glands, the liver, the 
spleen, and the kidneys, as well as the urinary bladder. Radioactivity at other 
sites is considered to be abnormal and indicates the presence of abnormal 
somatostatin receptor positive tissue. To define the localizations of 
somatostatin receptors as visualized during this scanning procedure, the 
joints were scored on a 0-3 scale, where 0 = no uptake, 1 = low uptake, 2 = 
moderate uptake, and 3 = high uptake. The scintigrams of all patients were 
analyzed by two examiners who were not aware of the patient's identity, 
medical history, or outcomes of other investigations. In order to compare the 
number of lesions found by physical examination with those visualized during 
somastostatin receptor scintigraphy, the images were divided into easily 
recognizable parts. At physical examination a total of 42 joints per patient 
had been evaluated: the shoulders, elbows, wrists, metacarpophalangeal 
joints, distal interphalangeal joints, hips, knees, ankles, and 
metatarsophalangeal joints. All these joints were also evaluated and scored 
on the scintigrams. 
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Somatostatin receptor autoradiography 
The presence of somatostatin receptors in synovial tissue was investigated 
by autoradiography on 10 flm thick frozen sections using an iodinated 
somatostatin octapeptide analogue, [, 25I-Tyr3J-octreotide. Tissue sections 
were mounted on precleaned microscope slides and stored at -20°C for at 
least 3 days to improve adhesion of tissue to the slide. Sections were then 
incubated for 2 hours at room temperature in the presence of the iodinated 
ligand (0.15-0.30 x 106 dpmlml, about 80-160 pM). The incubation solution 
was 170 mM Tris-HCI buffer, pH 7.4, containing 1 % bovine serum albumin 
(BSA), bacitracin (40 flg/ml) and MgCl, (5 mM). Non-specific binding was 
determined by adding 1 flM solution of unlabelled octreotide. Incubated 
sections were washed twice for 5 minutes in cold incubation buffer containing 
0.25% BSA and then in buffer alone, and dried quickly. The sections were 
exposed to 3H labelled ultrafilms (Cambridge Research, Nussdorf, Germany) 
and maintained for one week in X-ray cassettes. Displacement experiments 
were done on successive sections of synovial membranes. In addition, 
saturation experiments using increasing concentrations of octreotide were 
performed on tissue sections incubated with radioligand (30,000 cpm/100 fll). 
The autoradiograms were quantified using a computer assisted image 
processing system. Tissue standards for iodinated compounds (Amersham, 
Aylesburg, United Kingdom) were used for this purpose. Synovial tissue was 
designated somatostatin receptor positive when the optical density in the 
'total binding' section was at least twice the optical density of the 'non-
specific' binding section. These techniques have been described previously 
in detail for various types of tumorous and non-tumorous tissues (15-18). 
Autoradiography was performed on synovial biopsy specimen from two 
patients who underwent scintigraphy and five other patients who did not 
undergo scintigraphy, from whom synovial membrane tissue was obtained in 
the course of a surgical procedure. 
Results 
The results of somatostatin receptor scintigraphy in the 14 patients with 
rheumatoid arthritis and the four patients with osteoarthritis are listed in Table 
1. We observed uptake of ["'jn-DTPA-D-Phe'J-octreotide in a number of 
joints of all of the patients with rheumatoid arthritis (Figures 1-4). 
109 
~ Ii ~ 0 Table 1. Patient characteristics. 
0 
Number of joints '" or 
Eryth roeyte s: 
en Rheumatoid sedimentation Somatostatin C) 
Patient Sex* Age factor rate (mm/hour) Treatment Swollen Painful receptor positive {'l 
0 
.., 
Rheumatoid arthritis 
'" C) 
F 72 + 59 Corticosteroids, chloroquine, 17 12 24 I~ NSAIDt cQ-OJ 
"0 
2 M 73 + 28 Corticosteroids, chloroquine, 7 15 14 I; NSAIDt 
3 F 67 + 69 Corticosteroids, chloroquine, 34 23 34 3-CD 
methotrexaat, NSAID t <:: 
:3 
OJ 
4 F 38 30 Gold 34 34 27 0 Q: 
5 F 74 Corticosteroids, sulfasalazine 10 16 14 OJ 
6 F 66 + 39 NSAIDt 21 21 8 So ~ (;)-
7 F 55 + 79 NSAIDt 6 6 8 
8 F 80 + 66 NSAIDt 24 38 35 
9 M 52 + 56 Azathioprine, NSAID t 14 19 31 
10 M 77 + 94 NSAIDt 14 0 22 
Continued .. 
Table 1. (cont.) 
Number of joints 
Erythrocyte 
Rheumatoid sedimentation Somatostatin 
Patient Sex'" Age factor rate (mm/hour) Treatment Swollen Painful receptor positive 
Rheumatoid arthdtis (cant.) 
11 F 65 + 58 Corticosteroids, NSAJDt 10 14 33 
12 F 59 48 D~peniclllamine, 20 29 36 
corticosteroids, NSAID t 
13 M 68 + 87 NSAIOt 30 28 20 
14 F 32 + 80 Gold, NSAIOt 33 35 40 
Osteoarthritis 
15 F 68 24 NSAIOt 12 6 
16 F 84 18 Acetaminophen 7 6 
17 F 65 12 None 12 17 6 
18 F 77 10 NSAIOt 4 5 8 10 
::>-
M = male; F = female -€5 q;-
t NSAID = nonwsteroidal antiinflammatory drug ..., 
~ 
'" 
~ 
~ ~ 
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Figure 1. Visualization of the affected right 
wrist and left second metacarpophalangeal 
and proximal interphalangeal joints of patient 
8 (see Table 1) by l111n labelled somatostatin 
analogue scintigraphy (anterior view, 24 hours 
after injection). 
Figure 2. l111n labelled somatostatin analogue 
scintigraphy, visualizing both affected elbows 
of patient 8 (see Table 1) (24 hours after 
injection). 
Table 2 illustrates the relationships between somatostatin receptor 
scintigraphy findings and pain and swelling in the patients with rheumatoid 
arthritis. Five hundred and seventy-six joints were scored on the scintigrams. 
In two patients a total of 12 joints (all metatarsophalangeal jOints in patient 1 
and both shoulders in patient 11) could not be scored due to technical 
reasons. Two hundred and twenty (76%) of the 290 painful joints in the 14 
patients with rheumatoid arthritis were somatostatin receptor positive, 
whereas 125 (44%) of the remaining 286 non-painful joints were also 
positive. Of the remaining 70 painful joints that were negative on the 
somatostatin receptor scan, 32 were in two patients (patient 6 and 11). They 
did not differ from the other 12 patients with regard to either treatment or 
clinical symptoms. The median pain score was higher in the patients whose 
joints were positive at scintigraphy (p<0.0001, Wilcoxon rank-sum test). The 
sensitivity of scintigraphy for swollen joints was also 76% (207 of 274). 
Thirty-six of the 67 swollen joints that were negative at scintigraphy were 
also found in patients 6 and 11. Of 302 joints that were not swollen, 138 
(46%) were somatostatin receptor positive. The median degree of swelling 
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Figure 3. Visualization of the moderately 
painful and swollen right knee of patient 1 
(see Table 1) by l111n labelled somatostatin 
analogue scintigraphy (anterior view, 24 hours 
after injection). 
Chapter 5.1 
Figure 4. l111n labeJfed somatostatin analogue 
scintigraphy, visualizing the affected ankles 
and right forefoot of patient 7 (see Table 1) 
(anterior view, 24 hours after injection). 
correlated well with positivity at scintigraphy (p<0.0001, Wilcoxon rank-sum 
test). The sensitivity of scintigraphy for painful and/or swollen joints was 74% 
(252 of 340). Ninety-three of 236 joints without clinical involvement (39%) 
were visualized. When the combination 'pain and swelling' was scored, 80% 
of the jOints (175 of 220) were positive at scintigraphy. In patient 13 uptake of 
radioactivity was seen in the pericardium and pleurae, which was related to 
extraarticular rheumatoid arthritis involvement. 
In the patients with osteoarthritis, the sensitivity of scintigraphy for joint 
swelling and joint pain was only 20% and 14%, respectively, and the 
frequency of positive findings did not differ significantly between affected and 
clinically unaffected joints (p>0.05, Chi-square test). The median uptake of 
radioactivity in the patients with osteoarthritis was lower than that in patients 
with rheumatoid arthritis (85% of the osteoarthritis group had a scintigraphy 
score of 1, versus 36% of the rheumatoid arthritis group). In none of the 
control patients with ophthalmic Graves' disease, neuroendocrine tumours, or 
malignant lymphomas uptake of radioactivity was observed in the joints. 
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Table 2. Relationship between joint pain/swelling and somatostatin receptor scintigraphy 
results in 14 patients with rheumatoid arthritis. 
Scintigraphy 
Number of Number of Total number 
negative joints (%) positive joints (%) of joints 
Pain No 161 (56%) 125 (44%) 266 
Yes 70 (24%) 220 (76%) 290 
Swelling No 164 (54%) 136 (46%) 302 
Yes 67 (24%) 207 (76%) 274 
Pain andlor swelling No 143(61%) 93 (39%) 236 
Yes 68 (26%) 252 (74%) 340 
Pain and swelling No 186 (52%) 170 (48%) 356 
Yes 45 (20%) 175 (80%) 220 
The presence of specific somatostatin receptors in surgically excised synovial 
tissues was confirmed by in vitro autoradiography in two patients with 
rheumatoid arthritis. Both joints had also been visualized in vivo by 
scintigraphy. The displacement curve shown in Figure 5 illustrates the high 
affinity and specificity of the [1251-Tyr"J-octreotide binding in studies with these 
synovial tissue sections. This suggests the presence of somatostatin 
receptors in the tissue. However, we were unable to identify by 
autoradiographic studies which cell type(s) expressed somatostatin receptors 
in this tissue. The presence of specific somatostatin receptors was confirmed 
in four of five other patients with active rheumatoid arthritis who did not 
undergo in vivo scintigraphy, from whom metacarpophalangeal, knee, and 
ankle synovial membrane tissue samples were obtained. 
Discussion 
Somatostatin receptor scintigraphy has been used successfully in the 
visualization of neuroendocrine tumours as well as granulomatous diseases 
and malignant lymphomas (3,4,9,10). This is, to our knowledge, the first 
report of the use of this technique in the visualization of clinically affected 
joints in rheumatoid arthritis. Rheumatoid arthritis is a chronic inflammatory 
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Figure 5. In vitro detection of somatostatin receptors in a synovial tissue sample from a 
rheumatoid arthritis patient. The displacement curve of [125 1-Tyr3J-octreotide is shown in tissue 
sections incubated with the radioligand (30,000 cpm/100 )11) and increasing concentrations of 
unlabelled octreotide (0) or 100 11M of epidermal growth factor (0). 
disorder involving the synovial membranes of multiple joints. There is no 
'gold standard' for the assessment of the clinical activity of the disease. 
Subjective parameters are mainly used to quantify arthritis activity (19). Pain 
and swelling of the joints are the main clinical indicators of inflammatory 
activity in rheumatoid arthritis. In the 14 patients with active rheumatoid 
arthritis examined in this study, clinical activity correlated well with the results 
of somatostatin receptor scintigraphy. However, in two patients, a number of 
painful and swollen joints were negative at scintigraphy. The reason for this 
discrepancy in these two patients is not clear. The number of false positive 
scintigrams is unknown, because we did not perform synovial biopsies to 
exclude subclinical synovitis in these patients. Pleural and pericardial 
involvement of rheumatoid arthritis were visualized as well in one patient, 
suggesting that somatostatin receptor scintigraphy is also useful in the 
visualization of extraarticular involvement. 
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In the selected patients with severe osteoarthritis, no significant correlation 
between pain and/or swelling and uptake of radioactivity by the affected 
joints at scintigraphy was demonstrated. However, the osteoarthritic joints 
demonstrated a lower uptake of [111In-DTPA-D-Phe ']-octreotide in 
comparison with the joints of the patients with rheumatoid arthritis. We 
cannot rule out the presence of an inflammatory component in the affected 
joints of these selected osteoarthritis patients; this is substantiated by the 
finding of negative scan results in all of the 'control' patients. 
Different scintigraphic techniques have been used over the years for the 
visualization of affected joints in rheumatoid arthritis (20-25). The markers 
used can be classified according to the compartment involved. The vascular 
compartment reflects the increased blood flo~ and interstitial extravasation, 
the bone compartment reflects the normal response to bone destruction, and 
the inflammatory compartment reflects the infiltration of leucocytes. To our 
knowledge, no scintigraphic technique related to specific receptors in the 
affected synovial membranes in rheumatoid arthritis has been described 
previously. I n vitro binding assays showed the presence of specific 
somatostatin receptors in synovial biopsy specimen from our patients, but did 
not enable the recognition of the type of cells that expressed these 
somatostatin receptors. ['l1ln-DTPA-D-Phe']-octreotide may bind to 
somatostatin receptors on lymphocytes and monocytes that have infiltrated 
into the affected synovial membranes. The low grade uptake of radioactivity 
in osteoarthritis, which has only a minor inflammatory component, supports 
this hypothesis. 
The specificity of this in vivo method of somatostatin receptor visualization 
might be substantiated by investigation of the effect of simultaneous 
administration of high dose 'cold' octreotide. However, our in vitro studies 
already demonstrated specific binding of octreotide, which could be 
completely prevented by the addition of excess 'cold' octreotide, in the 
synovial membranes studied. 
The relationship between somatostatin receptor expression and disorders of 
the immune system have been described previously (3-8,26-35). T and B 
lymphocytes and monocytes express somatostatin receptors, and 
somatostatin has been shown to modulate the activity of the immune system 
(5-7,26,27,31). At low concentrations, somatostatin caused inhibition of the 
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lectin induced proliferation response of lymphocytes (26,27,31). Inhibition of 
cytotoxicity and of the release of cytokines by lymphocytes has also been 
described (33,35). Somatostatin suppresses immunoglobulin synthesis in 
Peyer's patches as well as in a myeloma cell line (28,30). Lymphoid cell lines 
of T cell origin have been shown to express somatostatin receptors (29). 
Somatostatin and somatostatin receptors have also been detected in 
schistosomiasis induced murine granulomas (32,34). Treatment with the long 
acting somatostatin analogue octreotide decreased the granulomatous 
response in this model by approximately 45% (36). In ten patients with active 
rheumatoid arthritis, a transient beneficial effect was observed after direct 
intraarticular administration of somatostatin (37). This may be related to the 
inhibition of the release of substance P by nerve endings within these joints 
or by modulation of the activity of infiltrating immune cells. Thus, the potential 
value of somatostatin in the treatment of rheumatoid arthritis, as well as in 
the monitoring of disease activity, merits further exploration. 
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CHAPTER 5.2 
VASCULAR SOMATOSTATIN RECEPTORS IN RHEUMATOID ARTHRITIS 
Vascular somatostatin receptors in rheumatoid arthritis 
Abstract 
The peripheral nervous system and its neuropeptidergic pathways may play an 
important role in the pathogenesis and development of rheumatoid arthritis. In 
the present study, the role of the neuropeptide somatostatin, which was recently 
shown to be implicated in inflammatory diseases of the gastrointestinal tract, 
was evaluated by measuring the expression of somatostatin receptors in 
synovium from patients with rheumatoid arthritis. Somatostatin receptors were 
detected using in vitro receptor autoradiography in the synovium from five 
patients with active disease. No receptors were found in one case, a 
successfully treated patient with quiescent disease. The receptors were of high 
affinity and specific for biologically active somatostatin analogues. Displacement 
by nanomolar concentrations of somatostatin 14, somatostatin 28, and 
octreotide was observed, suggesting that most of the receptors identified belong 
to the somatostatin receptor subtype 2. The somatostatin receptors were 
preferentially located in blood vessels, with specific labelling of the veins but not 
of the arteries. The whole vessel wall was homogeneously labelled, including 
the smooth muscle cells and probably the endothelium. These data suggest that 
the synovium in active rheumatoid arthritis expresses a high density of 
somatostatin receptors. Somatostatin may act through these venous receptors 
to influence the inflammatory process by induction of vasoconstriction, inhibition 
of plasma extravasation and cell migration, or inhibition of neovascularization. 
Introduction 
Clinical and experimental observations suggest the implication of the nervous 
system in the etiology and pathogenesis of human joint diseases (1-3): for 
instance, neurological lesions or stress are known to affect the development and 
severity of rheumatoid arthritis lesions (4-6). The human nervous system is also 
able to modulate inflammatory processes in peripheral tissues, in particular via 
blood vessels (7,8). There is good evidence that both the afferent (sensory) and 
efferent (sympathetic) components of the peripheral nervous system contribute 
to the inflammatory process (1). 
Neuropeptides play a major role within the peripheral nervous system (9). 
Moreover, several neuropeptides and their receptors, in particular SUbstance P, 
calcitonin gene related peptide and endothelin are known to be involved in joint 
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physiology. and in joint diseases, such as rheumatoid arthritis (10,11). There is, 
for instance, experimental evidence that sUbstance P can be released from 
peripheral nerve terminals into the joints (12) and that substance P nerve fibres 
are involved in the local regulation of blood flow, vascular permeability and 
smooth muscle tone (13,14). In rheumatoid arthritis, the concentration of 
substance P is elevated in the synovial fluid (13,15,16), and substance P 
receptors have been identified in synovial blood vessels (17). Similarly, in 
synovial tissue from patients with rheumatoid arthritis, endothelial cells in blood 
vessels display endothelin-like immunoreactivity and endothelin binding sites 
(18). Therefore, substance P and endothelin may influence the course of joint 
disease. 
Somatostatin, a small neuropeptide, has a wide range of actions within the 
central and peripheral nervous system, and the immune system (19). These 
actions are mediated by specific somatostatin receptors located in all these 
target tissues (20-22). Somatostatin and somatostatin receptors are also 
implicated in many pathological conditions. For instance, a great variety of 
human neoplasms express somatostatin receptors in high density (23,24). 
Recently, somatostatin was shown to be involved in inflammatory diseases: 
active granulomatous lesions in sarcoidosis and human tuberculosis express a 
high density of somatostatin receptors (25). Moreover, in Crohn's disease and 
ulcerative colitis, the intestines express somatostatin receptors on blood vessels 
in the inflamed areas (26). These data suggest an important role of somatostatin 
in these pathological conditions, and have led to useful therapeutic and 
diagnostic applications of somatostatin analogues as well (23). 
The aim of the present study was to investigate whether or not somatostatin 
receptors are expressed in rheumatoid arthritis. Somatostatin receptor 
autoradiography (20,27) was used to localize and characterize somatostatin 
receptors in biopsies of synovial tissue from rheumatoid arthritis patients, using 
either [1251-Tyr'j-octreotide (28) or the [,251-LeuB-D-Trp22-Tyr"j-somatostatin 28 
(29) as radioligands. 
Materials and methods 
Patients 
Samples of synovial tissue were obtained during replacement surgery in six 
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patients with rheumatoid arthritis. All samples were frozen without delay after 
surgical resection and stored at -70°C for 4-12 months. The diagnosis of 
rheumatoid arthritis was made according to standard clinical, radiological and 
histological criteria (30). The patient characteristics, the sites of surgical inter-
vention and the histological findings in the samples are summarized in Table 1. 
Somatostatin receptor autoradiography 
Cryostat sections of the tissue samples, 1 0-20 ~m thick, were processed for 
somatostatin receptor autoradiography as described in detail previously (20,27). 
The radioligands used were the somatostatin analogues ['25I-Tyr'j-octreotide and 
['2'I_Leu8 -0-Trp22 -Tyr'j-somatostatin 28, known to specifically label somatostatin 
receptors. Both ligands were iodinated, purified on high pressure liquid 
chromatography columns (specific activity 2000 Ci/mmol) and characterized in 
standard binding assays as described previously (28,29). For autoradiography, 
tissue sections were mounted on microscope slides and stored at -20°C for at 
least 3 days to improve adhesion of tissue to the slide. Sections were then 
incubated for 2 hours at ambient temperature in the presence of the iodinated 
ligand (0.15-0.30 x 10' dpm/ml, approximately 40-80 pM). The incubation 
solution was Tris-HCI buffer (170 mM, pH 8.2), containing 1% bovine serum 
albumin (BSA), bacitracin (40 ~g/ml), and MgCI2 (5 mM) to inhibit endogenous 
proteases. Non-specific binding was determined by adding 1 ~M unlabelled 
[Tyr'j-octreotide or somatostatin 28. Incubated sections were washed twice for 
5 minutes in cold incubation buffer containing 0.25% BSA, then in buffer alone, 
and dried quickly. Finally, the sections were apposed to 'H labelled ultrafilms 
(Amersham, United Kingdom) and exposed for one week in X-ray cassettes. In 
selected cases, displacement experiments were performed with successive 
tissue sections by means of increasing concentrations of various biologically 
active (somatostatin 14, somatostatin 28, octreotide, [Tyr'j-octreotide) or inactive 
somatostatin analogues (somatostatin 28-(1-12» and an unrelated peptide 
(epidermal growth factor). The autoradiograms were quantified using a 
previously described computer assisted image processing system (27). Tissue 
standards for iodinated compounds (Amersham, United Kingdom) were used for 
this purpose. A tissue was defined as somatostatin receptor positive when the 
optical density measured over an area in the total binding section was at least 
twice the optical density of the non-specific binding section (27). Adjacent 
sections from selected samples of tissues tested with [,2'I-Tyr'j-octreotide were 
also examined for specific binding with the radioligand ['2'I_Leu8_O_Trp 22_Tyr'j_ 
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somatostatin 28, to confirm that the same tissue elements were identified by 
both ligands. Adjacent sections were also studied by conventional histological 
techniques and immunohistochemical staining for better visualization and 
identification of blood vessels (smooth muscle actin, factor VIII), to establish the 
structural identity of somatostatin receptor positive tissues. 
Results 
All synovial tissue biopsies with histological signs of active rheumatoid arthritis 
showed specific binding ofthe radioligands [1251-Tyr3 j-octreotide and [1251_Leu8 _D_ 
Trp"-Tyr5J-somatostatin 28 (Table 1). The distribution was patchy in all 
specimens, suggesting that only selected structures were able to bind the 
somatostatin radioligands. Figure 1 shows an example at low magnification of 
the distribution of somatostatin receptors labelled by [1251-Tyr"j-octreotide in a 
synovial biopsy. The patchy distribution of the radioactivity correlates well with 
the distribution pattern of smooth muscle actin immunoreactivity. The 
somatostatin receptors were of high affinity and specific for somatostatin. As 
seen in Figure 2, bound [1251_ Tyr3j-octreotide could be displaced in the 
nanomolar range by somatostatin 28 or octreotide, but not by the biologically 
inactive somatostatin 28-(1-12), nor by epidermal growth factoL A biopsy from 
patient 6, with biochemically and clinically proven rheumatoid arthritis, showed 
no histological signs of active rheumatoid arthritis after successful treatment with 
cytostatic drugs. The synovial tissue specimen displayed a low density of 
vessels on which no somatostatin receptors could be identified (Table 1). 
The cellular localization of the somatostatin receptors was investigated by 
comparing the somatostatin receptor autoradiography results with the 
corresponding tissue section stained for special structures. As can be seen in 
Figure 3A-3C, the somatostatin receptors were clearly localized on blood 
vessels. Indeed, on comparison of the pattern of somatostatin receptors with the 
corresponding section stained for smooth muscle actin, it became evident that 
veins expressed somatostatin receptors, whereas arteries did not A similar 
picture was seen in another case, shown in Figure 3D-3F, where the pattern of 
somatostatin receptors was found to correspond with the localization of veins 
as depicted by immunohistochemical staining for factor VIII. Here again, the 
veins were somatostatin receptor positive whereas the arteries were not 
labelled; in all cases, the entire venous wall was receptor positive. Most of the 
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N Table 1. Patient characteristics and somatostatin receptor status in six patients with rheumatoid arthritis. ~ OJ en 
" Somatostatin receptors ~ 
.., 
Patient Sex* Age Diagnosis Therapy Site Histology Autoradiography Scintigraphy en 0 
3 
F 59 Rheumatoid Salazopyrine Toes Rheumatoid arthritis Positive Not done !l) 0-
arthritis Indomethacin compatible synovitist; en or 
leucocyte infiltration of g 
some blood vessels 
<il 
" 2 F 64 Rheumatoid Prednisone Wrist Rheumatoid arthritis Positive Not done ~
arthritis compatible synovitis t 0-
Cri 
3 F 75 Rheumatoid Prednisone Knee Rheumatoid arthritis Positive Positive S· 
arthritis Salazopyrine compatible synovitist 3-
"' 4 F 64 Rheumatoid ValtaTen Wrist Rheumatoid arthritis Positive Not done c:: :3 
arthritis compatible synovitist !l) 
0-
5 M 67 Rheumatoid None Fingers Rheumatoid arthritis Positive Positive a: 
arthritis compatible synovitist !l) So T cell lymphoma ~ 
6 F 61 Rheumatoid Methotrexate Fingers Synovial tissue without Negative Not done 
arthritis:t significant 
inflammatory changes 
M ::; male; F ::; female 
t Lymphoplasmocytic infiltrate, fibrinous exudate, occasional lymphatic follicles, occasional granulomas with central fibrinoid necrosis; 
no vasculitis. 
t Rheumatoid arthritis was diagnosed several years before joint replacement, and the patient had been succesfully treated with 
methotrexate; at the time of joint replacement, quiescent arthritis was diagnosed. 
Figure 1. Visualization of somatostatin 
receptors in a synovial membrane from a 
patient with rheumatoid arthritis. (A) 
Immunohistochemical staining for smooth 
muscle actin, with intensively labelled blood 
vessels. (8) Autoradiogram showing total 
binding of C251-Tyr3]-octreotide. A non-
homogeneous, patchy distribution of the label is 
seen, related to the vessel distribution. (C) 
Autoradiogram showing non-specific binding of 
C251_Tyr3]_octreotide in the presence of 1 J..lM 
octreoUde. Bar represents 1 mm. 
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synovial tissues showed inflammatory signs such as Iymphoplasmocytic 
infiltrates, but the wall of the veins did not consistently display inflammatory 
changes. A receptor positive vein in a rheumatoid arthritis sample without 
inflammatory infiltrate is seen in Figure 4. This suggests that the somatostatin 
receptors are likely to be located on the smooth muscle cells, and perhaps also 
on the endothelial cells of these veins, rather than on occasional infiltrating 
leucocytes. In general, the veins were the most prominently labelled structures 
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Figure 2. Displacement curve of [1251~Tyr3]_octreotjde in tissue sections from a synovial membrane 
of a patient with rheumatoid arthritis. Tissue sections were incubated with [1251_Tyr3]_octreotide 
(30,OOD cpm/1 00 Ill), and increasing concentrations of unlabelled octreotide (0) or somatostatin 28 
(li), or 100 nM of somatostatin 28-{1-12) (v) or epidermal growth factor (0). Each point represents 
the optical density of binding measured in a region rich in blood vessels in at least two sections. 
Non-specific binding, in the presence of 100 nM octreotide, was subtracted from all values. 
in the synovial biopsies, with very little label, if any, on other structures such as 
normal synovial membranes, connective tissue or lymphocytic infiltrates. 
However, if lymphatic follicles with germinal centres were present, the germinal 
centres were labelled as well (21). 
Two of the receptor positive patients were investigated in vivo with "'In labelled 
somatostatin analogue scintigraphy (31,32) before surgical resection of the 
damaged joints; the jOints which could be clearly localized in vivo were shown 
to have somatostatin receptor positive lesions in vitro. 
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Figure 3. Visualization of somatostatin receptors in blood vessels in synovial membranes from two 
patients with rheumatoid arthritis. (A) Section stained for smooth muscle actin, showing various veins 
(arrowheads) and arteries (arrow) in inflamed synovial tissue. (D) Section stained for factor VIII, 
showing various veins (arrowheads) and arteries (arrow) in inflamed synovial tissue. (8) and (E) 
Autoradiograms showing total binding of [125I-Tyr3]-octreotide. The veins (arrowheads) are labeHed 
but the arteries (arrows) are not. (C) and (F) Autoradiograms showing non-specific binding of [125 1_ 
Tyr3]-octreotide, in the presence of 1 f-lM octreotide. Bars represent 0.1 mm. 
Discussion 
This study reports the presence of somatostatin receptors in blood vessels 
localized in diseased synovial tissues of patients suffering from rheumatoid 
arthritis. The receptors are homogeneously distributed in the whole wall of veins 
but are not identified in arteries. The fact that the venous wall rarely contained 
non-vascular constituents such as infiltrating leucocytes, indicates that the 
muscular wall and perhaps the endothelium are the most likely sites of 
somatostatin receptor expression in rheumatoid arthritis. 
Somatostatin receptors were identified in all synovial tissues displaying 
histological changes compatible with active rheumatoid arthritis. Conversely, the 
synovial biopsy from a patient with clinically inactive rheumatoid arthritis and 
histological findings compatible with a quiescent stage of the disease does not 
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Figure 4. Visualization of somatostatin 
receptors in a vein in synovial membrane from 
a patient with rheumatoid arthritis. (A) 
Haematoxylin-eosin stained section. (8) 
Autoradiogram showing total binding of [1251_ 
Tyr31-octreotide. Somatostatin receptors are 
localized in the entire wall of the vein. (C) 
Autoradiogram showing non-specific binding of 
[1251_Tyr3J_octreotide in the presence of 1 ).1M 
Detrectide. Bar represents 0.1 mm. 
express measurable amounts of somatostatin receptors. 
Histologically normal human synovial tissue, collected under conditions identical 
to those used for rheumatoid arthritis tissue, is difficult to obtain and could not 
be evaluated in this study. Whereas the present investigation clearly 
demonstrated the expression of somatostatin receptors in active rheumatoid 
arthritis, the results do not exclude the possibility that normal synovial tissue or 
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diseased, non-rheumatoid synovia also express somatostatin receptors. 
The somatostatin receptors identified in active rheumatoid arthritis tissue have 
the same characteristics as somatostatin receptors in established somatostatin 
target tissue, Le. they are of high affinity and specific for biologically active 
somatostatin analogues (21-22,33). The displacement of the radioligand by 
somatostatin 28 as well as by octreotide in the nanomolar range, strongly 
suggests that the venous somatostatin receptors belong mainly to the 
somatostatin receptor subtype 2 (34). Indeed, human somatostatin subtype 2 
receptors can be distinguished from the other four human somatostatin receptor 
subtypes by their very high affinity for octreotide (34-36). 
The presence of somatostatin receptors on veins and venules in rheumatoid 
arthritis may be of functional interest. Somatostatin, by itself, or by interacting 
and antagonizing other peptides such as substance P, may regulate and 
influence inflammatory and repair processes. Firstly, the high density of venous 
somatostatin receptors may allow somatostatin to have a vasoconstrictor effect, 
as exerted in various parts of the body such as the mesenterium (37). 
Alternatively, somatostatin may counterregulate the vasodilator effect of 
substance P in human synovial tissue (14), and thus reduce inflammation. 
Secondly, somatostatin may have an effect on small blood vessels by directly 
altering fluid imbalance and the extravasation of leucocytes associated with 
inflammation, or by counterregulating the influence of substance P on the 
extravasation of plasma and white blood cells (38-40). Thirdly, somatostatin may 
also affect synovial vascular growth, since somatostatin analogues can inhibit 
myointimal proliferation in certain animal models (41). More generally, by 
affecting different stages of the inflammatory process and different tissue 
elements involved in inflammation, somatostatin may be part of the nUmerous 
mechanisms which determine the extent and course of this process. 
Although the most widely held view is that rheumatoid arthritis is an autoimmune 
disease, there are numerous observations implicating the nervous system in the 
etiology of the disease. For instance, the important contribution of the 
unmyelinated afferents as well as of sympathetic efferents to neurogenic 
inflammation has been emphasized during the last decade (1-3). Interestingly, 
some of the unmyelinated afferents as well as sympathetic efferents are known 
to contain somatostatinergic neurons (42-44). An altered neuronal activity in 
these somatostatinergic pathways may lead to a disturbed synaptic release of 
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somatostatin which, in turn, may influence the behaviour of its vascular targets. 
Moreover, it has been reported that the concentration of neuropeptide degrading 
enzymes is increased in inflamed human synovium (45). Thus, these enzymes 
may lower the local concentration of somatostatin. Subsequently, the lack of 
local endogenous somatostatin may also affect the vascular system in 
rheumatoid arthritis, possibly by altering the somatostatin receptor expression. 
The presence of somatostatin receptors in rheumatoid arthritis may constitute 
the molecular basis for therapy of rheumatoid arthritis using somatostatin 
analogues. Recent reports on the use of somatostatin in patients with 
rheumatoid arthritis suggest that such drugs may have a beneficial symptomatic 
effect (46). Exogenous somatostatin analogues may inhibit the inflammatory 
process by a direct, complex, local action through vascular somatostatin 
receptors, resulting in induction of vasoconstriction, inhibition of plasma 
extravasation, inhibition of white blood cell migration or even inhibition of 
neovascularization. Ultimately, such changes may lead to a reduction of pain 
(46). However, the possibility of an additional local and systemic action of 
somatostatin on the immune system (47) should also be considered, since 
somatostatin receptors are known to be expressed by most normal human 
lymphoid tissues (21,22), and since rheumatoid arthritis appears to have an 
autoimmune component. 
The large numbers of somatostatin receptors in vessels in rheumatoid arthritis 
may have diagnostic consequences. Radiolabelled somatostatin analogues are 
currently being used successfully in the in vivo detection of somatostatin 
receptor positive tumours (31,32). 
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CHAPTER 5.3 
SOMATOSTATIN RECEPTOR SCINTIGRAPHY 
IN SJOGREN'S SYNDROME 
Somatostatin receptor scintigraphy in Sjogren's syndrome 
Clinical aspects of Sjogren's syndrome 
Sjogren's syndrome is a systemic autoimmune disease, in which predominantly 
the salivary and lacrimal glands are affected. Histological examination of the 
mucosa is characterized by mononuclear infiltrates around the salivary ducts, 
in which CD4 positive lymphocytes predominate. Activated CD4 positive 
lymphocytes are supposed to express somatostatin receptors (1). The clinical 
spectrum of Sjogren's disease is very heterogeneous, varying from mild 
complaints of dryness of the eyes or mouth to severe keratoconjunctivitis sicca, 
xerostomia, and extraglandular features like lung involvement. No single 
diagnostic test has been found for Sjogren's syndrome. There are different 
criteria used by various investigators to establish the diagnosis of Sjogren's 
syndrome. In our study the European criteria for the classification of Sjogren's 
syndrome were used (2). Until now no effective therapy is available. The 
treatment of Sjogren's syndrome remains conservative and symptomatic. 
Arthralgia and myalgia are generally treated with simple non-steroidal 
antiinflammatory drugs (NSAIDs) or antimalarials. NSAIDs and low dose 
corticosteroids are effective for systemic symptoms like fever and weariness. 
High dosages of corticosteroids and immunosuppressive drugs may be 
considered in case of severe extraglandular manifestations with life threatening 
organ failure (3). 
Somatostatin receptor scintigraphy in Sjogren's syndrome 
In chapter 2 the somatostatin receptor expression by activated lymphocytes is 
described. Recently, we performed somatostatin receptor scintigraphy, using 
['"In-DTPA-D-Phe' ]-octreotide, in 12 patients with Sjogren's syndrome, in order 
to detect somatostatin receptor expression in the affected tissue. I n nine 
patients uptake of radioactivity was found in the affected salivary glands (Figure 
1 and Figure 2), lungs, joints, and even in the heart. Interestingly, the uptake in 
the region of the lung decreased during treatment with hydroxychloroquine, 
which is supposed to be stored in the lungs. 
Somatostatin receptor scintigraphy enables the visualization of the extent of 
disease in Sjogren's syndrome, and may be used in the monitoring of the 
efficacy of therapy, especially in the case of lung involvement. 
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Figure 1. Visualization of the salivary gland in 
a patient with Sjogren's syndrome by 1111n 
labelled somatostatin analogue scintigraphy 
(lateral view, 24 hours after injection). 
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Figure 2. Visualization of the left lacrimal gland, 
parotid gland, submaxillary gland and 
associated lymphadenopathy in a patient with 
Sjogren's syndrome (lateral view, 24 hours after 
injection). 
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CHAPTER 6 
SOMATOSTATIN RECEPTOR SUBTYPE EXPRESSION 
IN HUMAN LYMPHOID CELL LINES 
Somatostatin receptor subtype expression in human lymphoid cell lines 
Abstract 
Previous studies have shown that human lymphoid cells express somatostatin 
receptors. Recently, five somatostatin receptor subtypes have been identified. 
In this study the expression of messenger ribonucleic acid (mRNA) for 
somatostatin receptor subtypes was investigated in ten B cell lines and eight T 
cell lines by reverse transcriptase polymerase chain reaction (RT-PCR). Two B 
cell lines (JY and TMM) and two T cell lines (HSB-2 and MT-1) expressed 
mRNA for somatostatin receptor subtype 2, resulting in the expression of 
membrane somatostatin receptors in the cell lines JY, TMM and MT-1. We 
therefore conclude that only somatostatin receptor subtype 2 mRNA is 
expressed in human lymphoid cells. 
Introduction 
Somatostatin receptor expression in non-activated peripheral lymphocytes and 
monocytes was first described by Bhathena et al. (1). Several groups have 
reported the expression of somatostatin receptors by human and animal white 
blood cells (2). Recently, somatostatin receptor subtype 2 was found in 
Schistosoma mansoni egg induced granulomas in mice (3). Furthermore, in situ 
hybridization showed the expression of somatostatin receptor subtype 2 in 
Hodgkin's lymphomas and of somatostatin receptor subtypes 2 and 3 in non-
Hodgkin's lymphomas (4). In the immune system, the density of somatostatin 
receptors is low, which makes the identification of somatostatin receptors on 
single cells or tissue sections extremely difficult. 
In this report we present our results concerning the detection of mRNA encoding 
for five somatostatin receptor subtypes in lymphoid cell lines by a subtype 
specific RT-PCR. Ten human lymphoid B cell lines and eight human lymphoid 
T cell lines were investigated for somatostatin receptor mRNA expression in 
relation to their haematopoietic differentiation state. 
Materials and methods 
Cell lines 
Eighteen lymphoid cell lines were investigated (Table 1 and Table 2). The T cell 
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Table 1. B cell lines. 
Pre B cells 
RS4,11a 
Nalm-1 
BV-173 
Nalm-6 
Table 2. T cell lines. 
CD3 negative cells 
HSB-2 
Moll-3 
ALL-1 
MT-1 
Immatu re 8 cells 
Raji 
Daudi 
JY 
TcR-o positive cells 
Peer 
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Mature B cells / plasma cells 
TMM 
LP-1 
L-363 
TeR-all positive cells 
Moll-16 
HuT-78 
HPB-ALL 
lines were characterized by T cell receptor (TcR) gene rearrangement as 
described previously (5). 
RNA isolation 
Total cytoplasmic RNA was isolated according to standard procedures 
described by Chomczynski et al. (6). Briefly, cells (5-10 x 106 ) were 
homogenized with 0.5 ml of solution D in a 1.5 ml Eppendori tube. Sequentially, 
50 III of 2 M sodium acetate (pH 4.0), 0.5 ml of water saturated phenol, and 0.1 
ml of chloroform were added to the homogenate, with thorough mixing after the 
addition of each reagent. The final suspension was cooled on ice for 15 
minutes. Samples were centrifuged at 10,000 x g for 15 minutes at 4°C. The 
aqueous phase was transferred to a fresh tube containing 0.6 ml of isopropanol, 
and then placed at 4°C for at least 6 hours to precipitate RNA. RNA was 
recovered by centrifugation (10,000 x g, 15 minutes, 4°C), dissolved in 0.3 to 
0.5 ml solution D, and precipitated again with 1 volume of isopropanol. After 
centrifugation (10,000 x g, 15 minutes, 4°C), the RNA pellet was washed in 0.6 
to 1.0 ml 75% ethanol and eventually dissolved in 25-50 III RNase-free water. 
From 10 Ilg of total cytoplasmic RNA, polyA + mRNA was isolated using 
paramagnetic oligo-(dT) beads (Dynabeads Oligo (dT)25' Dynal AS, Oslo, 
Norway) according to the manufacturers instructions. For each polyA + mRNA 
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isolation 30 ~I of the oligo-( dT)-beads suspension was used in a volume of 200 
~I and the polyN mRNA was finally eluted in 20 ~I 2 mM EDTA, pH 8.0. 
Synthesis of complementary deoxyribonucleic acid (cDNA) 
cDNA was synthesized from 2 ~I of the isolated polyA' mRNA by using AMV 
Reverse Transcriptase (SuperRT, HT Biotechnology Ltd, Cambridge, United 
Kingdom), under conditions described by the manufacturer, and 5 pmol oligo-
(dT),2_18 primer (Gibco BRL, Renfrewshire, Scot/and) (7). Each cDNA reaction 
was performed in duplicate. 
Polymerase chain reaction (PCR) 
One-thirteenth of the synthesized cDNA was used for each PCR reaction. The 
50 ~I reaction mixtures contained, in addition to the DNA template, 0.1 units 
SuperTaq DNA polymerase (HT Biotechnology Ltd, Cambridge, United 
Kingdom), buffer provided with the enzyme, 50 ~M of each of the four 
deoxynucleotides dATP, dCTP, dGTP and dUTP (HT Biotechnology Ltd, 
Cambridge, United Kingdom), and 5 pmol of forward and reverse primers 
specific for one of the five somatostatin receptor subtypes or for the Il actin 
gene. With each of the duplicate cDNA samples PCR reactions were performed 
for all primer pairs. The primers specific for somatostatin receptor subtype 1 and 
2 were described by Wulfsen et al. (8), the primers for receptor subtype 3, 4 
and 5 by Kubota et al. (9) and the Il actin primers by Vidal et al. (10). The 
reactions were performed in a DNA thermal cycler (Perkin Elmer Cetus 
Instruments, Gouda, the Netherlands). After an initial denaturation for 5 minutes 
at 94°C, the samples were subjected to 35 cycles of denaturation, annealing 
and extension of 1 minute at 94°C, 2 minutes at 59°C and 1 minute at 72°C, 
respectively. After a final extension of 10 minutes at 72°C, 10 ~I aliquots of the 
resulting PCR products were analyzed on 1 % agarose gels. 
Controls 
To ascertain that no DNA was present in the polyA' mRNA preparations, the 
cDNA reactions were also performed once without reverse transcriptase, and 
amplified with primers specific for somatostatin receptor subtype 1. Amplification 
of the duplicate cDNA samples with the Il actin specific primers served as a 
positive control for the quality of the cDNA. To exclude contamination of the 
PCR reaction mixtures the reactions were also performed in the absence of 
DNA template in parallel with the cDNA samples. Plasmid DNA, containing the 
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genes for receptor subtypes 1-5, was amplified in parallel with the cDNA 
samples as a positive control for the PCR. These plasm ids were a generous gift 
of Dr. G.I. Bell (Howard Hughes Medical Institute Research Laboratories, 
University of Chicago, Chicago, Illinois, USA). The plasmids were used in 
dilutions down to 0.01 pg per PCR reaction, which gives a weak but consistent 
signal when analyzed on gel. This amount of plasmid DNA contains 
approximately 3000 copies of the template. Assuming that 10 Ilg of total 
cytoplasmic RNA represents the amount of RNA of 106 cells (10.5 Ilg RNA per 
cell), and that the combined efficiencies of the polyA' mRNA isolation with the 
oligo-( dT) beads and the cDNA reaction is in the order of 50%, approximately 
4000 copies of template would be expected in the amount of cDNA used in the 
PCR reactions, if the cells contained 1 mRNA molecule per cell. Therefore, 
signals that were consistently weaker than the signal produced by amplification 
of 0.01 pg plasmid DNA were considered not to be biologically relevant, and 
were depicted as negative result. 
Ligand binding assay 
Reaction conditions were the same as described by Reubi et al. (11). The 
radioligand used in the binding stUdies was the [1251-Tyr3]-octreotide (Sandoz, 
Basel, Switzerland). Briefly, membrane preparations (corresponding to 15-30 Ilg 
protein) of cells cultured for 14 days (JY cell line), 18 days (TMM and HSB-2 
cell lines) or 32 days (MT-1 cell line) in RPMI without HEPES (Gibco BRL, 
Renfrewshire, Scotland), with 10% foetal calf serum were incubated in a total 
volume of 100 III at room temperature for 90 minutes with radioligand (30,000-
50,000 cpm) and increasing concentrations of unlabelled [Tyr3]-octreotide in 
HEPES buffer (10 mM HEPES, 5 mM MgCI2 and 0.2 g/l bacitracin, pH 7.6) 
containing 0.2% bovine serum albumin. After the incubation, 1 ml ice cold 
HEPES buffer was added to the assay mixture, and membrane bound 
radioactivity was separated from unbound by centrifugation during 2 minutes at 
14,000 rpm in an Eppendorf microcentrifuge (12). The remaining pellet was 
washed twice with ice cold HEPES buffer, and the final pellet was counted in 
a gamma counter. Specific binding was taken to be the total binding minus the 
binding in the presence of 10 11M unlabelled [Tyr3]-octreotide. Unrelated 
compounds, such as thyrotropin releasing hormone, luteinizing hormone-
releasing hormone, and epidermal growth factor, added in a 1000-fold excess 
were not able to displace ['251_Tyr3]_octreotide binding. 
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Results 
All cell lines were investigated with RT-PCR for the expression of human 
somatostatin receptor mRNA (subtypes 1-5). The results are shown in Table 3 
and Table 4. The two B cell lines JY and TMM and the two T cell lines HSB-2 
and MT-1 were found to express mRNA for somatostatin receptor subtype 2. No 
mRNA for the other receptor subtypes was detected in these human lymphoid 
cell lines. The expression of mRNA for somatostatin receptor subtype 2 in the 
two human B cell lines was in cells of the immature B cell range. Somatostatin 
receptor subtype 2 mRNA in the T cell lines was found in the CD3 negative 
'early' differentiation range. It should be mentioned, however, that not all 
immature and mature B cell lines tested were somatostatin receptor subtype 2 
mRNA positive, while only two of the four CD3 negative T cell lines tested 
expressed the somatostatin receptor subtype 2 mRNA 
Scatchard analyses with [1251-Tyr'J-octreotide revealed high affinity binding sites 
in the TMM, JY, and MT-1 cell lines (Figure 1). Ligand binding analyses with 
[ '25I-Tyr'J-somatostatin 28 showed identical results, indicating that only 
somatostatin receptor subtype 2 was expressed (data not shown). The presence 
of somatostatin receptor subtype 2 mRNA in the HSB-2 cell line did not result 
in the expression of this somatostatin receptor subtype in the cellular 
membrane. 
Discussion 
Radioligand binding studies as well as biochemical and physiological evidence 
suggested the existence of at least two somatostatin receptor subtypes (13,14). 
Recently, somatostatin receptor heterogeneity was further demonstrated by 
molecular cloning of a family of five putative somatostatin receptors (15-23). 
Somatostatin receptors are expressed by human lymphoid cell lines, normal 
lymphocytes as well as malignant lymphoid cells (2). Previously, specific 
somatostatin binding sites were found on the human T cell leukaemia cell line 
MT-2, the Epstein-Barr virus transformed B cell line Isk, and the human 
lymphoblastic cell line Molt-4 (24). They were also found in human thymus and 
spleen, and were identified within the germinal centres of gastrointestinal 
associated lymphoid tissue (25,26). These observations led to the suggestion 
that somatostatin receptor expression is related to the proliferative state of 
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Table 3. Detection of messenger ribonucleic acid (mRNA) for somatostatin receptors in 
lymphoid B eel! lines by reverse transcriptase polymerase chain reaction (RT~PCR). 
Pre B cell 
RS4, 11 a 
Nalm-1 
BV-173 
Nalm~6 
Immature B cell 
Raji 
Daudi 
JY 
Mature B cell / plasma cell 
TMM 
LP-1 
L-363 
Somatostatin receptor subtype 
2 3 4 5 
Not done Not done Not done 
+ 
+ 
lymphoid cells. Recently, somatostatin receptor subtypes 2 and 3 were found 
in malignant lymphomas with in situ hybridisation techniques (somatostatin 
receptor subtypes 4 and 5 were not investigated) (4). 
In our scintigraphic studies with ['l1ln-DTPA-D-Phe' J-octreotide, radioactivity was 
localized in 'activated' or malignant lymph nodes while normal lymph nodes 
were negative. This radiopharmaceutical, which is strongly related to octreotide, 
binds with high affinity to human somatostatin receptor subtype 2 and 5 and 
with low affinity to receptor subtype 3 (27). 
In the literature different techniques have been reported for the detection of 
somatostatin receptors in the immune system, such as autoradiography, ligand 
binding assays, and fluorescent techniques using a fluorescent labelled 
somatostatin analogue (2). In our hands, no reproducible binding experiments 
with avidin-biotin labelled somatostatin analogues could be obtained. 
Fluorescent techniques may be too insensitive for the detection of low numbers 
of somatostatin receptors on individual cells. 
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Table 4. Detection of messenger ribonucleic acid (mRNA) for somatostatin receptors in 
lymphoid T cell lines by reverse transcriptase polymerase chain reaction (RT~PCR). 
CD3 negative cell 
HSB-2 
Molt-3 
ALL-l 
MT-l 
TcR~o positive cell 
Peer 
TcR-a/J positive cell 
Molt-16 
HuT-78 
HPB-ALL 
Somatostatin receptor subtype 
2 3 4 5 
+ 
+ 
In this study mRNA for somatostatin receptor subtype 2 was found in two B-
and two T cell lines without expression of other somatostatin receptors, 
suggesting that somatostatin receptor expression in human lymphoid cells is 
restricted to receptor subtype 2. In the B cell lines the immature (JY) and 
mature (TMM) differentiated cell lines were somatostatin receptor subtype 2 
mRNA positive; in the T cell lines the cytoplasmic CD3 negative ('early') T cell 
lines MT-1 and HSB-2 were positive. 
Somatostatin receptors were found in vitro and in vivo in patients with specific 
autoimmune diseases and with malignant lymphomas (2), while no somatostatin 
receptor expression was found in non-activated lymph nodes in patients by 
somatostatin receptor scintigraphy. These results suggest that somatostatin 
receptor expression may be related to the activation/differentiation state of 
lymphoid cells. Somatostatin receptor subtype 2 specific agents, like octreotide, 
RC-160 and BIM-23014 may be potential tools to influence the differentiation 
and/or proliferation of activated and malignant lymphoid cells. 
Clearly, more primary human tissues of autoimmune diseases and malignant 
lymphomas need to be investigated for their expression of somatostatin receptor 
subtypes, in order to establish whether the conclusions drawn from our study 
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Figure 1. Scatchard analysis of [1251-Tyr]-octreotide binding on human T and B cell lines. 0 JY cell 
line (K, = 0.3 nM,n = 186 fmoles/mg), 0 TMM cell line (K, = 0.4 nM, n = 206 fmoles/mg), 0 HS8-2 
cell line (not detectable), 6. MT-1 cell line (Kd = 0.3 nM, n = 332 fmoles/mg). 
in cell lines are representative for the somatostatin receptor status in vivo in the 
abovementioned diseases. 
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CHAPTER 7 
AN INTRODUCTION TO SUBSTANCE P 
An introduction to substance P 
Substance P 
Substance P is a peptide of eleven amino acids (Figure 1), discovered by Euler 
et al. (1), and chemically characterized many years later. It was initially found 
to be present in very high concentrations in the substantia nigra (1-4). 
Substance P is a member of the family of tachykinins. Tachykinins are 
neuropeptides that are synthesized primarily by neurons, and share a common 
C terminal amino acid sequence (-Phe-X-Gly-Leu-Met-NH, ). 
Currently the mammalian tachykinin family is known to be composed of three 
neuropeptides, i.e. substance P, neurokinin A and neurokinin B. The neurokinin 
1 receptor, which is present in both the central and peripheral nervous system, 
preferentially interacts with substance P, as substance P has the highest affinity 
(Kd = 0.5-1.0 nM) for this receptor. The affinities of neurokinin A and neurokinin 
B for the neurokinin 1 receptor are generally two- to fourfold lower (5-7). The 
neurokinin 1 receptor has recently been cloned and was shown to belong to the 
family of G protein coupled receptors (8,9). 
Substance P is found in the peripheral sensory nerves, which innervate organs 
and tissues, such as the gastrointestinal and respiratory tract, the visual system, 
the skin and, relevant to the immune system, the lymph nodes and the spleen 
(10). Tachykinin receptors have a wide tissue distribution. Interaction between 
the tachykinins and their receptors is associated with diverse responses, such 
as sensory transmission, both contraction and endothelium dependent relaxation 
of vascular smooth muscle, nociception, histamine release, plasma 
extravasation, inflammation and, potentially, nerve regeneration and wound 
healing (11). 
Substance P and the immune system 
Substance P modulates several immune and hypersensitivity activities. It has 
been reported to modulate the functional activities of inflammatory cells by 
causing degranulation of mast cells (but not basophils), stimulation of lysosomal 
enzyme release from neutrophils, enhancement of neutrophil chemotaxis and 
phagocytosis, and activation of macro phages (11-15). Chemotaxis and 
lysosomal secretion, induced by substance P, operate via cross reactivity with 
the receptor for the chemotactic peptide N-formylmethionyl-Ieucyl-phenylalanine 
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(fMet-Leu-Phe). Substance P has also been shown to stimulate T lymphocyte 
proliferation (60-70%), as measured by ['H)-thymidine incorporation, to enhance 
the effect of T cell mitogens and the production of immunoglobulins by plasma 
cells (16-19). The proliferative effects of substance P reside in the C terminal 
end of the molecule. Some investigators were unable to obtain any mitogenic 
effect of substance P or to detect substance P receptors on human peripheral 
blood lymphocytes, however (20). Evidence was found that substance P binds 
to a non-neurokinin 1 receptor in monocytes, which activates a mitogen 
activated protein kinase (20). 
Substance P binds to specific receptors on rat tissue mast cells to induce 
histamine and leukotriene release at micromolar concentrations (11). It has been 
suggested that the C terminal portion of substance P is required for binding to 
the receptor and that the N terminal basic amino acids are required for cell 
activation (21). The hypersensitivity effects, such as vasodilatation and alteration 
of the microvascular permeability appear to be mediated by substance P 
induced factors such as histamine and leukotrienes. In contrast to the activation 
of tissue mast cells to release mediators, substance P has no effect on 
basophils (11). Thus, the hypersensitivity effects of substance P are cell type 
specific. 
There are several reports showing that substance P is involved in cytokine 
production. Substance P and 12-phorbol-12-myristate-13-acetate synergistically 
and dose dependently induce interleukin 2 production in murine EL-4 thymoma 
cells and human peripheral blood cells (22,23). Substance P stimulates the 
production of interleukin 1, tumour necrosis factor IX, and interleukin 6 (24). On 
the other hand interleukin 1 increases the level of substance P in cultured 
neonatal superior cervical ganglions (25). Recently, it has been shown that 
substance P selectively activates gene expression and secretion of tumour 
necrosis factor IX in murine mast cells (26). Substance P is present in nerve 
fibres that innervate the spleen, thymus and lymph nodes, and in nerve fibres 
that are in close contact with the mast cells in the intestine. This supports the 
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concept that substance P influences the activity of the immune system (27-29). 
Substance P in inflammatory conditions 
Several lines of evidence indicate that tachykinin neuropeptides like substance 
P play a role in the inflammatory and immune response, both in peripheral 
tissues, such as the lungs, jOints and colon, as well as in the central nervous 
system. Terminals of substance P containing sensory nerves were observed in 
association with blood vessels. Electric stimulation of these peripheral nerves 
at intensities that stimulate sUbstance P release reproduces many of the 
physiological changes that are seen in acute inflammation. I n recent years, the 
focus of attention has shifted from the central nervous system neurons 
themselves, which appear to have the capacity to regenerate, to the central 
nervous system glia, which apparently inhibits the regrowth ofaxons in the 
central nervous system. It has been demonstrated that, after injury, regenerating 
axons grow a short distance until they reach the glial scar, where they appear 
to stop growing and degenerate (30). The major cellular constituent of a central 
nervous system glial scar is the reactive astrocyte (astrocytes originate in the 
monocyte lineage) (31). In the normal optic nerve tract no substance P 
receptors are expressed, but after injury binding sites for substance Pare 
expressed by the glial scar (32). These results demonstrate that glial cells in 
vivo express high concentrations of substance P receptors after transection of 
retinal ganglion cell axons. 
Substance P receptors are expressed at high concentrations in arterioles, 
venules and lymph nodules in surgical specimens obtained from patients with 
ulcerative colitis and Crohn's disease (33). In the normal colon a low 
concentration of substance P binding sites is expressed by submucosal 
arterioles and venules, and a moderate level is expressed by the external 
circular muscle. These findings reveal that in a disease state a specific 
tachykinin binding site for substance P appears to be overexpressed by specific 
cells. A key question is whether sUbstance P receptors are an etiological factor, 
or whether they are concomitant with inflammation. Corticosteroids do not 
down regulate the substance P receptors, suggesting a more etiological role for 
substance P in these diseases. I n ulcerative colitis and Crohn's disease the 
number of substance P- and vasoactive intestinal peptide positive nerves 
decreased in severe inflammatory lesions (34). A difference in the substance P 
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concentration was found between ulcerative colitis and Crohn's disease (35). 
The substance P concentration in rectal biopsies from patients with ulcerative 
colitis was increased, when compared with control patients and patients with 
Crohn's disease. Thus, the role of substance P in the pathogenesis of ulcerative 
colitis and Crohn's disease may be different. 
Clinical evidence for the involvement of the nervous system in arthritis came 
from paralysed patients. In patients with upper motor neuron hemiplegia or 
lower motor neuron lesions, such as poliomyelitis, no symptoms of any 
subsequent development of rheumatoid arthritis were found in the affected limbs 
(36,37). Evidence from animal studies showed that sectioning of one sciatic 
nerve, seven days before the induction of adjuvant arthritis in the rat, delayed 
the onset and reduced the severity of disease in the operated limb (38). 
However, the opposite finding was reported by another group (39). Another 
indication of nervous involvement is the exact symmetry of a number of arthritic 
conditions (40). In rheumatoid arthritis synovia samples, a decrease in 
substance P containing nerve fibres was found, with a simultaneous increase 
in substance P receptor density (41). It was suggested that activation of 
nociceptors by chemical stimuli, for example prostaglandins, might have caused 
an increased release of substance P and therewith a lowering of the SUbstance 
P content (41). Substance P concentrations in serum and synovial fluid in 
patients with rheumatoid arthritis are increased. Lymphocytes, obtained from the 
peripheral blood and the synovial fluid from patients with rheumatoid arthritis, 
were not responsive to exogenous substance P, in contrast to peripheral blood 
lymphocytes from control patients (42). Lymphocyte receptors for substance P 
may be desensitized because of large amounts of the peptide found in situ (42). 
Repeated stimulation with substance P causes a typical tachyphylaxis in many 
systems (43). Substance P is capable of stimulating synoviocytes, which 
enhances pannus formation and increases connective tissue damage (44). 
Substance P does not accumulate in significant amounts within the synovial fluid 
(45). In synovial tissue a high expression of the enzyme neural endopeptidase 
was found in cells surrounding the blood vessels compared with normal human 
synovium (46). This finding suggests an increase in the metabolism of 
tachykinins. Intraarticular injections of substance P in rat knee joints resulted in 
a pronounced inflammatory response (47). Substance P perfusion of an 
inflamed jOint was shown to exacerbate the inflammation and enhance 
extravasation of plasma proteins into the synovial cavity (48). It has also been 
demonstrated that the number of substance P receptors in rheumatoid synovium 
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is largely increased when compared with normal synovium (49,50). The highest 
concentrations of these receptors are present in blood vessels, on endothelial 
lining cells, and on the surrounding smooth muscle cells. It is now widely 
accepted that there is a neurogenic mechanism in the pathophysiology of 
arthritis, and substance P may be one of the important mediators. 
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CHAPTER 8.1 
SUBSTANCE P RECEPTOR SCINTIGRAPHY: 
INITIAL STUDIES IN RATS 
Substance P receptor scintigraphy: initial studies in rats 
Abstract 
We have evaluated the potential usefulness of a new radiolabelled substance 
P analogue, ['11ln_DTPA_Arg ' J-substance P, as a radiopharmaceutical for the 
in vivo detection of substance P receptor positive immunological disorders 
and tumours. Substance P, [3-(p-hydroxyphenyl)propionyl-Arg 1 J-substance P 
(Bolton-Hunter-substance P, BH-substance P), and [DTPA-Arg 'J-substance 
P, inhibited dose-dependently the binding of [' 2sIJ-BH-substance P to the 
substance P receptors in rat brain cortex membranes with IGso values of 0.2, 
2 and 4 nM, respectively. In an autoradiographic displacement study of the 
submandibular gland with [125IJ-BH-substance P as radiopharmaceutical, an 
IGso of 2.7 nM was found for [DTPA-Arg 'J-substance P. In vivo metabolism of 
the radiopharmaceutical in the rat revealed a renal clearance of 50% of the 
injected radioactive dose in 30 minutes, and a rapid enzymatic degradation of 
the radiopharmaceutical, resulting in an effective half-life in blood of 
approximately 3 minutes. Four and 24 hours after the injection of ['"In_ 
DTPA-Arg' J-substance P, uptake in and specific binding to substance P 
receptor positive organs and tumours were found, with a (substance P 
receptor positive) target to background optimum at 24 hours. Tissue 
distribution and ex vivo autoradiographic studies in rats, with and without 
pretreatment with the selective non-peptide neurokinin 1 receptor antagonist 
GP96,345, showed uptake and specific binding of radioactivity in isolated 
tumours, and in the submandibular and parotid glands. Visualization of 
normal substance P receptor positive tissues such as the salivary glands by 
gamma camera scintigraphy, after administration of ['11ln_DTPA_Arg' J-
substance P, was demonstrated in untreated rats. Pathological substance P 
receptor positive processes were visualized in rats bearing the transplantable 
pancreatic tumour GA20948, and in rats with adjuvant arthritis, induced by 
injection of a homogenate of Mycobacterium tuberculosis. We conclude that 
['11 I n-DTPA-Arg'J-substance P can be used successfully to visualize 
sUbstance P receptor positive processes in vivo by substance Preceptor 
scintigraphy. 
Introduction 
Tachykinins are a family of peptides which share a common G terminal 
amino acid sequence, -Phe-X-Gly-Leu-Met-NH 2, where X represents either 
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Phe, lie, or Val (1). The mammalian tachykinins include substance P, 
neurokinin A, neurokinin B, and two N terminally extended forms of 
neurokinin A, i.e. neuropeptide K and neuropeptide Y. Currently accepted 
tachykinin receptor nomenclature defines three homologous receptor types: 
(a) the neurokinin 1 receptor, preferring substance P, (b) the neurokinin 2 
receptor, preferring neurokinin A, and (c) the neurokinin 3 receptor, preferring 
neurokinin B. The tachykinin receptors have a wide tissue distribution, and 
interaction with their ligands is associated with diverse responses, such as 
sensory neurotransmission, immunological responses, both contraction and 
endothelium dependent relaxation of vascular smooth muscle, nociception, 
histamine release, plasma extravasation, inflammation, and, potentially, nerve 
regeneration and wound healing (1,2). 
The involvement of substance P in the carcinoid syndrome (3) and vascular 
(migraine) headache (4) has been suggested. In rats with adjuvant arthritis 
the synovium was found positive for high affinity substance Preceptors (5). 
This has also been described in patients with rheumatoid arthritis (6). In 
addition, very high concentrations of substance P receptors are expressed in 
the germinal centre of lymph nodes (7), and on a human astrocytoma cell 
line (8). Large numbers of high affinity substance P receptors are found in 
surgical specimens obtained from patients with inflammatory bowel disease. 
The substance P binding neurokinin 1 receptor is expressed by arterioles and 
venules located in the submucosa, muscularis mucosa, external longitudinal 
muscle, and serosa (7,9). 
In the present study several animal models were used to evaluate the 
potential usefulness of ['11ln-DTPA-Arg 'J-substance P as a radioligand for the 
in vivo detection of substance P receptor positive tissues. Firstly, the 
substance P receptor positive submandibular and parotid gland (10-12) were 
studied in normal rats. As a second model, rats bearing the substance P 
receptor positive transplantable rat pancreatic tumour CA20948 were 
investigated. Thirdly, the possible accumulation ['11ln-DTPA-Arg'J-substance 
P was studied in the joints of rats with adjuvant arthritis, induced by 
Mycobacterium tuberculosis (13). The specific non-peptide neurokinin 1 
receptor antagonist CP96,345 (14) was used in these models in order to 
block specific binding of ['11ln-DTPA-Arg 'J-substance P to substance P 
receptors. 
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Materials and methods 
Radiopharmaceuticals 
[3-(p-hydroxyphenyl)propionyl-Arg 'j-substance P (Bolton-Hunter-substance P, 
BH-substance P), [DTPA-Arg ' j-substance P, the substance P antagonist 
send ide (15) and [DTPA-Tyr ' j-sendide were purchased from Sanbio (Uden, 
The Netherlands). The amino acid sequences are shown in Figure 1. Amino 
acid analysis yielded a peptide content of more than 95%. The identity of the 
peptides was confirmed by amino acid analysis and fast atom bombardment 
mass spectrometry. 111lnCI, (ORN 4901, 370 MBq/ml in HCI, pH 1.5-1.9) was 
obtained from Mallinckrodt (Petten, the Netherlands). The radiolabelling of 
[DTPA-Arg ' j-substance P with 111ln to a specific activity of 150 MBq 1111n per 
~g [DTPA-Arg 'j-substance P, and consecutive quality control by instant thin 
layer chromatography (ITLC, Silica gel) and SEP-PAK C18 reversed phase 
extraction were performed as described earlier (16). High performance liquid 
chromatography (HPLC) was performed with a Waters 600E multi solvent 
delivery system, connected to a ~Bondapak C 18 reversed phase column 
(300x3.9 mm, particle size 10 ~m). Elution was carried out at a flow of 1.5 ml 
per minute with a linear gradient of 10 to 50% acetonitrile in 0.1 % 
trifluoroacetic acid in 30 minutes. The latter composition was kept constant 
for another 5 minutes. The radiochemical purity of the radio labelled 
substance P analogues was greater than 98%. Although it is not excluded 
that additional groups of the peptide participate in 111ln complexation, the 
labelled product is referred to as ['11ln-DTPA-Arg' j-substance P. [ '15ln_DTPA_ 
Arg ' j-substance P was prepared by mixing [DTPA-Arg ' j-substance P (stock 
concentration of 10" M) with a 80-fold molar excess of 1151nCI, (Aldrich, Axel, 
the Netherlands) in 0.05 M acetic acid, as described earlier (17). The binding 
characteristics of [DTPA-Arg 'j-substance P and ["5In-DTPA-Arg 'j-substance 
P to the substance P receptor were examined. [125Ij-BH-substance P was 
purchased from Amersham (United Kingdom) and also prepared in our 
laboratory essentially as described earlier (18). The radioiodination was 
carried out by adding 105 ~g BH-substance P in 150 ~I 0.05 M acetic acid 
and 8 ~g chloramine T in 100 ~I 0.05 M phosphate buffer (pH 7.5) to 185 
MBq (50 ~I) Na1251 (specific activity 0.62 TBq 125//mg, Amersham, United 
Kingdom). The mixture was vortexed for 1 minute. The radioiodination was 
stopped by adding 1 ml 10% human serum albumin (Merieux, Lyon, France). 
After vortexing for 30 seconds, 2 ml 5 mM ammonium acetate was added. 
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Figure 1. Sequences of synthetic substance P, C1'ln-DTPA-Arg ']-substance P, send ide 
and [111In-DTPA-Tyr']-sendide. 
Purification was performed using a SEP-PAK C18 reversed phase extraction 
cartridge (Waters Associates, Milford, Massachusetts, USA), which was 
washed successively with 5 ml 70% ethanol, 5 ml isopropanol and 5 ml 
distilled water. After application of the sample, the SEP-PAK C18 cartridge 
was washed with 5 ml distilled water and 5 ml 0.5 M acetic acid, and 
radioiodinated BH-substance P was eluted with 1 ml 96% ethanol. The 
solvent was evaporated at 25°C under a gentle stream of nitrogen. HPLC of 
[ 1251]-BH-substance P was performed on an identical flBondapak C18 reversed 
phase column as mentioned above, and elution was carried out at a flow of 1 
ml per minute with a linear gradient of 40 to 70% methanol in 0.05 mM 
acetate (pH 5.5) in 50 minutes. The latter composition was kept constant for 
another 5 minutes. The in vitro binding and autoradiography studies were 
performed with HPLC purified monoiodinated [1251]-BH-substance P. 
Reagents 
The selective non-peptide neurokinin 1 receptor antagonist CP96,345 (14) 
was kindly provided by Pfizer (Capelle aan de IJssel, the Netherlands). 
Substance P was purchased from Saxon-Biochemicals GMBH (Germany) 
and luteinizing hormone-releasing hormone (LHRH) and thyrotropin-releasing 
hormone (TRH) from Hoechst (Germany). Octreotide was obtained from 
Sandoz (Switzerland) and [DTPA-D-Phe ']-octreotide from Mallinckrodt (the 
Netherlands). All chemicals used were of the highest purity available. 
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Substance P receptor binding studies and autoradiography 
Receptor binding studies were performed with membrane fractions of the 
submandibular gland, brain stem, brain cortex and the pancreatic tumour 
CA2094B. The incubation mixture consisted of 40 kcpm of ['2sIJ-BH-substance 
P, while the remainder of the incubation mixture was identical as described 
earlier (19). Binding curves and ICso values for displacement of [12sIJ_BH_ 
substance P binding by unlabelled peptide were calculated using the 
computer fitting program of Graphpad (lSI software, Philadelphia, 
Pennsylvania, USA). Receptor autoradiography was carried out as described 
earlier (20) with some modifications. In short, 10 flm cryostat sections of the 
tissue samples were mounted onto precleaned gelatin coated microscope 
slides, and stored at -BO°C. To wash out endogenous substance P, sections 
were preincubated for 15 minutes at room temperature with 50 mM Tris-HCI 
buffer, pH 7.4. Thereafter, sections were incubated for 1 hour at 20°C in 50 
mM Tris-HCI buffer, pH 7.4, containing bovine serum albumin (200 mgll), 
bacitracin (40 mgll), and 5 mM MnCI2 to inhibit endogenous proteases, in the 
presence of iodinated ligand (400 kcpm/ml, about 0.1 nM). Non-specific 
binding was determined on parallel sections by adding unlabelled native 
substance P at a concentration of 1 flM. Incubated sections were washed 
four times for 5 seconds in ice cold 50 mM Tris-HCI buffer, pH 7.4, and four 
times for 5 seconds in ice cold distilled water to remove salt. The sections 
were then dried quickly, and were exposed to Hyperfilm TM3H (Amersham, 
United Kingdom) for one week in X-ray cassettes without intensifying screens 
at -BO°C. Histology was performed on haematoxylin-azophloxine stained 
sequential cryosections. Specificity of binding was tested by addition of 1 flM 
substance P, [DTPA-Arg 'J-substance P, CP96,345, LHRH, TRH and 
octreotide. Autoradiographic displacement experiments in the submandibular 
gland were performed as described earlier (21). Ex vivo autoradiography was 
performed on kidney, parotid and submandibular gland and tumour tissue 
from male Lewis CA20948 pancreatic tumour bearing rats. For this study rats 
were injected intravenously with either 3.4 mg CP96,345 per kg body weight 
or vehicle. After 10 minutes the rats were injected with 37 MBq (1 fl9) ["1In_ 
DTPA-Arg' J-substance P and exsanguinated 24 hours later. 
Tissue distribution and specific binding of substance P in control rats 
Male Wistar rats (220-260 g) were injected under ether anaesthesia into the 
dorsal vein of the penis and/or into a sublingual vein. In order to find the 
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optimal injected mass of [DTPA-Arg 'j-substance P, groups of three or four 
rats were injected with 0.1, 1 or 5 fl9 [DTPA-Arg' j-substance P labelled with 
3 MBq 11lln. Parallel groups of three or four rats were injected similarly 10 
minutes after intravenous administration of 3.4 mg CP96,345 per kg body 
weight in 0.05 M acetic acid in 154 mM NaCI, as described by Bertrand et al. 
(22). Specific binding was defined as the difference in tissue uptake of 
radioactivity between untreated (total binding) and CP96,345-treated (non-
specific binding) rats, and was expressed as percentages of the injected 
radioactivity per gram tissue, as described previously (17). Twenty-four hours 
after administration of [l11ln-DTPA-Arg ' j-substance P the rats were 
exsanguinated. The following organs and tissues were isolated and 
subsequently analyzed for radioactivity content: blood, bronchi, lungs, 
thymus, pancreas, spleen, adrenals, kidneys, aorta, esophagus, jejunum, 
colon, thigh (soft tissue), liver, parotid and submandibular glands, neck lymph 
nodes, anterior pituitary gland, brain cortex and striatum. The tissue 
distribution and metabolism of the l11ln labelled substance P analogues in 
vivo were also studied by gamma camera scintigraphy (23). 
Metabolism 
Male Wistar rats (220-280 g) were sacrificed at 15 minutes, 1 hour, or 24 
hours after administration of the radiolabelled substance P analogue. Blood 
was collected in ethylenediaminetetraacetic acid (EDTA) containing tubes 
and immediately cooled on ice. Since substance P is readily metabolized by 
various enzymes in blood (24,25) samples were immediately centrifuged at 
OOG and plasma components were separated by SEP-PAK C18 
chromatography. Using the separation technique described above, ['11ln_ 
DTPA-Arg' j-substance P binds to the SEP-PAK C18 stationary phase and is 
only eluted with ethanol, while l11ln_DTPA is not retained on SEP-PAK C
'8 
columns. The radioactivity in plasma and urine samples, which was eluted 
with ethanol from the SEP-PAK C
'8 column, is termed peptide bound 
radioactivity but was not further characterized. 
Substance P receptor scintigraphy in arthritic and tumour bearing rats 
Adjuvant arthritis was induced in female rats by injection of a homogenate of 
Mycobacterium tuberculosis, as described earlier (13). Seventeen days after 
inoculation the rats had developed an adjuvant reactive arthritis, mostly 
located in the hind leg joints, and a granuloma at the site of inoculation, as 
was confirmed by light microscopy. These rats were injected with either 37 
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MBq (1 fig) ['l1ln-DTPA-Arg' j-substance P or 37 MBq (0.5 fig) C"ln-DTPA-D-
Phe' j-octreotide (Octreoscan, Mallinckrodt, Petten, The Netherlands), since 
granuloma can be visualized by octreotide scintigraphy (26). Imaging was 
performed 24 hours after injection of the radiopharmaceutical. In a second 
imaging study two groups of four male Lewis rats, bearing the transplantable 
rat pancreatic tumour CA20948, were used. One group was treated 
intravenously with 3.4 mg CP96,345 per kg body weight 10 minutes prior to 
the administration of ["'In-DTPA-Arg' j-substance P, in order to block specific 
receptor binding of the latter. The other group was similarly treated with 
vehicle prior to the radiopharmaceutical. 
Data analysis 
The results are expressed as the mean with standard deviation (SD). One-
way analysis of variance (ANOVA), was used for statistical analysis. Means 
were compared using Bonferroni or Newman-Keuls test (27). Tissue binding 
values were evaluated using Student's t-test. A p<0.05 was considered 
statistically significant. 
Results 
The efficiency of labelling of BH-substance P with 1251 was 30-35%. 
Purification of the iodination mixture using the SEP-PAK C1B reversed phase 
cartridge resulted in the elution of mainly radioiodine in the water fraction and 
peptide bound radioiodine in the ethanol fraction, as revealed by HPLC. 
Figure 2 shows a typical HPLC analysis of peptide(s) eluted in the SEP-PAK 
C1B ethanol fraction, indicating a radiochemical purity of more than 95% of 
monoradioiodinated BH-substance P. Simultaneous measurement of UV 
absorbance at 254 nm and radioactivity shows a clear separation between 
unlabelled BH-substance P, mono- and diiodinated C25 lj-BH-substance P with 
retention volumes of 37.0, 35.5 and 45.0 ml, respectively, using the methanol 
gradient. The retention volume of the commercially available [125Ij_BH_ 
substance P (specific activity approximately 2000 Ci/mmol, Amersham, 
United Kingdom) was identical with our monoiodinated ['25 Ij-BH-substance P 
(data not shown). Since our HPLC purified monoiodinated ['25Ij-BH-substance 
P is carrier free, its specific activity will also reach this value of approximately 
2000 Ci/mmol for carrier free monoiodinated 1251 labelled peptides. 
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Figure 2. High performance liquid chromatography (HPLC) elution pattern of the 
ethanol fraction after SEP-PAK C1S purification of the BH-substance P radio iodination 
mixture. Non-radioiodinated BH-substance P (broken line) is measured by UV absorbance 
(J.,. = 254 nm), with a retention volume of 37.0 ml. Mono- and diiodinated [1251]_BH_ 
substance P (solid line) are detected by gamma detection at 35.5 and 45.0 ml, 
respectively. 
An over 98% efficiency of labelling of the DTPA conjugated peptides was 
assured within 15 minutes, as revealed by ITLC and HPLC, when a five- to 
tenfold molar excess of peptide over 111ln was used. Therefore, a specific 
activity of over 150 MSq 111ln per fl9 [DTPA-Arg ' j-substance P or [DTPA-
Tyr' j-sendide could be achieved. ['11ln-DTPA-Arg' j-substance P and ['"In_ 
DTPA-Arg ' j-sendide were stable for at least 1 hour after preparation, and for 
longer than 4 hours if stabilized by addition of the quencher gentisic acid at a 
final concentration of 2 mg per ml. The retention volumes for ['11ln-DTPA-
Arg 'j-substance P and [DTPA-Arg 'j-substance P with the acetonitrile gradient 
were 31 and 34 ml, respectively (Figure 3). 
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Figure 3. High performance liquid chromatography elution pattern of [111In.OTPA_Arg 1J_ 
substance P (solid line), measured by gamma detection, and [DTPA-Arg 1]-substance P 
(broken line), measured by UV absorbance (A = 254 nm) with a 10 to 50% acetonitrile 
elution gradient. The dotted line represents the HPLC elution pattern of the ethanol 
fraction of SEp·PAK C16 extract of serum collected 15 minutes after injection of the 
radiopharmaceutical. 
Studies of the binding of [ '2sIJ-BH-substance P to the substance Preceptors 
in rat parotid gland membranes in the presence of increasing concentrations 
of substance P, [DTPA-Arg 'J-substance P and [' 15ln-DTPA-Arg 'J-substance P 
revealed ICso values of 1, 35 and 31 nM, respectively. In brain stem 
membranes ICso values for substance P and [DTPA-Arg'J-substance P were 
0.5 and 5 nM, respectively, while for sendide and [DTPA-Tyr 'J-sendide ICso 
values were found in the micromolar range. In another study with membrane 
fractions of the CA20948 tumour, the binding of ['2s IJ-BH-substance P was 
inhibited in the presence of 1 IlM of sUbstance P, [DTPA-Arg 'J-substance P 
or CP96,345,respectively, to 67 ±6, 66±6 and 66±0% of the control value in 
the absence of competitive ligand. In a study with rat brain cortex 
membranes ICso values of 0.2, 4 and 2 nM were found for substance P, 
[DTPA-Arg 'J-substance P and BH-substance P, respectively. 
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Figure 4. Visualization of specifically 
labelled substance P receptors in the 
serous part of the rat submandibular 
gland. (A) Autoradiogram showing total 
binding of [ 1251]_BH_su bsta nee P. (8) 
Autoradiogram showing non-specific 
binding of [125 1]_BH substance P in the 
presence of 1 ).lM substance P. No 
displacement occurred in the presence 
of: (C) 1 !-1M octreotide, (D) luteinizing 
hormone-releasing hormone (LHRH), or (E) 
thyrotropin-releasing hormone (TRH). Bar 
represents 1 mm. 
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Figure 5. Visualization of the distribution of substance P receptors in rat 
submandibular gland. (A) Haematoxylin-azophloxine stained section. (8) Autoradiogram 
showing total binding of C251]-BH-substance P. (C) Autoradiogram showing non-specific 
binding of {1251-BH-substance P in the presence of 1 J..lM substance P. (D) Autoradiogram 
showing non-specific binding of [125j]-BH-substance P in the presence of 1 f-lm CP96,345. 
m = mucous,S = serous 
Autoradiography of submandibular gland slices incubated with ['25I]-BH-
substance P demonstrated a high density of substance P receptors in the 
serous part of the gland (Figure 4), which contrasted with the lack of 
substance P receptors in the mucous part (Figure 4 and Figure 5A-D). In the 
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Figure 5. Visualization of the distribution of substance P receptors in rat parotid 
gland. (E) Haematoxylin~azophloxine stained section. (F) Autoradiogram showing total 
binding of [1251]-BH-substance P. (G) Autoradiogram showing non-specific binding of 
C251]-BH-substance P in the presence of 1 jlM substance P. (H) Autoradiogram showing 
non-specific binding of [i25Ij-BH-substance P in the presence of 1 Ilm CP96,345. m = 
mucous, S = serous, mu = skeletal muscle 
presence of 1 11M substance P the binding of [12511-BH-substance P was 
completely inhibited, while in parallel incubations with 1 11M octreotide, LHRH 
or TRH the binding of radioactivity was not affected. The exorbital lacrimal 
175 
Substance P receptor sCintigraphy: initial studies in rats 
% of maximum 
100 
50 
o L--,-------r------.------.------~~--~ 
-14 
-12 -10 -8 -6 -4 
Log [M] [DTPA-Arg1]-substance P 
Figure 6. Autoradiographic displacement curve of [1251]~BH-substance P on 10 f!m thick 
sections of rat submandibular gland. Uptake of radioactivity in the tissue sections 
was assessed at increasing concentrations of the radioligand [DTPA-Arg 1]-substance P. 
gland and lymph nodes adjacent to the submandibular gland showed low 
non-specific binding of ['2sIJ-BH-substance P (data not shown). Figure 5A-H 
shows the binding of ['2sIJ-BH-substance P to substance P receptors in rat 
submandibular and parotid gland, respectively, in the absence or presence of 
1 flM substance P or 1 11M CP96,345. The serous part of the rat 
submandibular gland had a high density of high affinity binding sites to the 
substance P receptor, whereas the mucous part of the gland had a less high 
density. The rat parotid gland also had a high density of high affinity binding 
sites to the substance P receptor. Some non-specific binding was present on 
the skeletal muscle tissue in the parotid gland section. 
Figure 6 shows an autoradiographic displacement study using 10 flm slices 
of the submandibular gland. An ICso value of 2.7 nM was found for 
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Table 1. Tissue distribution (% of injected dose per gram), 24 hours after 
intravenous administration of 3 MBq 1111n labelled with indicated mass of [DTPA~ 
Arg 1]-substance P in male Wistar rats. 
Administered dose of [111In_DTPA_Arg I)-substance P 
Tissue 
Blood 
Lungs 
Bronchi 
Thymus 
Pancreas 
Spleen 
Adrenals 
Kidneys 
Aorta 
Esophagus 
Jejunum 
Colon 
Soft tissue 
Liver 
Submandibular gland 
Parotid gland 
Pituitary gland 
Brain cortex 
Striatum 
so = standard deviation 
0.1 ~g 
(n = 3) 
1 ~g 
(n = 3) 
Mean SD Mean SO 
0.0062 0.0009 0.0055 0.002 
0.022 0.004 0.020 0.004 
0.068 0.011 0.089 0.020 
0.049 0.004 0.088 0.015 
0.019 0.004 0.023 0.005 
0.31 0.07 0.32 0.11 
0.029 0.006 0.033 0.001 
1.1 0.1 1.9 0.3 
0.023 0.008 0.018 0.008 
0.049 0.009 0.069 0.020 
1.1 0.11 1.4 0.2 
0.24 0.03 0.22 0.04 
0.011 0.002 0.019 0.003 
0.18 0.03 0.24 0.02 
0.65 0.07 1.1 0.0 
0.16 0.02 0.29 0.05 
0.020 0.001 0.041 0.008 
<0.001 
<0.001 
<0.001 
<0.001 
[DTPA-Arg'J-substance P 
5 ~g 
(n = 4) 
Mean SD 
0.0054 0.0005 
0.020 0.003 
0.069 0.011 
0.048 0.011 
0.022 0.006 
0.25 0.06 
0.055 0.013 
2.9 1.1 
0.044 0.009 
0.030 0.005 
1.0 0.21 
0.33 0.10 
0.015 0.003 
0.17 0.04 
1.3 0.2 
0.32 0.08 
0.015 0.004 
<0.001 
<0.001 
The target to background ratio increased between 4 and 24 hours, as 
measured by the uptake of radioactivity in isolated substance Preceptor 
positive tissues (salivary glands = target) compared with the radioactivity in 
blood (= background). This calculated ratio increased from 23± 11 at 4 hours 
up to 200±16 at 24 hours after the administration of the radiopharmaceutical. 
Table 1 and Table 2 show the radioactivity measured in the isolated tissues, 
24 hours after injection of 0.1, 1 and 5 fl9 of [DTPA-Arg'J-substance P, 
177 
Substance P receptor scintigraphy: initial studies in rats 
Table 2. Specific binding (% of injected dose per gram) in tissues of male Wistar 
rats, 24 hours after intravenous administration of 3 MBq l111n labelled with 
indicated mass of [DTPA-Arg 1 I-substance P. 
Administered dose of [111In_DTPA_Arg 1J-substance P 
0.1 ~g 1 ~g 5 ~g 
(n = 3) (n = 3) (n = 4) 
Tissue Mean SO Mean SO Mean SO 
Bronchi 0.044 0.011 0.047 0.020 0.048 0.011 
Thymus 0.029 0.004 0.058 0.015 0.000 0.011 
Spleen 0.19 0.07 0.27 0.04 0.03 0.06 
Esophagus 0.029 0.009 0.063 0.020 0.002 0.005 
Jejunum 0.86 0.11 0.60 0.25 0.0 0.2 
Colon 0.17 0.03 0.062 0.037 0.0 0.1 
Submandibular gland 0.52 0.07 0.83 0.04 0.77 0.15 
Parotid gland 0.15 0.04 0.21 0.08 0.16 0.09 
Pituitary gland 0.008 0.004 0.033 0.008 0.004 0.004 
so = standard deviation 
* specific binding different from zero, p<O.05 
labelled with a constant amount of 111ln (3 MBq). Table 1 represents the total 
binding, and Table 2 the specific binding of [DTPA-Arg ' ]-substance P. The 
high concentration of radioactivity in the kidneys after injection of ['11ln-DTPA-
Arg ']-substance P was evident, since renal excretion is the predominant 
route for clearance of ["'In-DTPA-Arg ' ]-substance P. About 50% of 
radioactivity was excreted via the kidneys in the first 30 minutes after 
injection of ['11ln-DTPA-Arg ']- substance P. Most of the tissues mentioned in 
Table 1 and Table 2 were selected as potential targets because of their 
substance P receptor content, while blood and soft tissue were selected as 
substance P receptor negative background. Background values were low and 
were comparable with the values found after the administration of ['"In_ 
DTPA-D-Phe' ]-octreotide (23). The uptake of radioactivity in the substance P 
receptor positive colon, jejunum, and submandibular and parotid glands was 
also similar to the uptake found in somatostatin receptor positive organs with 
['"In-DTPA-D-Phe' ]-octreotide scintigraphy (23). However, the uptake of 
radioactivity in substance P receptor positive adrenals, pituitary gland, aorta, 
esophagus and lungs was low. No significant uptake nor specific binding of 
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Figure 7" Substance P analogue scintigraphy in rats with adjuvant arthritis, 24 hours 
after injection of 37 MBq (1 ~g) ["'In-DTPA-Arg']-substance P (A) or 37 MBq (0.5 ~g) 
Clln-DTPA~D-Phel1-octreotide (8) (posterior view). The arrow indicates the site of 
inoculation. 
["'In-DTPA-Arg 'J-substance P was found in the brain cortex and striatum, 
suggesting that ["1 I n-DTPA-Arg' J-substance P was unable to pass the blood-
brain barrier. In most tissues total and specific binding were optimal with the 
intermediate mass (1 fl9) of the radiopharmaceutical administered. In 
CA20948 tumour bearing male Lewis rats total binding amounted to 
O.13±O.01% of the injected dose per gram tumour tissue, and specific binding 
to O.O7±O.01% of the injected dose per gram tumour tissue. 
SEP-PAK C18 columns were used for analysis of peptide bound radioactivity 
in blood and urine of rats, 15 minutes, 1 hour and 24 hours after the injection 
of [l11ln_DTPA_Arg ' J-substance P. The percentage peptide bound radioactivity 
in blood was 10±2, 4±1 and O.5±O.1, respectively. HPLC analysis of the 
ethanol fractions of the SEP-PAK C18 extractions of these blood samples 
showed that less than 25, 15 and 5%, respectively, of this peptide bound 
1111n was intact [l11ln-DTPA-Arg' J-substance P. The subsequent half-life of the 
intact radiopharmaceutical in the first 15 minutes after the injection 
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Figure 8. Substance P analogue scintigraphy in CA20948 tumour bearing rats, 24 hours 
after injection of 37 MBq (1 ~g) ['''In-DTPA-Arg'j-substance P (lateral view). (A) No 
pretreatment with CP96,345. (8) Pretreatment with CP96,345. The arrows indicate the 
salivary gland and the tumour, located at the back of the rat. 
approximately 3 minutes. This is illustrated for the 15 minutes serum sample 
in Figure 3. The nature of the metabolites of [,11ln-DTPA-Arg']-substance P 
was not further investigated. 
The percentage of peptide bound '"In in urine samples collected 1 hour and 
24 hours after injection of C"ln-DTPA-Arg']-substance P was less than 10% 
and 5%, respectively, of the total radioactivity. More than 90% of the 
radioactivity excreted in the urine collected 1 hour after injection of the 
radiopharmaceutical had a molecular weight of less than 1500 dalton, as 
shown by PD-10 gel chromatography, i.e. smaller than that of the injected 
['"In-DTPA-Arg']-substance P (data not shown). 
Dynamic images during the first 20 minutes after injection of C"ln-DTPA-
Arg ']-substance P showed a rapid distribution of radioactivity over the whole 
body. In the first minutes after injection of [,11ln-DTPA-Arg']-substance P the 
kidneys were rapidly visualized and excretion of radioactivity in the urine was 
demonstrated. The dynamic images were comparable to those obtained with 
[,11ln-DTPA-D-Phe']octreotide (23) and C"ln-DTPA-D-Phe']-RC160 (17). 
Digital static images obtained 24 hours after injection of [,11ln-DTPA-Arg']-
substance P revealed a whole body retention of less than 7% of the injected 
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Figure 9. Visualization of substance P receptors in a CA20948 tumour bearing rat by ex 
vivo autoradiography, after administration of r111 In-DTPA_Arg1]_substance P. (A) 
Haematoxylin-azophloxine stained section of pancreatic tumour, without CP96,345 
pretreatment. (8) Autoradiogram of pancreatic tumour section, without CP96,345 
pretreatment. (C) Haematoxylin-azophloxine stained section of pancreatic tumour, 
with CP96,345 pretreatment. (D) Autoradiogram of pancreatic tumour section, with 
CP96,345 pretreatment. (E) Haematoxylin-azophloxine stained section of submandibular 
gland, without CP96,345 pretreatment. (F) Autoradiogram of submandibular gland 
section, without CP96,345 pretreatment. (G) Haematoxylin-azophloxine stained section 
of kidney section, without CP96,345 pretreatment. (H) Autoradiogram of kidney 
section, without CP96,345 pretreatment. 
dose, which was predominantly accounted for by the radioactivity in the 
kidneys, the liver, the salivary glands, the jejunum and the colon (see also 
Table 1). Figure 7 represents the static analogue images in two rats with 
adjuvant arthritis of the hind leg joints and an inflammation granuloma at the 
site of injection of the homogenate of Mycobacterium tuberculosis. The 
images were obtained 24 hours after the injection of 37 MBq (1 ~g) ["'In_ 
DTPA-Arg'j-substance P (Figure 7A) or 37 MBq (0.5 ~g) ['"In-DTPA-D-Phe' j-
octreotide (Figure 7B). A clear difference in tissue uptake of these 
radiopharmaceuticals was seen. The salivary glands and the arthritic hind leg 
joints had a high uptake of the radiolabelied substance P, while no uptake of 
['"In-DTPA-D-Phe'j-octreotide was seen. The granuloma at the site of 
injection, however, showed a high uptake of the radiolabelied octreotide, but 
181 
Substance P receptor scintigraphy: initial studies in rats 
less uptake of ['l1ln-DTPA-Arg' j-substance P. A high uptake of radioactivity 
was seen in the liver and the kidneys in both images. 
In Figure 8 the static lateral analogue images of two CA20948 tumour 
bearing rats are shown, 24 hours after injection of 37 M8q (1 I'g) ['11ln_ 
DTPA-Arg' j-substance P. Accumulation of radioactivity was observed in the 
tumour, the kidneys and the salivary glands (Figure BA). Uptake of 
radioactivity in the tumour, the parotid and submandibular glands was 
reduced by 50% after pretreatment of the rats with the substance P 
antagonist CP96,345 (3.4 mg/kg bodyweight) (Figure 88). The reduction was 
in agreement with the concentrations of radioactivity that were measured in 
the isolated organs. The uptake of radioactivity in the kidneys and liver was 
not affected by pretreatment with CP96,345. 
Figure 9 shows the ex vivo autoradiography of the transplantable pancreatic 
tumour CA20948, with and without pretreatment of the rats with CP96,345 
(3.4 mg per kg bodyweight), the submandibular gland, and the kidney, after 
injection of 37 M8q (1 I'g) ['l1ln-DTPA-Arg' j-substance P. The submandibular 
gland showed a high uptake of radioactivity in the serous acini, and a lower 
uptake in the mucous acini, as was also demonstrated in the 
abovementioned in vitro autoradiographic study. Serous and Paneth cells, 
localized in the mucous part of the submandibular gland, seem responsible 
for the uptake of radioactivity in this part of the gland. The autoradiogram of 
the kidney demonstrated the uptake of radioactivity in the proximal tubuli, 
which was not affected by pretreatment with CP96,345 (data not shown). 
Discussion 
['25 lj-8H-substance P has been shown to be a specific, high affinity 
radiopharmaceutical for the neurokinin 1 receptor (substance P receptor). In 
the present study it was demonstrated that [DTPA-Arg 'j-substance P was a 
potent competitor for [125 Ij-8H-substance P binding to substance Preceptors 
in isolated membranes from cerebral cortex, brain stem and salivary glands, 
as well as in tissue sections of the submandibular gland. These results 
suggest that ['l1ln-DTPA-Arg' j-substance P is an attractive radioligand for 
substance P receptor scintigraphy. 
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A low uptake of ['11ln-DTPA-Arg ' ]-substance P was seen in blood and soft 
tissue (substance P receptor negative), while sUbstance P receptor positive 
organs, such as the colon, the jejunum, the submandibular and parotid 
glands showed a higher uptake of radioactivity. Uptake of ['"In-DTPA-Arg ' ]-
substance P in the pituitary gland was low, corresponding to the small 
number of substance P receptors detected in this tissue (28,29). In contrast 
to the findings of several other groups (30,31) we could not demonstrate 
specific uptake in the lungs, although we did find uptake and specific binding 
in the bronchi. The presence of substance P receptors in smooth muscle, 
arterioles, and venules has been detected by autoradiography with [1251]_BH_ 
substance P as radiopharmaceutical (7,9). However, these structures 
represent only a minor part of the total mass of the investigated tissues, such 
as the aorta, bronchi and esophagus. Hence, the total uptake of radioactivity 
in these tissues is low. The lack of uptake of radioactivity in the brain cortex 
and the striatum suggests the inability of [DTPA-Arg ' ]-substance P and ['11ln_ 
DTPA-Arg ']-substance P to penetrate the intact blood-brain barrier. These 
data suggests that substance P receptor positive brain tumours, such as 
astrocytoma and glioma, might be visualized by gamma camera scintigraphy 
only when the blood-brain barrier is affected. 
The relatively high non-specific binding of ['11ln-DTPA-Arg ']-substance P to 
substance P receptor positive tissues is in contrast with the high specific 
uptake of radioactivity in somatostatin receptor positive tissues, as seen in 
somatostatin receptor scintigraphy in animals. To study the non-specific 
binding of ['11ln-DTPA-Arg ' ]-substance P we used the substance P 
antagonist CP96,345, as described by Bertrand et al. (22), since homologous 
blocking of the substance P receptor is not possible for pharmacological 
reasons. In rats pretreated with CP96,345 a high level of non-specific tissue 
uptake of ['11ln-DTPA-Arg' ]-substance P was still seen. This may partially be 
due to incomplete blockade of the substance P receptors, since CP96,345 is 
known to have lower affinity for rat substance Preceptors (Kd = 35 nM) than 
for human substance Preceptors (Kd = 0.5 nM) (32-34). Furthermore, little is 
known about the pharmacokinetics of CP96,345 in rats. Non-specific binding 
of [1251]-BH-substance P in the presence of CP96,345 was relatively low in 
the in vitro autoradiography tissue. However, the antagonist was added at a 
high concentration (1 flM), and it is unknown whether the concentration 
required to saturate substance P receptors is reached in vivo after 
administration of 3.4 mg CP96,345 per kg bodyweight. Therefore, our 
183 
Substance P receptor scintigraphy: initial studies in rats 
estimates of the non-specific binding of ['11ln_DTPA_Arg ' J-substance P in 
tissues using this dose of CP96,345 may be overestimations of the true 
values. The total uptake of ['11ln-DTPA-Arg'J-substance P in substance P 
receptor positive tissues was also very low compared with results obtained 
by somatostatin receptor scintigraphy in somatostatin receptor positive 
tissues. 
The tissue distribution of ['"In-DTPA-Arg 'J-substance P was studied after 
administration of varying masses of [DTPA-Arg 'J-substance P labelled with a 
constant amount of 111ln (3 MBq). In contrast to the general belief that 
receptor scintigraphy shows an optimal target to background ratio at the 
lowest possible mass of the radiopharmaceutical with the highest specific 
radioactivity, we found that the uptake of ['11ln_DTPA_Arg' J-substance P in 
substance P receptor positive tissue was usually optimal at intermediate 
doses. This phenomenon may also apply to substance P receptor positive 
immunological disorders, the visualization of which may be enhanced by 
optimizing the mass of ['11ln-DTPA-Arg'J-substance P. We previously 
reported similar findings on the binding of ['''In-DTPA_D_Phe' J-octreotide to 
somatostatin receptor positive tissues (35,36). However, the tissue specific 
bell-shaped function of ['11ln-DTPA_D_Phe' J-octreotide uptake versus the 
injected mass of [DTPA-D-Phe' J-octreotide was explained in part by the 
homologous upregulation of the somatostatin receptors. It is unknown if 
substance P receptors are (up- or down)regulated by substance P, but it has 
been reported that substance P receptors are downregulated by substance P 
antagonists (37). 
In vivo metabolism of C"ln-DTPA-Arg 'J-substance P in the rat revealed a 
renal clearance of 50% of the injected radioactivity in 30 minutes, and a rapid 
enzymatic degradation of the radiopharmaceutical, resulting in an effective 
half-life of the intact radiopharmaceutical in blood of approximately 3 minutes. 
The presence of the DTPA-group in C"ln-DTPA-Arg'J-substance P does not 
seem to affect the biological half-life in serum, since similar half-lives have 
been reported for serum in dogs (2.1 minutes) (24) and humans (1.6 
minutes) (3). Less than 10% of the injected dose was found intact in the 
urine, during the first 30 minutes after injection of the radiopharmaceutical, 
which is another indication of the rapid degradation of the 
radiopharmaceutical. These data are in contrast with previously reported 
findings on ['11ln-DTPA-D-Phe'J-octreotide (23) and C"ln-DTPA-D-Phe' J-
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RC160 (17) scintigraphy in rats, where a larger fraction of the 
radiopharmaceutical was excreted intact in the urine. Nevertheless, salivary 
glands, arthritic joints, and the substance P receptor positive tumour were 
visualized by gamma camera scintigraphy. These data suggest that the 
receptor-ligand interactions in vivo must be very rapid, since the 
concentration of intact radiopharmaceutical in the circulation rapidly 
diminishes. 
Send ide was reported to be a potent and selective neurokinin 1 receptor 
antagonist (15). In our hands, however, ['"In-DTPA-Tyr' j-sendide did not 
show selective binding characteristics to the neurokinin 1 receptor, neither in 
vitro nor in vivo. After intravenous administration of [ll1ln-DTPA-Tyr' j-sendide 
in rats a rapid clearance was observed, without specific binding to the 
substance P receptor positive salivary glands or to any part of the 
gastrointestinal tract. 
The binding characteristics of ['"In-DTPA-Arg ' j-substance P to human 
substance P receptors is currently under investigation. Several studies have 
reported discrepancies between the potencies of several substance P 
analogues in different species, and differences of less than 10% in the amino 
acid sequences of substance P receptors of rats and humans (2,38). 
Different types of substance P receptors are also reported in rat 
submandibular gland (39). Before [ll1ln-DTPA-Arg ' j-substance P can be 
applied in humans, the pharmacological properties of radiolabelled and 
unlabelled [DTPA-Arg ' j-substance P have to be investigated thoroughly, 
since substance P is known to exert various unwanted cardiovascular effects. 
Schaffalitzky et al. (3) and Coiro et al. (40-42) have demonstrated that such 
side effects do not occur when substance P is infused at low infusion rates 
(1.5 pmol/kg per minute). However, for the visualization of substance P 
receptor positive processes, substance P antagonists may be more attractive 
radiopharmaceuticals than substance P. 
We conclude that ['"In-DTPA-Arg1j-substance P can be used successfully to 
visualize substance P receptor positive tissues in vivo by substance P 
receptor scintigraphy. Further studies in patients with immunological 
disorders need to be performed, with special attention to disorders that have 
been proven to be substance P receptor positive. 
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VISUALIZATION OF THE THYMUS BY SUBSTANCE P 
RECEPTOR SCINTIGRAPHY IN MAN 
Visualization of the thymus by substance P receptor scintigraphy in man 
Abstract 
Substance P, an eleven amino acid neuropeptide, plays an important role in the 
modulation of pain transmission through neurokinin 1 and 2 receptors. 
Substance P and other tachykinins may play a role in the pathogenesis of 
inflammatory diseases as well. In this study we present our results concerning 
the metabolism of the substance P analogue ["'In-DTPA-Arg']-substance Pin 
men, as well as the visualization of the thymus in patients with immune 
mediated diseases. Twelve selected patients, five with inflammatory bowel 
disease, one with ophthalmic Graves' disease, one with sarcoidosis, one with 
Sjogren's syndrome, one with rheumatoid arthritis, two with myasthenia gravis, 
and one with systemic lupus erythematosus were investigated. During and after 
intravenous administration of 200 MBq (2.5 [1g) ['"In-DTPA-Arg']-substance P, 
blood pressure, heart rate, and oxygen saturation were monitored. Radioactivity 
was measured in blood, urine and faeces during 48 hours after injection. Planar 
and single photon emission computed tomography (SPECT) images were 
obtained 4 and 24 hours after injection. After administration of["'ln-DTPA-Arg']-
substance P a transient flush was observed in all patients. Degradation of ['"In_ 
DTPA-Arg']-substance P started in the first minutes after administration, 
resulting in a half-life of 10 minutes for the total plasma radioactivity, and of 4 
minutes for the intact radiopharmaceutical, as identified with high performance 
liquid chromatography (HPLC). Urinary excretion amounted in >95% of the 
radioactivity within 24 hours post injection, and up to 0.05% was found in the 
faeces up to 60 hours. In all patients uptake of radioactivity was found in the 
parotid glands, areolae of the mammae (in women), liver, kidneys, and urine 
bladder. In eight patients a high uptake of ["'In-DTPA-Arg']-substance P was 
observed in the thymus. We conclude that, despite its short half-life, C"ln-
DTPA-Arg']-substance P, a new radiopharmaceutical, can be used to visualize 
the thymus. This may contribute to the investigation of the role of thymus in 
immune related diseases. Also, inflammatory sites in various diseases could be 
visualized. 
Introduction 
Substance P is an eleven amino acid neuropeptide and is known as a powerful 
member of the family of tachykinins which are characterized by the C terminal 
sequence -Phe-X-GIY-Leu-Met-NH2 (1). It has been well established that 
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substance P plays an important role in modulating pain transmission from 
peripheral and central primary afferents through neurokinin 1 and 2 receptors. 
Substance P and other tachykinins may play a role in the pathogenesis of 
inflammatory diseases (2-7). Substance P was shown to induce degranulation 
of mast cells in vitro, regulate chemotaxis, release lysosomal enzymes from 
macrophages, and regulate expansion of T and B cells and production of 
immunoglobulins (8-11). The thymus seems to be involved in immune mediated 
diseases. Lymphofollicular hyperplasia of the thymus has been described in 
autoimmune diseases such as myasthenia gravis, systemic lupus 
erythematosus, scleroderma, rheumatoid arthritis, Hashimoto's thyroiditis and 
Sjogren's syndrome (12-15). 
Recently, substance P was detected in the outer cortex of the thymus and in the 
peptidergic neurons that innervate the thymus (16,17). Specific substance P 
receptors were found in the rat thymus in association with the vessels and the 
medulla (18). Large numbers of high affinity binding substance P receptors were 
found in surgical specimens obtained from patients with inflammatory bowel 
disease. The substance P binding neurokinin 1 receptor was expressed by 
arterioles and venules located in the submucosa, muscularis mucosa, external 
longitudinal muscle, and serosa (2). 
We developed a scintigraphic technique using an 1111 n labelled substance P 
analogue, ['11ln-DTPA-Arg' ]-substance P, to visualize affected tissues in 
immune disorders, e.g. the thymus. In this study results are presented 
concerning the metabolism of 111ln labelled [DTPA-Arg ' ]-substance P and the 
scintigraphic detection of the thymus in immune mediated diseases. 
Methods 
Patients 
Twelve selected patients were investigated (with informed consent), five with 
inflammatory bowel disease, one with ophthalmic Graves' disease, one with 
sarcoidosis, one with Sjogren's syndrome, one with rheumatoid arthritis, two with 
myasthenia gravis, and one with systemic lupus erythematosus. The diagnosis 
was established according to the clinical presentation and histopathological 
examination of gastrointestinal biopsies in the patients with inflammatory bowel 
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disease, and by liver biopsy in the patient with sarcoidosis. In rheumatoid 
arthritis, Sjogren's syndrome and systemic lupus erythematosus the diagnosis 
was made according to the internationally accepted diagnostic criteria. The 
patient with Graves' disease had lowered serum thyroid stimulating hormone 
concentration and elevated serum free thyroxine and specific thyroid stimulating 
immunoglobulin concentrations. The diagnosis myasthenia gravis was based on 
the characteristic medical history and findings at physical examination, the 
presence of antibodies against acetylcholine receptors and positive 
anticholinesterase tests. Uptake of radioactivity was investigated in six control 
patients, i.e. three with carcinoid tumours, one with carcinoma of the lung and 
two with non-Hodgkin's lymphoma. 
Radiopharmaceutica/s 
[DTPA-Arg']-substance P was labelled with "'lnCI, (370 MBq/ml in HCI, pH 1.5-
1.9, Mallinckrodt, Pelten, The Netherlands), up to a specific activity of 150 MBq 
"'In per I1g [DTPA-Arg']-substance P. Quality control by instant thin layer 
chromatography (ITLC, Silica-gel) and SEP-PAK C18 reversed-phase extraction 
were performed essentially as described earlier (19,20). HPLC was performed 
using a Waters 600E multi solvent delivery system, connected to a I1Bondapak 
C'8 reversed-phase column (300x3.9 mm, particle size 10 11m). Elution was 
carried out at a flow of 1.5 ml per minute with a linear gradient of 10 to 50% 
acetonitrile in 0.1 % trifluoroacetic acid in 30 minutes, and the lalter composition 
was kept constant for another 5 minutes. The radiochemical purity of the 
radiolabelled substance P analogue was greater than 98%. Although it is not 
excluded that additional groups of the peptide participate in "'In complexation, 
the labelled product is referred to as ['"In-DTPA-Arg']-substance P. 
Substance P receptor imaging 
In our study 2.5-5.0 I1g ['"In-DTPA-Arg']-substance P (200 MBq) was infused 
intravenously in 10 minutes. In all patients blood pressure, heart rate and 
oxygen saturation of the blood were monitored. Planar and SPECT images were 
obtained with a large field gamma camera equipped with a medium-energy 
parallel-hole collimator. SPECT analysis was performed with a Wiener filter on 
original data. The preset counting time for images obtained 24 hours and 48 
hours after injection of ['"In-DTPA-Arg'j-substance P was 15 minutes. Planar 
images were obtained from the head and neck, chest, upper abdomen and 
lower abdomen. SPECT studies were performed 4 or 24 hours after injection of 
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the radiopharmaceutical. 
Measurement of radioactivity in blood, urine and faeces 
Radioactivity in blood, urine and faeces was measured with an LKB-1282-
Compugamma system or a GeLi-detector equipped with a multi channel 
analyzer (Series 40, Canberra). Blood was collected in tubes containing 
ethylenediaminetetraacetic acid (EDTA) and immediately cooled on ice. Since 
substance P is readily metabolized by various enzymes in blood, samples were 
immediately centrifuged at DoC, and plasma was fractionated on SEP-PAK C18 
columns. Using the separation technique described previously (20), ['"In-DTPA-
Arg 'J-substance P binds to SEP-PAK C18 stationary phase and is only eluted 
with ethanol, while 111ln_DTPA is not retained on SEP-PAK C18 columns. The 
radioactivity in plasma and urine samples, which was eluted with ethanol from 
the SEP-PAK C
'B column, is termed peptide bound radioactivity, but was not 
further characterized. Blood samples were collected directly before and 2, 5, 10, 
20, and 40 minutes, and 1, 4, 20 and 48 hours after infusion. Urine was 
collected from the time of injection in two 3-hour intervals and thereafter in 
intervals of 6 hours until 48 hours after injection. If feasible, faeces was 
collected until 72 hours after injection. The chemical status of the radionuclide 
in blood and urine was analyzed as a function of time using the SEP-PAK C,B' 
HPLC and PD-1O gel filtration techniques as described previously (19,20). 
Results 
After administration of ['"In-DTPA-Arg'J-substance P a transient flush was 
observed in all patients. In one patient with Crohn's disease and anaemia, 
significant hypotension was observed associated with bradycardia. This patient 
recovered after 30 seconds in Trendelenburg's position, suggesting the 
presence of a vasovagal collapse. 
In Figure 1 the time courses of total and peptide bound radioactivity in plasma 
are presented until 48 hours after administration. The average plasma 
radioactivity decreased rapidly after injection of ['"In-DTPA-Arg 'J-substance P. 
Degradation of ['11ln-DTPA-Arg 'J-substance P started in the first minutes after 
administration, resulting in a half-life of 10 minutes for total plasma radioactivity 
and of 4 minutes for the intact radiopharmaceutical, as identified with HPLC. 
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10 50 
hours after injection 
Figure 1. Total plasma (e), peptide bound (.6.) and cell bound (0) radioactivity during 48 hours 
after injection of C11 In-DTPA·Arg1]-substance P. 
Renal excretion resulted in the excretion of >95% of the radioactivity in the urine 
within 24 hours after injection, as shown in Figure 2. Up to 0.05% was 
found in the faeces until 60 hours after injection. 
In all patients uptake of radioactivity was found in the salivary glands (low 
uptake), liver, kidneys, urine bladder, and in women in the areolae of the 
mammae 4 hours after injection. The uptake of radioactivity at these sites was 
supposed to be due to receptor binding (parotid gland and areolae) or 
metabolism (liver, kidneys and urine bladder) of the 1111 n labelled substance P 
analogue. Deposition of radioactivity at other sites was considered to be due to 
other causes, which may be pathology related. In eight patients a high uptake 
of ['11ln-DTPA-Arg' ]-substance P was found in the thymus. The highest uptake 
of radioactivity in the thymus was observed in the two patients with liver 
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Figure 2. Cumulative urinary excretion pattern of total (e) and peptide bound (0) radioactivity 
during 48 hours after injection. The radioactivity in the urinary bladder is also shown ( .... ). 
sarcoidosis and Sjogren's syndrome (Figure 3 and Figure 4). CTscanning of the 
thorax confirmed an enlarged thymus in both patients. In patients with systemic 
lupus erythematosus, ophthalmic Graves' disease, rheumatoid arthritis and two 
patients with inflammatory bowel disease the thymus was visualized as well. In 
one patient with myasthenia gravis the thymus was visualized. In contrast, the 
other patient with myasthenia gravis, using high dose corticosteroids, was 
negative at scintigraphy. No uptake of radioactivity in the thymus was observed 
in the three control patients with either carcinoid tumours, lung carcinoma or 
non-Hodgkin's lymphoma. In addition to the thymus, in the patient with Sjogren's 
syndrome, the affected parotid glands showed a high uptake of radioactivity 
(Figure 5). In the patient with unilateral ophthalmic Graves' disease, high uptake 
of radioactivity was observed in the eye mostly affected (Figure 6). In three of 
the five patients with inflammatory bowel disease accumulation of radioactivity 
was found at the sites of inflammation (data not shown). 
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Figure 3. Three-dimensional representation of the chest of a patient with Sjogren's syndrome, in 
whom the thymus is visualized, by 11I1n labelled substance P analogue scintigraphy (24 hours after 
injection). 
Discussion 
Substance P is found in the central nervous system as well as in peripheral 
neuronal circu its. In the peripheral nervous system substance P is found in the 
primary afferent neurons (A-delta pain fibres and C fibres). that are involved in 
the transmission of noxious stimuli. Bioactive substance P has been infused 
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Figure 4. Accumulation of radioactivity in the 
thymus and salivary glands of a patient with 
liver sarcoidosis, 24 hours after injection of 
[111In-DTPA-Arg 1]-substance P (anterior view). 
Chapter B.2 
intravenously in humans in doses of 0.5-1.5 pmollkg per minute over 60 minutes 
or 0.5-8.0 pmollkg per minute over 20 minutes without serious side effects 
(21,22). A very short half-life of 1.6 minute was measured, indicating a very high 
metabolic clearance. In normal plasma substance P is degraded by enzymatic 
hydrolysis involving multiple proteases (23). 
In this study the [DTPA-Arg 'J-substance P was injected in patients with immune 
mediated diseases. In one out of twelve patients hypotension was observed with 
the clinical impression, that a vasovagal collapse caused the hypotension. After 
administration of ['11ln_DTPA_Arg ' J-substance P a transient flush was observed 
in all patients. 
A very short half-life of 10 minutes for plasma radioactivity and of 4 minutes for 
the intact radiopharmaceutical was measured. Radioactivity was excreted 
almost exclusively by the kidneys resulting in a low accumulation of radioactivity 
in the intestinal tract. Despite the high degradation rate of this 
radiopharmaceutical it could visualize affected tissues like the thymus and the 
salivary glands. 
In eight patients with immune mediated diseases the thymus was visualized. In 
the control patients with cancer no thymus could be visualized, suggesting a 
high receptor expression in immune mediated diseases. Substance Preceptors 
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Figure 5. Three-dimensional represen tation of the parotid glands and the nose in a patient with 
Sjogren's syndrome, by 1I1 1n labelled substance P analogue scintigraphy (24 hours after injection). 
have been described recently to be present in the rat thymus, but their role is 
still obscure. Substance P has been identified in nerve fibres of sensory origin 
in the thymus (18). The outer cortex of the human thymus contains an 1-2 cell 
thick layer that is immunoreactive with antisera against substance P. In this 
reg ion the most immature and recently migrated thymocytes are found 
emphasizing the role of neuropeptides in regulating the microenvironment for T 
cell development (16). The gene encoding both substance P and neurokinin A 
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Figure 6. Uptake of radioactivity in a patient with unilateral ophthalmic Graves' disease, visualized 
by single photon emission computed tomography (SPEeT) imaging , 24 hours after injection of C 1'ln_ 
DTPA-Arg']-substance P. 
was shown to be expressed in rat thymus, especially in a subpopulation of cells 
in the medulla (24). 
The thymus is known to play an important role in myasthenia gravis. The 
negative scintigram in one of the patients with myasthenia gravis may be related 
to the use of high dose corticosteroids, which are known to cause involution of 
the thymus. Microscopy of thymuses of patients with myasthenia gravis revealed 
in 70% a follicular hyperplasia of the medulla, containing germinal centres 
resembling a stimulated lymph node (25,26). It may be that primary sensitisation 
against the acetylcholine receptor, which plays a crucial role in myasthenia 
gravis, occurs in the thymus. The reason why substance P receptors are 
present in the thymus of patients with immune mediated disease, as suggested 
in our patients, is obscure. However, it may mean that a similar process of 
sensitisation as is hypothesized in myasthenia gravis takes place in other 
autoimmune diseases as well. 
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Besides the thymus, inflammation sites in two patients with inflammatory bowel 
disease, the affected orbit in ophthalmic Graves' disease, the salivary glands in 
Sjogren's syndrome and the joints in rheumatoid arthritis were visualized. 
Although in patients with inflammatory bowel disease accumulation of 
radioactivity due to gut stenosis cannot be ruled out, the very low excretion of 
['"In-DTPA-Arg' ]-substance P into the bowel «0.05%) does not favour this 
explanation. Therefore, this accumulation is most likely due to the presence of 
substance P receptors at the sites of inflammation in these patients. 
Substance P is supposed to be involved in inflammatory bowel disease. 
Upregulation of receptor binding sites at venules and muscle was previously 
shown by autoradiography (2). In these patients a high expression of substance 
P receptors was observed in comparison with control patients (1000-2000 times 
normal). 
Substance P receptors were described in inflammatory synovitis in rats and 
humans (5,6). 125 1 labelled substance P, binding to microvascular endothelium, 
paralleled the distribution of substance P immunoreactive nerves and had the 
characteristics of the neurokinin 1 receptor (6). 
In this study we present our preliminary results concerning the use of ['11ln_ 
DTPA-Arg ']-substance P as a new radiopharmaceutical with a very short half-life 
in the circulation. The thymus, which is usually involuted after puberty, 
expressed enough substance P receptors to allow in vivo visualization. The role 
of the thymus in autoimmune diseases is obscure; only enlargement of the 
thymus has been described in these diseases. Further investigations are 
necessary to evaluate the role of substance P receptor expression in the thymus 
in these diseases. Also, inflammatory sites in various diseases could be 
visualized by substance P receptor scintigraphy. 
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CHAPTER 9 
SOMATOSTATIN AND SUBSTANCE P ANALOGUES: 
APPLICATIONS IN AUTOIMMUNE AND HAEMATOLOGICAL DISEASES 
Somatostatin and substance P analogues 
Neuroimmunoendocrinology 
Neuroimmunoendocrinology is a rapidly evolving field, which until recently has 
had only limited clinical applications. A well-known link between the immune 
system and the neuroendocrine system at the molecular level is formed by the 
glucocorticoids, which play an important role in the suppression of a hyperactive 
reacting immune system, for example in systemic lupus erythematosus. On the 
other hand, however, adrenalectomized animals are functionally 
immunosuppressed (1). Besides corticosteroids, many neuroendocrine peptides 
are involved in both the regulation of the immune system and the bidirectional 
communication between the immune and neuroendocrine systems. 
Somatostatin 
The modulation of immune functions by somatostatin 
Somatostatin receptors are known to be expressed by human lymphoid cell 
lines, normal activated lymphocytes, and malignant lymphoid cells (2). They 
have been identified in the human thymus and spleen, and within the germinal 
centres of gastrointestinal associated lymphoid tissue (3,4). These observations 
led to the suggestion that somatostatin receptor expression might be related to 
an activated and/or proliferative state of lymphoid cells. Somatostatin might 
modulate the immune response by a variety of mechanisms. These include 
modification of immunoglobulin secretion by plasma cells, suppression or 
enhancement of lymphocyte proliferation, cytotoxicity and changes in cytokine 
production, release of mediators by basophils, recruitment of eosinophils, and 
changes in macrophage function. 
Somatostatin inhibits all three classes of immunoglobulin production by 
unstimulated as well as pokeweed mitogen stimulated lymphocytes (5,6). The 
highest percentage of inhibition was observed in the IgG and IgA synthesis. 
Somatostatin analogues have direct antiproliferative effects on a variety of 
experimental human solid tumour cell lines (7). The influence of somatostatin 
on lymphocyte and lymphoid cell line proliferation was extensively studied using 
cells originating from different species. Result of these studies were summarized 
in a recently published review (2,this thesis). Most investigations reviewed (10 
204 
Chapter 9 
out of 16) showed a concentration dependent modulation of the spontaneous 
and lectin induced proliferation response of lymphocytes and cell lines by 
somatostatin (2). In particular, an inhibitory effect on the proliferation was 
observed in the range of 10 pM - 1 nM. In three out of 16 reports, a biphasic 
proliferation response of lymphoid cells was observed. This response was 
antimitotic at low somatostatin concentrations, but became stimulating at 
concentrations above 0.1 11M. At present, the pathophysiological meaning of this 
biphasic response is not known. 
In vivo administration of somatostatin and the somatostatin analogue BIM-
23014c affects the natural killer activity in vitro of lymphocytes from mouse 
spleen and Peyer's patches (8). At nanomolar concentrations somatostatin 
inhibits the release of Iymphotoxin and tumour necrosis factor a (9). 
Somatostatin was shown to inhibit interferon y by granuloma and splenic T 
lymphocytes by as much as 75% (10,11). Somatostatin may be involved in 
hyperreactivity by regulation of mediator release by basophils and the 
recruitment of eosinophils; at low somatostatin concentrations an inhibitory 
effect was observed (12-13). 
Somatostatin receptors in malignant lymphomas 
In non-Hodgkin's lymphoma of low, intermediate and high grade malignancy 
somatostatin receptors have been detected with in vitro autoradiography in, 
respectively, 92%, 100% and 70% of the patients (this thesis). Non-Hodgkin's 
lymphoma and Hodgkin's disease could be visualized with in vivo somatostatin 
receptor scintigraphy, using ['l1ln-DTPA-D-Phe'J-octreotide. This radioligand is 
strongly related to octreotide, and binds with high affinity to two of the five 
known somatostatin receptor subtypes, i.e. receptor subtypes 2 and 5, and with 
low affinity to receptor subtype 3 (14). Somatostatin receptor scintigraphy was 
found to be a sensitive method for the staging of malignant lymphomas, and 
revealed an upgrade in the clinical stage in six of 40 patients with Hodgkin's 
disease, when compared to the use of conventional staging methods alone. In 
17 out of 62 patients with non-Hodgkin's lymphoma somatostatin receptor 
scintigraphy disclosed lymphoma localizations that were not detected by 
conventional staging methods, resulting in an upgrade of the clinical stage in 13 
patients. However, scintigraphy failed to demonstrate selected sites in five 
205 
Somatostatin and substance P analogues 
patients with Hodgkin's disease and in 14 patients with non-Hodgkin's 
lymphoma. 
Somatostatin receptors in granulomatous diseases 
Somatostatin receptors are expressed in human granulomatous diseases. 
These receptors have been detected by autoradiography in tissue biopsies from 
patients with sarcoidosis and human tuberculosis, and were predominantly 
located in the epithelioid cell regions (this thesis). Biopsy of a lymph node of a 
patient with sarcoidosis who had been treated successfully with corticosteroids 
showed no somatostatin receptor expression. Histopathological examination of 
this lymph node showed complete sclerosis. 
The role of neuropeptides in granulomatous inflammation was extensively 
studied by Weinstock et al. (15-21). Eosinophils and macrophages in 
granulomas induced by Schistosoma mansoni eggs secrete neuropeptides. 
These granuloma macrophages produce somatostatin 14, but not somatostatin 
28. Somatostatin receptors in granulomas from murine schistosomiasis were 
found to be displayed exclusively by a subset of granuloma CD4 positive T 
lymphocytes. These data are in contrast with our observations in granulomas 
from patients with sarcoidosis and tuberculosis. Somatostatin receptors in these 
human granulomas were predominantly located in the epithelioid cell regions. 
In almost all patients with granulomatous diseases, like sarcoidosis, 
tuberculosis, aspergillosis and Wegener's granulomatosis, inflammation 
localizations could be visualized with somatostatin receptor scintigraphy (this 
thesis). Positive scintigraphy in sarcoidosis seems to be related to the efficacy 
of therapy. These findings suggest a relation between the activity of 
granulomatous disease and the expression of somatostatin receptors. 
Somatostatin receptors in rheumatoid arthritis and Sjogren's syndrome 
Somatostatin receptors were found to be localized in blood vessels of diseased 
synovial tissues of patients suffering from rheumatoid arthritis (this thesis). The 
receptors were homogeneously distributed in the whole wall of veins but could 
not be identified in arteries. The fact that the venous wall rarely contained 
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non-vascular constituents such as infiltrating leucocytes, indicates that the 
muscular wall and perhaps the endothelium are the most likely sites of 
somatostatin receptor expression in rheumatoid arthritis. Displacement 
experiments with somatostatin 14, somatostatin 28, and octreotide suggest that 
the receptors expressed are subtype 2 receptors. Affected joints in patients with 
rheumatoid arthritis could be visualized with in vivo somatostatin receptor 
scintigraphy, using "'In labelled octreotide as radioligand. The clinical degree 
of inflammation correlated closely with the degree of uptake of ['"In-DTPA-D-
Phe']-octreotide. Uptake of radioactivity was also found in the affected joints of 
patients with systemic lupus erythematosus, sarcoidosis and Crohn's disease. 
In nine out of 12 patients with Sjogren's syndrome the affected salivary glands, 
associated lymph nodes or affected lungs were visualized. In SjOgren's 
syndrome the salivary glands are infiltrated with foci of CD4 positive 
lymphocytes. 
All the diseases described above are characterized by the involvement of 
malignant lymphoid cells, activated lymphocytes and monocytes, or by 
vasculitis. Normal lymph nodes as well as acute bacterial infections cannot be 
visualized by octreotide scintigraphy, while the normal spleen is visualized in all 
patients. Activation or malignant transformation of immunocompetent cells 
results in the expression of high affinity somatostatin receptors, which can be 
visualized as localizations of tumour or inflammation. 
Substance P 
Modulation of the immune system by substance P 
Substance P is another neuropeptide that is extensively involved in immune 
related diseases. Substance P modulates several immune and hypersensitivity 
activities. It has been reported to modulate the functional activities of 
inflammatory cells by causing degranulation of mast cells, stimulation of 
lysosomal enzyme release from neutrophils, enhancement of neutrophil 
chemotaxis and phagocytosis, and activation of macro phages (22-26). 
Substance P has also been shown to stimulate T lymphocyte proliferation, to 
enhance the effect of T cell mitogens and the production of immunoglobulins by 
plasma cells (27-30). Substance P binds to specific receptors on rat tissue mast 
cells to induce histamine and leukotriene release at micromolar concentrations 
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(22). The hypersensitivity effects, such as vasodilatation and alteration of the 
microvascular permeability appear to be mediated by substance P induced 
factors such as histamine and leukotrienes. There are several reports showing 
that substance P is involved in cytokine production. Substance P stimulates the 
induction of interleukin 2 (31,32), interleukin 1, interleukin 6, and tumour 
necrosis factor a (33). Substance P is present in nerve fibres that innervate the 
spleen, thymus and lymph nodes, and in nerve fibres that are in close contact 
with the mast cells in the intestine. This supports the concept that substance P 
influences the activity of the immune system (34-36). 
Substance P in inflammatory conditions 
Several lines of evidence indicate that tachykinin neuropeptides like substance 
P play a role in the inflammatory and immune response, both in peripheral 
tissues, such as the lungs, joints and colon, as well as in the central nervous 
system. Glial cells in vivo express high concentrations of substance Preceptors 
after transection of retinal ganglion cell axons (37). Receptor binding sites for 
substance P are expressed at high concentrations in arterioles, venules and 
lymph nodules in surgical specimens obtained from patients with ulcerative 
colitis and Crohn's disease (38). It has also been shown, that there is a large 
increase in substance P receptors in rheumatoid synovium compared with 
normal synovium (39,40). It is now widely accepted that there is a neurogenic 
mechanism in the pathophysiology of arthritis, and substance P may be one of 
the important mediators. 
Structural changes in the substance P molecule, namely the coupling of a DTPA 
group, allowed the convenient production of a radiopharmaceutical, despite its 
short half-life. With this compound we were able to visualize the involved joints 
in rat adjuvant arthritis (this thesis). In man uptake of radioactivity was found in 
the thymus of patients with immune mediated diseases like Sjogren's syndrome. 
The precise role of substance P receptor expression in the thymus is not clear. 
However, the expression of a neuropeptide receptor in an organ that is involved 
in the immune regulation suggests an interaction between the neuroendocrine 
and the immune system. Apart from the thymus, we found uptake of substance 
P bound radioactivity in the parotid glands in Sjogren's syndrome, and in the 
affected eyes in ophthalmic Graves' disease (this thesis). 
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Somatostatin analogues and substance P antagonists in the treatment of 
autoimmune diseases? 
In vitro somatostatin and somatostatin analogues have inhibitory effects on the 
immune system, such as inhibition of lymphocyte proliferation, immunoglobulin 
synthesis, cytokine secretion, histamine release and monocyte chemotaxis as 
mentioned above (2). Results of studies on somatostatin analogue therapy in 
'autoimmune disease' in animal models are still preliminary. Important results 
are reported by Weinstock et aI., who found a reduction of the granulomatous 
response in Schistosoma mansoni egg induced murine hepatic granulomas by 
octreotide treatment, presumably because of decrease of the interferon y 
production (10). Further, the somatostatin agonists BIM-23014 and octreotide 
suppress the in vivo inflammatory reaction in aseptic subcutaneous carrageenin 
induced inflammation in rat (41). A reduction of the volume and the leucocyte 
concentration of the exudate was reported. Immunohistochemical evaluation of 
the local mediators substance P, tumour necrosis factor ex and corticotropin 
releasing factor showed a significant inhibitory effect of these mediators. 
Only preliminary data are available on the use of somatostatin analogues in 
humans. A beneficial effect of somatostatin injected intraarticularly in patients 
with rheumatoid arthritis has been reported (42-44). We found a beneficial effect 
during short treatment with systemic octreotide in a patient with arthritis 
(unpublished data). In psoriasis the use of octreotide has resulted in a decrease 
in the skin thickness (45). Furthermore, octreotide was successfully used in the 
treatment of diarrhoea in patients with systemic sclerosis (46). Octreotide 
showed to have a beneficial response in the treatment of patients with low 
grade non-Hodgkin's lymphoma (47). Recently, a patient with intestinal 
lymphangiectasia, who had been steroid dependent for years, was successfully 
treated with octreotide monotherapy (48). The lalter observation may be related 
to the expression of somatostatin receptors on veins and venules in 
inflammatory tissue (49). Modulation of the vascular somatostatin receptors may 
result in a decrease in the inflammation associated extravasation of plasma and 
leucocytes. Moreover, octreotide has been found to decrease the mucosal 
damage in experimental colitis, and somatostatin receptors are known to be 
expressed on the mucosal veins and venules in inflammatory bowel disease 
(49,50). 
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Substance P has antagonistic effects on the immune system, when compared 
with somatostatin. Substance P is supposed to be an activator of the immune 
system. Inhibition of substance P by specific antibodies was found to decrease 
the inflammatory activity in experimental murine intestinal inflammation (51). 
Besides, the non-peptide substance P antagonist CP96,345 inhibits the 
inflammation completely in this model with an increasing substance P tissue 
level (52). Octreotide treatment of this intestinal inflammation resulted also in a 
significant decrease of the inflammatory activity and a decreased sUbstance P 
tissue level (52). Peripheral localized inflammation induces increased substance 
P synthesis and transport towards to the inflammatory tissue (53). Somatostatin 
is known to inhibit the release of substance P. This may result in a decreased 
inflammatory activity, apart from the primary effect of somatostatin on the 
immune system (50,54,55). Furthermore, like octreotide, CP96,345 decreases 
the granuloma size after intravenous administration, possibly by inhibiting the 
secretion of interferon y (56). The secretion of interferon y was unaffected when 
both substance P and somatostatin were added to the medium, suggesting 
opposite effects of the two peptides. Substance P receptors are expressed in 
both arteries and veins in inflammatory tissue (38-40). These vascular receptors 
may be a target for treatment as well. Substance P produces a dose dependent, 
transient vasodilatation of the rat knee joint microvasculature, which can be 
reduced by CP96,345 (57). 
Human lymphoid cells were found to selectively express somatostatin receptor 
subtype 2, which makes these cells a target for somatostatin analogues with 
high affinity to somatostatin receptor subtype 2, like octreotide, RC-160 and 
BIM-23014 (this thesis). 
In conclusion, the somatostatin analogue octreotide and, in the future, 
substance P antagonists may be of use in the treatment of inflammatory 
diseases, like sarcoidosis, rheumatoid arthritis and inflammatory bowel disease. 
The neuropeptide receptor status in these patients, which can be obtained by 
peptide receptor scintigraphy may be related to and predictive for the efficacy 
of therapy. 
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This thesis describes the results of several studies on somatostatin and 
substance P receptor expression in autoimmune diseases and haematological 
malignancies. Receptor studies were performed by in vitro receptor 
autoradiography, ligand binding assays, and reverse transcriptase polymerase 
chain reaction techniques, and by in vivo receptor scintigraphy with the 11lln 
labelled somatostatin analogue octreotide or l11ln labelled substance P. 
The biological aspects of somatostatin are summarized in Chapter 1. 
Somatostatin is a 14 or 28 amino acid peptide which is found throughout the 
human body, but mainly in the endocrine glands and central nervous system. 
Recently, five subtypes of somatostatin receptors have been identified, which 
are all coupled to a G protein. Somatostatin acts as a neurohormone and 
neurotransmitter with a generally inhibitory effect. Long-acting somatostatin 
analogues, like octreotide, are clinically used in the treatment of hormone 
production by endocrine tumours. Radiolabelled octreotide is successfully used 
in the visualization of tumours derived from the amine precursor uptake and 
decarboxylation (APUD) system. Physiological uptake of this radioimager is 
found in the thyroid, liver, pituitary, spleen, kidneys and urinary bladder. 
Deposition of radioactivity at other sites is supposed to be pathological. 
In Chapter 2, the relation between somatostatin and the immune system is 
reviewed. Somatostatin and somatostatin receptors have been demonstrated in 
non-pathological and pathological lymphoid tissue and may play a regulatory, 
mostly inhibitory, role in the immune response. Somatostatin is produced by 
lymphocytes and monocytes, suggesting an autocrine or paracrine regulatory 
role, but it may also be released by nerve endings. It can therefore be 
hypothesized that, apart from a role of somatostatin in local immunomodulation 
of cells belonging to the immune system, a second pathway exists in which this 
peptide exerts its effects via neuroendocrine modulation of the immune 
response. This might represent a direct regulatory relation between the nervous 
and the immune system. 
In Chapter 3 the somatostatin receptor status is evaluated in malignant 
lymphomas that had been surgically removed from 31 patients. Somatostatin 
receptors were visualized by in vitro somatostatin receptor autoradiography with 
the somatostatin analogue [1251-Tyr'J-octreotide as radioligand. Of eleven 
patients with low grade malignancy B cell non-Hodgkin's lymphoma ten patients 
were somatostatin receptor positive, with a high receptor density restricted to 
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the neoplastic follicles. All of the eight intermediate grade non-Hodgkin's 
lymphomas were somatostatin receptor positive. Seven out of ten non Hodgkin's 
lymphomas of high grade malignancy were somatostatin receptor positive, often 
with a high density of receptors. Somatostatin receptors were of high affinity and 
were specific for bioactive somatostatin analogues. Somatostatin receptor 
scintigraphy, using ["'In-DTPA-D-Phe' ]-octreotide as radioligand, was used in 
ten consecutive patients with malignant lymphomas (Hodgkin's disease or 
non-Hodgkin's lymphoma). In all patients the lymphoma deposits could be 
visualized. In four patients, additional tumour localizations were observed as 
compared to the results of combined physical and radiological examinations 
(computer tomography and ultrasonography). In three cases tissue biopsies 
were taken and confirmed by autoradiography to be somatostatin receptor 
positive. These data indicate that malignant lymphomas may express 
somatostatin receptors in sufficient numbers and density to allow in vivo tumour 
visualization with a radiolabelled somatostatin analogue. Recently, the overall 
sensitivity in larger series revealed a sensitivity rate for Hodgkin's disease and 
non-Hodgkin's lymphoma of 97.5% and 85%, respectively. This resulted in an 
upgrade of clinical stage in 15% of the patients with Hodgkin's disease and in 
21 % of the patients with non-Hodgkin's lymphoma. 
In Chapter 4 the results on somatostatin receptor expression in granulomatous 
diseases are presented. Twenty consecutive patients were investigated, 12 
patients with sarcoidosis, one with both sarcoidosis and aspergillosis, four with 
tuberculosis, and three with Wegener's granulomatosis. For in vivo somatostatin 
receptor imaging, total body scintigraphy was performed 24 and 48 hours after 
the administration of ['"In-DTPA-D-Phe ']-octreotide. Granuloma localizations 
were visualized in almost all patients studied. In vitro autoradiography of fresh 
tissue biopsies, using the somatostatin analogue [1251-Tyr3]-octreotide, showed 
binding at sites that were microscopically identified as granulomatous 
inflammation. These observations demonstrate the expression of somatostatin 
receptors by human granulomas. This scintigraphy procedure may contribute to 
a more precise staging and evaluation of granulomatous diseases. 
Chapter 5 describes the in vivo and in vitro investigations of somatostatin 
receptor expression on synovial membranes in patients with rheumatoid arthritis. 
The joints of 14 consecutive patients with active rheumatoid arthritis, four 
patients with severe osteoarthritis, and 30 control patients were stUdied. The 
somatostatin analogue ['l1ln-DTPA-D-Phe' ]-octreotide was used for in vivo 
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somatostatin receptor scintigraphy and the somatostatin analogue [1251_Tyr3J_ 
octreotide was used for in vitro somatostatin receptor autoradiography. Seventy-
six percent of both the painful and the swollen joints of the patients with 
rheumatoid arthritis were visualized. The degree of pain and swelling correlated 
well with positive scintigraphic findings in the joints. In patients with 
osteoarthritis the uptake of radioactivity in the affected joints was significantly 
lower than that in patients with rheumatoid arthritis. None of the joints of the 
control patients demonstrated uptake of radioactivity. The expression of 
somatostatin receptors in synovium from patients with rheumatoid arthritis was 
studied by in vitro receptor autoradiography. Receptors were absent in one 
case, a successfully treated patient with quiescent disease. Somatostatin 
receptors were of high affinity and specific for biologically active somatostatin 
analogues. Displacement by nanomolar concentrations of somatostatin 14, 
somatostatin 28, and octreotide was observed, suggesting that most of the 
receptors identified belong to the somatostatin receptor subtype 2. The 
somatostatin receptors were preferentially located in blood vessels, with specific 
labelling of the veins but not of the arteries. The whole vessel wall was 
homogeneously labelled, including the smooth muscle cells and probably the 
endothelium. These data suggest that the synovium in active rheumatoid 
arthritis expresses a high density of somatostatin receptors. Somatostatin may 
act through these venous receptors to influence the inflammatory process by 
induction of vasoconstriction, inhibition of plasma extravasation and cell 
migration, or inhibition of neovascularization. 
In twelve patients with Sjogren's syndrome somatostatin receptor expression 
was found in the affected tissue. In nine patients uptake of radioactivity was 
found in the affected salivary glands, lungs, joints, and even in the heart. 
Somatostatin receptor scintigraphy enables the visualization of the extent of 
disease, and may be used in the monitoring of the efficacy of therapy in 
Sjogren's syndrome, especially in the case of lung involvement. 
In Chapter 6 we described the expression of somatostatin receptor subtype 
messenger ribonucleic acid (mRNA) and membrane somatostatin receptor 
expression in human lymphoid cell lines. Recently, five somatostatin receptor 
subtypes have been identified. In this study the expression of mRNA for 
somatostatin receptor subtypes was investigated in ten B cell lines and eight T 
cell lines by reverse transcriptase polymerase chain reaction. Two B cell lines 
(JY and TMM) and two T cell lines (HSB-2 and MT-1) expressed mRNA for 
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somatostatin receptor subtype 2, resulting in the expression of membrane 
somatostatin receptors in the cell lines JY, TMM, and MT-1. These data indicate 
that only somatostatin receptor subtype 2 mRNA is expressed in lymphoid cells. 
In Chapter 7 the role of substance P in immune mediated diseases is 
summarized. Substance P is a peptide of eleven amino acids, and is a member 
of the family of tachykinins. The neurokinin 1 receptor, which is present in both 
the central and peripheral nervous system, preferentially interacts with 
substance P. This neuropeptide modulates several immune and hypersensitivity 
activities. The substance P concentrations in serum and synovial fluid in patients 
with rheumatoid arthritis are increased. Also, the number of substance P 
receptors in rheumatoid synovium is increased compared with normal synovium. 
It is now widely accepted that there is a neurogenic mechanism in the 
pathophysiology of arthritis, and substance P may be one of the important 
mediators. Receptor binding sites for substance P are expressed at high 
concentrations in arterioles, venules and lymph nodules in surgical specimens 
obtained from patients with ulcerative colitis and Crohn's disease. 
In Chapter 8.1 the potential usefulness of a new radiolabelled substance P 
analogue, ['"In-DTPA-Arg']-substance P, as a radiopharmaceutical for the in 
vivo detection of substance P receptor positive immunological disorders and 
tumours is evaluated. Substance P, [3-(p-hydroxyphenyl)propionyl-Arg ']-
substance P (Bolton-Hunter-substance P, BH-substance P), and [DTPA-Arg ']-
sUbstance P, inhibited dose-dependently the binding of [, 25I]-BH-substance P to 
the substance P receptors in rat brain cortex membranes with ICso values of 0.2, 
2 and 4 nM, respectively. In an autoradiographic displacement study of the 
submandibular gland with [12sl]-BH-substance P as radiopharmaceutical, an ICso 
of 2.7 nM was found for [DTPA-Arg ']-substance P. In vivo metabolism of the 
radiopharmaceutical in the rat revealed a renal clearance of 50% of the injected 
radioactive dose in 30 minutes, and a rapid enzymatic degradation of the 
radiopharmaceutical, resulting in an effective half-life of the radiopharmaceutical 
in blood of approximately 3 minutes. Four and 24 hours after the injection of 
['"In-DTPA-Arg']-substance P, uptake in and specific binding to sUbstance P 
receptor positive organs and tumours were found, with a (substance Preceptor 
positive) target to background optimum at 24 hours. Tissue distribution and ex 
vivo autoradiographic studies in rats, with and without pretreatment with the 
selective non-peptide neurokinin 1 receptor antagonist CP96,345, showed 
uptake and specific binding of radioactivity in isolated tumours, and in the 
219 
Summary 
submandibular and parotid glands. Visualization of normal substance Preceptor 
positive tissues such as the salivary glands by gamma camera scintigraphy, 
after administration of ["'In-DTPA-Arg' J-substance P, was demonstrated in 
untreated rats. Pathological substance P receptor processes were visualized in 
rats bearing the transplantable pancreatic tumour CA20948, and in rats with 
adjuvant arthritis, induced by injection of a homogenate of Mycobacterium 
tuberculosis. 
In Chapter 8.2 we present our results concerning the metabolism of the 
substance P analogue ['"In-DTPA-Arg' J-substance P in man, as well as the 
visualization of the thymus in patients with immune mediated diseases. Twelve 
selected patients, five with inflammatory bowel disease, one with ophthalmic 
Graves' disease, one with sarcoidosis, one with Sjogren's syndrome, one with 
rheumatoid arthritis, two with myasthenia gravis, and one with systemic lupus 
erythematosus were investigated. During and after intravenous administration 
of 200 MBq (2.5 fl9) ['"In-DTPA-Arg'J-substance P, blood pressure, heart rate, 
and oxygen saturation were monitored. Radioactivity was measured in blood, 
urine and faeces during 48 hours after injection. Planar and single photon 
emission tomography (SPECT) images were obtained 4 and 24 hours after 
injection. After administration of['"ln-DTPA-Arg'J-substance P a transient flush 
was observed in all patients. Degradation of ['"In-DTPA-Arg 'J-substance P 
started in the first minutes after administration, resulting in a half-life of 10 
minutes for the total plasma radioactivity, and of 4 minutes for the intact 
radiopharmaceutical, as identified with high performance liquid chromatography. 
Urinary excretion amounted in >95% of the radioactivity within 24 hours after 
injection, and up to 0.05% was found in the faeces up to 60 hours. In all 
patients uptake of radioactivity was found in the parotid glands, areolae of the 
mammae (in women), liver, kidneys, and urinary bladder. In eight patients a high 
uptake of ['"In-DTPA-Arg'J-substance P was observed in the thymus. These 
data indicate that, despite its short half-life, ['"In-DTPA-Arg 'J-substance P, a 
new radiopharmaceutical, can be used to visualize the thymus. This may 
contribute to the investigation of the role of the thymus in immune related disea-
ses. 
In Chapter 9 the applications of somatostatin and substance P are summarized 
with respect to their use as radioimagers. The number of neuropeptide receptors 
are upregulated in autoimmune diseases and haematological malignancies. The 
immune modulating properties of these neuropeptides may warrant speculations 
220 
Summary 
on the possible role of neuropeptide receptors as a new target in the treatment 
of these diseases in the near future. Neuropeptide scintigraphy will be important 
in the determination of the neuropeptide receptor status, which may be related 
to the efficacy of therapy. 
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Samenvatting 
Dit proefschrift beschrijft de resultaten van onderzoek naar de expressie van 
somatostatine en substance P receptoren bij autoimmuun ziekten en maligne 
Iymfomen. In dit onderzoek zijn verschillende onderzoekstechnieken 
toegepast. Voor het in vitro onderzoek werd gebruik gemaakt van peptide 
receptor autoradiografie, ligand binding studies en polymerase ketting 
reacties. In vivo onderzoek werd verricht met behulp van peptide receptor 
scintigrafie. 
In Hoofdstuk 1 word! de biologie van somatostatine besproken. 
Somatostatine is een klein peptide, bestaat uit 14 aminozuren en komt in 
vrijwel het gehele lichaam voor. De hoogste concentraties somatostatine 
worden gevonden in het centraal zenuwstelsel en in de endocriene klieren. 
Somatostatine remt de afgifte van bepaalde hormonen, zoals groeihormoon. 
Van deze eigenschap wordt gebruik gemaakt bij de behandeling van 
endocrien actieve tumoren. Behandeling met een somatostatine analogon, 
zoals octreotide, resulteert in een vermindering van de hormoon afgifte door 
deze tumoren. De somatostatine receptor heeft zeven transmembraan 
domeinen en is gebonden aan een G eiwit. Momenteel zijn vijf receptor 
subtypen bekend. De voor therapeutische doeleinden beschikbare 
somatostatine analoga, zoals octreotide en BIM-23014, binden vooral aan 
receptor subtypen 2 en 5. 
Een andere toepassing van somatostatine analoga is het afbeelden van 
ziekteprocessen door middel van peptide receptor scintigrafie. Door binding 
van een radionuclide ("'Indium) aan octreotide, via een DTPA groep, 
ontstaat een radioimager waarvan is aangetoond dat deze zeer goed 
bruikbaar is voor de detectie van endocriene tumoren. Laatst genoemde 
tumoren hebben een hoge dichtheid aan somatostatine receptoren. 
In Hoofdstuk 2 wordt de literatuur samengevat omtrent de relatle tussen 
somatostatine en het immuun systeem. Somatostatine receptoren komen 
voor op geactiveerde Iymfocyten en monocyten. Somatostatine heelt een 
overwegend remmende werking op het immuunsysteem. De produktie van 
immuunglobulines (vooral IgA), de proliferatie van Iymfocyten, de afgifte van 
cytokines, zoals interferon y en tumor necrosis factor a, en de afgilte van 
histamine door mestcellen worden geremd. Verschillende onderzoeken 
hebben aangetoond dat somatostatine geproduceerd kan worden in 
granulomateuze ontstekingsprocessen, wat betekent dat somatostatin 
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mogelijk een autocrien of paracrien regulerende functie heeft. Somatostatine 
wordt bovendien uitgescheiden door zenuw vezels, hetgeen een interactie 
tussen het zenuwstelsel en het immuun apparaat suggereert. 
In Hoofdstuk 3 worden de resultaten beschreven van autoradiografisch 
onderzoek naar de expressie van somatostatine receptoren in vitro op 
weefsel coupes van patienten met maligne Iymfomen. In de groep non-
Hodgkin Iymfomen bleek 91% van de laaggradige Iymfomen, 100% van de 
Iymfomen van intermediaire maligniteitsgraad, en 70% van de hooggradige 
Iymfomen receptoren voor somatostatine tot expressie te brengen. Deze 
receptoren hebben een hoge affiniteit voor het somatostatine analogon [Tyr3_ 
octreotide]. Met behulp van somatostatine receptor scintigrafie werden tumor 
lokalisaties zichtbaar gemaakt bij patie nten met de ziekte van Hodgkin of een 
non-Hodgkin Iymfoom. Met deze techniek werden meer tumor lokalisaties 
gevonden dan met conventionele stageringsmethoden, hetgeen bij een 
aantal patiMten leidde tot een verandering van het ziektestadium. Dit laatste 
kan gevolgen hebben voor de te volgen therapie. Recent werd aangetoond 
dat octreotide behandeling een gunstig effect heeft op Iymfomen met een 
lage maligniteitsgraad. Expressie van somatostatine receptoren biedt in de 
toekomst wellicht mogelijkheden voor de toepassing van somatostatine 
analoga, gebonden aan een B stralend radionuclide, bij de bestraling van 
tumoren. 
Hoofdstuk 4 en 5 beschrijven onderzoek naar het voorkomen van 
somatostatine receptoren bij granulomateuze ontstekingen, reumatoide 
artritis en de ziekte van Sjogren. In vitro receptor autoradiografie toonde 
specifieke hoge affiniteits receptoren aan in granulomen in de epitheloid cel 
regio en in de hoog endothelia Ie venulen in synovia van patienten met 
reumatoide artritis. Met behulp van somatostatine receptor scintigrafie was 
het mogelijk ontstekingslokalisaties en ontstoken gewrichten bij vrijwel aile 
patienten af te beelden en aldus uitbreiding van de ziekte te objectiveren. De 
expressie van somatostatine receptoren is sterk gerelateerd aan de activiteit 
van deze ziekten. Bij sarco"ldose toonde het scintigram bij patienten die goed 
reageerden op therapie geen afwijkingen meer, terwijl bij patienten die niet 
goed reageerden op therapie het scintigram onveranderd, dus afwijkend, 
bleef. Ook bij patienten met reumatoide artritis correleerden de klinische 
symptomen (pijn en zwelling van de gewrichten) goed met de opname van 
radioactiviteit in de gewrichten. 
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Hoofdstuk 6 beschrijft het onderzoek naar de expressie van somatostatine 
receptor subtypen in lymfatische cellijnen met behulp van een polymerase 
ketting reactie. Vier van de 18 onderzochte cellijnen brachten messenger 
RNA coderend voor somatostatine receptor subtype 2 tot expressie. Ligand 
binding studies toonden aan dat dit bij drie cellijnen leidde tot expressie van 
membraan receptoren. 
In Hooldstuk 7 wordt de relatie beschreven tussen substance P en het 
immuun systeem. Substance P komt vooral voor in het centraal 
zenuwstelsel, alwaar het als neurotransmitter een rol speelt in de 
nociceptieve signaal transmissie. In tegenstelling tot de remmende werking 
van somatostatine, heeft substance Peen activerende invloed op het 
immuun systeem, zoals stimulatie van de synthese van immuunglobulines, 
de algifte van histamine door mestcellen, en de afgifte van interleukine 1, 
interleukine 6 en tumor necrosis factor ex door monocyten. Upregulatie van 
substance P receptoren wordt gevonden bij een aantal immuungemedieerde 
ziekten, onder andere bij reumatoide artritis in de aangedane synovia, bij 
inflammatory bowel disease en ook bij zenuw laesies waar substance P 
receptoren tot expressie worden gebracht door glia cellen. Substance P en 
somatostatine lijken ten aanzien van het immuun systeem een tegengestelde 
werking te hebben. 
In Hoofdstuk 8 worden het metabolisme en de bindingskarakteristieken 
beschreven van de nieuwe radioimager ["'In-DTPA-Arg' ]-substance P. Deze 
radioimager heeft een hoge affiniteit voor submandibulaire klieren en hersen 
cortex membranen in de rat. Ondanks de korte halfwaarde tijd kan deze stof 
gebruikt worden voor het albeelden van substance Preceptor positieve 
processen. In dierexperimenten (rat) konden adjuvant artritis en 
transplantabele tumoren worden algebeeld. Bij de mens werd, door middel 
van substance Preceptor scintigrafie, de thymus zichtbaar gemaakt bij 
patienten met autoimmuun ziekten. Tevens konden ontstekingsprocessen 
zichtbaar worden gemaakt bij patienten met ophtalmic' Graves disease, 
inflammatory bowel disease en de ziekte van Sjogren. 
In Hoofdstuk 9 wordt de mogelijke rei besproken van somatostatine en 
substance Preceptor expressie in de behandeling van maligne Iymfomen en 
autoimmuun processen. 
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